Johnson & Johnson (JNJ) 10-K17 Feb 222021 FY Annual reportFinancial data

Company Profile

Cover Page

Cover Page - USD ($) $ in Billions	12 Months Ended
Cover Page - USD ($) $ in Billions	Jan. 02, 2022	Feb. 10, 2022	Jul. 04, 2021
Document Information [Line Items]
Document Type	10-K
Document Annual Report	true
Document Period End Date	Jan. 2, 2022
Document Transition Report	false
Entity File Number	1-3215
Entity Registrant Name	JOHNSON & JOHNSON
Entity Incorporation, State or Country Code	NJ
Entity Tax Identification Number	22-1024240
Entity Address, Address Line One	One Johnson & Johnson Plaza
Entity Address, City or Town	New Brunswick
Entity Address, State or Province	NJ
Entity Address, Postal Zip Code	08933
City Area Code	732
Local Phone Number	524-0400
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Emerging Growth Company	false
Entity Small Business	false
ICFR Auditor Attestation Flag	true
Entity Shell Company	false
Entity Public Float			$ 445
Entity Common Stock, Shares Outstanding		2,629,268,158
Entity Central Index Key	0000200406
Current Fiscal Year End Date	--01-02
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	FY
Amendment Flag	false
Common Stock, Par Value $1.00
Document Information [Line Items]
Title of 12(b) Security	Common Stock, Par Value $1.00
Trading Symbol	JNJ
Security Exchange Name	NYSE
0.650% Notes Due May 2024
Document Information [Line Items]
Title of 12(b) Security	0.650% Notes Due May 2024
Trading Symbol	JNJ24C
Security Exchange Name	NYSE
5.50% Notes Due November 2024
Document Information [Line Items]
Title of 12(b) Security	5.50% Notes Due November 2024
Trading Symbol	JNJ24BP
Security Exchange Name	NYSE
1.150% Notes Due November 2028
Document Information [Line Items]
Title of 12(b) Security	1.150% Notes Due November 2028
Trading Symbol	JNJ28
Security Exchange Name	NYSE
1.650% Notes Due May 2035
Document Information [Line Items]
Title of 12(b) Security	1.650% Notes Due May 2035
Trading Symbol	JNJ35
Security Exchange Name	NYSE

Audit Information

Audit Information	12 Months Ended
Audit Information	Jan. 02, 2022
Auditor Information [Abstract]
Auditor Name	PricewaterhouseCoopers LLP
Auditor Location	Florham Park, New Jersey
Auditor Firm ID	238

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Millions	Jan. 02, 2022	Jan. 03, 2021
Current assets:
Cash and cash equivalents (Notes 1 and 2)	$ 14,487	$ 13,985
Marketable securities (Notes 1 and 2)	17,121	11,200
Accounts receivable trade, less allowances for doubtful accounts $230 (2020, $293)	15,283	13,576
Inventories (Notes 1 and 3)	10,387	9,344
Prepaid expenses and other receivables	3,701	3,132
Total current assets	60,979	51,237
Property, plant and equipment, net (Notes 1 and 4)	18,962	18,766
Intangible assets, net (Notes 1 and 5)	46,392	53,402
Goodwill (Notes 1 and 5)	35,246	36,393
Deferred taxes on income (Note 8)	10,223	8,534
Other assets	10,216	6,562
Total assets	182,018	174,894
Current liabilities
Loans and notes payable (Note 7)	3,766	2,631
Accounts payable	11,055	9,505
Accrued liabilities	13,612	13,968
Accrued rebates, returns and promotions	12,095	11,513
Accrued compensation and employee related obligations	3,586	3,484
Accrued taxes on income (Note 8)	1,112	1,392
Total current liabilities	45,226	42,493
Long-term debt (Note 7)	29,985	32,635
Deferred taxes on income (Note 8)	7,487	7,214
Employee related obligations (Notes 9 and 10)	8,898	10,771
Long-term taxes payable (Note 1)	5,713	6,559
Other liabilities	10,686	11,944
Total liabilities	107,995	111,616
Commitments and Contingencies (Note 19)
Shareholders’ equity
Preferred stock — without par value (authorized and unissued 2,000,000 shares)	0	0
Common stock — par value $1.00 per share (Note 12) (authorized 4,320,000,000 shares; issued 3,119,843,000 shares)	3,120	3,120
Accumulated other comprehensive income (loss) (Note 13)	(13,058)	(15,242)
Retained earnings	123,060	113,890
Stockholders' Equity before Treasury Stock	113,122	101,768
Less: common stock held in treasury, at cost (Note 12) (490,878,000 shares and 487,331,000 shares)	39,099	38,490
Total shareholders’ equity	74,023	63,278
Total liabilities and shareholders’ equity	$ 182,018	$ 174,894

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Millions	Jan. 02, 2022	Jan. 03, 2021
Current assets:
Allowances for doubtful accounts	$ 230	$ 293
Shareholders’ equity
Preferred stock, shares authorized (in shares)	2,000,000	2,000,000
Common stock, par value per share (in dollars per share)	$ 1	$ 1
Common stock, shares authorized (in shares)	4,320,000,000	4,320,000,000
Common stock, shares issued (in shares)	3,119,843,000	3,119,843,000
Treasury stock, shares	490,878,000	487,331,000

Consolidated Statements of Earn

Consolidated Statements of Earnings - USD ($) shares in Millions, $ in Millions	12 Months Ended
	Jan. 02, 2022	Jan. 03, 2021	Dec. 29, 2019
Income Statement [Abstract]
Sales to customers	$ 93,775	$ 82,584	$ 82,059
Cost of products sold	29,855	28,427	27,556
Gross profit	63,920	54,157	54,503
Selling, marketing and administrative expenses	24,659	22,084	22,178
Research and development expense	14,714	12,159	11,355
In-process research and development (Note 5)	900	181	890
Interest income	(53)	(111)	(357)
Interest expense, net of portion capitalized (Note 4)	183	201	318
Other (income) expense, net	489	2,899	2,525
Restructuring (Note 20)	252	247	266
Earnings before provision for taxes on income	22,776	16,497	17,328
Provision for taxes on income (Note 8)	1,898	1,783	2,209
Net earnings	$ 20,878	$ 14,714	$ 15,119
Net earnings per share (Notes 1 and 15)
Basic (in dollars per share)	$ 7.93	$ 5.59	$ 5.72
Diluted (in dollars per share)	$ 7.81	$ 5.51	$ 5.63
Average shares outstanding (Notes 1 and 15)
Basic (in shares)	2,632.1	2,632.8	2,645.1
Diluted (in shares)	2,674	2,670.7	2,684.3

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Income - USD ($) $ in Millions	12 Months Ended
	Jan. 02, 2022	Jan. 03, 2021	Dec. 29, 2019
Statement of Comprehensive Income [Abstract]
Net earnings	$ 20,878	$ 14,714	$ 15,119
Other comprehensive income (loss), net of tax
Foreign currency translation	(1,079)	(233)	164
Securities:
Unrealized holding gain (loss) arising during period	(4)	1	0
Reclassifications to earnings	0	0	0
Net change	(4)	1	0
Employee benefit plans:
Prior service credit (cost), net of amortization	(169)	1,298	(18)
Gain (loss), net of amortization	4,318	(1,135)	(714)
Effect of exchange rates	106	(229)	(1)
Net change	4,255	(66)	(733)
Derivatives & hedges:
Unrealized gain (loss) arising during period	(199)	1,000	(107)
Reclassifications to earnings	(789)	(53)	7
Net change	(988)	947	(100)
Other comprehensive income (loss)	2,184	649	(669)
Comprehensive income	$ 23,062	$ 15,363	$ 14,450

Consolidated Statements of Co_2

Consolidated Statements of Comprehensive Income (Parenthetical) - USD ($) $ in Millions	12 Months Ended
	Jan. 02, 2022	Jan. 03, 2021	Dec. 29, 2019
Statement of Comprehensive Income [Abstract]
Foreign currency translation	$ (346)	$ (536)	$ 19
Securities	(1)
Employee benefits	1,198	(21)	(222)
Derivatives & hedges	$ (263)	$ 252	$ (27)

Consolidated Statements of Equi

Consolidated Statements of Equity - USD ($) $ in Millions	Total	Retained Earnings	Accumulated Other Comprehensive Income (Loss)	Common Stock Issued Amount	Treasury Stock Amount
Beginning Balance at Dec. 30, 2018	$ 59,752	$ 106,216	$ (15,222)	$ 3,120	$ (34,362)
Net earnings	15,119	15,119
Cash dividends paid	(9,917)	(9,917)
Employee compensation and stock option plans	1,933	(758)			2,691
Repurchase of common stock	(6,746)				(6,746)
Other	(1)	(1)
Other comprehensive income (loss), net of tax	(669)		(669)
Ending Balance at Dec. 29, 2019	59,471	110,659	(15,891)	3,120	(38,417)
Net earnings	14,714	14,714
Cash dividends paid	(10,481)	(10,481)
Employee compensation and stock option plans	2,217	(931)			3,148
Repurchase of common stock	(3,221)				(3,221)
Other	(71)	(71)
Other comprehensive income (loss), net of tax	649		649
Ending Balance at Jan. 03, 2021	63,278	113,890	(15,242)	3,120	(38,490)
Net earnings	20,878	20,878
Cash dividends paid	(11,032)	(11,032)
Employee compensation and stock option plans	2,171	(676)			2,847
Repurchase of common stock	(3,456)				(3,456)
Other comprehensive income (loss), net of tax	2,184		2,184
Ending Balance at Jan. 02, 2022	$ 74,023	$ 123,060	$ (13,058)	$ 3,120	$ (39,099)

Consolidated Statements of Eq_2

Consolidated Statements of Equity (Parenthetical) - $ / shares	12 Months Ended
	Jan. 02, 2022	Jan. 03, 2021	Dec. 29, 2019
Statement of Stockholders' Equity [Abstract]
Cash dividends paid (in dollars per share)	$ 4.19	$ 3.98	$ 3.75

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Millions	12 Months Ended
	Jan. 02, 2022	Jan. 03, 2021	Dec. 29, 2019
Cash flows from operating activities
Net earnings	$ 20,878	$ 14,714	$ 15,119
Adjustments to reconcile net earnings to cash flows from operating activities:
Depreciation and amortization of property and intangibles	7,390	7,231	7,009
Stock based compensation	1,135	1,005	977
Asset write-downs	989	233	1,096
Contingent consideration reversal	0	(1,148)	0
Net gain on sale of assets/businesses	(617)	(111)	(2,154)
Deferred tax provision	(2,079)	(1,141)	(2,476)
Credit losses and accounts receivable allowances	(48)	63	(20)
Changes in assets and liabilities, net of effects from acquisitions and divestitures:
(Increase)/Decrease in accounts receivable	(2,402)	774	(289)
Increase in inventories	(1,248)	(265)	(277)
Increase in accounts payable and accrued liabilities	2,437	5,141	4,060
Increase in other current and non-current assets	(1,964)	(3,704)	(1,054)
(Decrease)/Increase in other current and non-current liabilities	(1,061)	744	1,425
Net cash flows from operating activities	23,410	23,536	23,416
Cash flows from investing activities
Additions to property, plant and equipment	(3,652)	(3,347)	(3,498)
Proceeds from the disposal of assets/businesses, net	711	305	3,265
Acquisitions, net of cash acquired (Note 18)	(60)	(7,323)	(5,810)
Purchases of investments	(30,394)	(21,089)	(3,920)
Sales of investments	25,006	12,137	3,387
Credit support agreements activity, net	214	(987)	338
Other (primarily licenses and milestones)	(508)	(521)	44
Net cash used by investing activities	(8,683)	(20,825)	(6,194)
Cash flows from financing activities
Dividends to shareholders	(11,032)	(10,481)	(9,917)
Repurchase of common stock	(3,456)	(3,221)	(6,746)
Proceeds from short-term debt	1,997	3,391	39
Repayment of short-term debt	(1,190)	(2,663)	(100)
Proceeds from long-term debt, net of issuance costs	5	7,431	3
Repayment of long-term debt	(1,802)	(1,064)	(2,823)
Proceeds from the exercise of stock options/employee withholding tax on stock awards, net	1,036	1,114	954
Credit support agreements activity, net	281	(333)	100
Other	114	(294)	475
Net cash used by financing activities	(14,047)	(6,120)	(18,015)
Effect of exchange rate changes on cash and cash equivalents	(178)	89	(9)
Increase/(Decrease) in cash and cash equivalents	502	(3,320)	(802)
Cash and cash equivalents, beginning of year (Note 1)	13,985	17,305	18,107
Cash and cash equivalents, end of year (Note 1)	14,487	13,985	17,305
Cash paid during the year for:
Interest	990	904	995
Interest, net of amount capitalized	941	841	925
Income taxes	4,768	4,619	4,191
Supplemental schedule of non-cash investing and financing activities
Treasury stock issued for employee compensation and stock option plans, net of cash proceeds/ employee withholding tax on stock awards	1,811	1,937	1,736
Conversion of debt	0	27	1
Acquisitions
Fair value of assets acquired	61	7,755	7,228
Fair value of liabilities assumed and noncontrolling interests	(1)	(432)	(1,418)
Net cash paid for acquisitions (Note 18)	$ 60	$ 7,323	$ 5,810

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
Summary of Significant Accounting Policies	Jan. 02, 2022
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies Principles of Consolidation The consolidated financial statements include the accounts of Johnson & Johnson and its subsidiaries (the Company). Intercompany accounts and transactions are eliminated. Columns and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures. Description of the Company and Business Segments The Company has approximately 141,700 employees worldwide engaged in the research and development, manufacture and sale of a broad range of products in the healthcare field. The Company conducts business in virtually all countries of the world and its primary focus is on products related to human health and well-being. The Company is organized into three business segments: Consumer Health, Pharmaceutical and Medical Devices. The Consumer Health segment includes a broad range of products used in the Baby Care, Oral Care, Skin Health/Beauty, Over-the-Counter pharmaceutical, Women’s Health and Wound Care markets. These products are marketed to the general public and sold online (eCommerce) and to retail outlets and distributors throughout the world. The Pharmaceutical segment is focused on six therapeutic areas, including Immunology, Infectious diseases, Neuroscience, Oncology, Pulmonary Hypertension, and Cardiovascular and Metabolic diseases. Products in this segment are distributed directly to retailers, wholesalers, distributors, hospitals and healthcare professionals for prescription use. The Medical Devices segment includes a broad range of products used in the Orthopaedic, Surgery, Interventional Solutions (cardiovascular and neurovascular) and Vision fields. These products are distributed to wholesalers, hospitals and retailers, and used principally in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. In November 2021, the Company announced its intention to separate the Company’s Consumer Health business, with the intention to create a new, publicly traded company. The Company is targeting completion of the planned separation in 18 to 24 months after initial announcement. New Accounting Standards Recently Adopted Accounting Standards There were no new material accounting standards adopted in fiscal 2021. Recently Issued Accounting Standards Not Adopted as of January 2, 2022 The Company assesses the adoption impacts of recently issued accounting standards by the Financial Accounting Standards Board on the Company's financial statements as well as material updates to previous assessments, if any, from the Company’s Annual Report on Form 10-K for the fiscal year ended January 3, 2021. There were no new material accounting standards issued in fiscal 2021 that impacted the Company. ASU 2021-01: Reference Rate Reform In mid- 2017, the Financial Conduct Authority (FCA) announced that it will no longer require banks to submit rates for the London Interbank Offered Rate (LIBOR) after 2021 hence market participants should work to transition to alternative reference rates (Reference Rate Reform) and should not rely on LIBOR being available after the end of 2021. Reference rate reform is the term used to refer to the efforts that have been undertaken by regulators and other market participants to introduce new reference rates that are based on a larger and more liquid population of observable transactions. The Company evaluated the implications of reference rate reform and applicable financial reporting guidance in ASU 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting on its key financial and commercial contracts that referenced LIBOR including any hedging relationships. Most contracts reviewed will mature prior to the termination of LIBOR or will be modified to apply a new reference rate (primarily the Secured Overnight Financing Rate “SOFR” where applicable). The company also applied available practical expedients under ASC 848 to in scope financial and commercial contracts that previously referenced LIBOR when applicable. As a result, the Company's implementation of any reference rate reform provisions to commercial and financial contracts did not result in any material change for the Company. Cash Equivalents The Company classifies all highly liquid investments with stated maturities of three months or less from date of purchase as cash equivalents and all highly liquid investments with stated maturities of greater than three months from the date of purchase as current marketable securities. The Company has a policy of making investments only with commercial institutions that have at least an investment grade credit rating. The Company invests its cash primarily in government securities and obligations, corporate debt securities, money market funds and reverse repurchase agreements (RRAs). RRAs are collateralized by deposits in the form of Government Securities and Obligations for an amount not less than 102% of their value. The Company does not record an asset or liability as the Company is not permitted to sell or repledge the associated collateral. The Company has a policy that the collateral has at least an A (or equivalent) credit rating. The Company utilizes a third party custodian to manage the exchange of funds and ensure that collateral received is maintained at 102% of the value of the RRAs on a daily basis. RRAs with stated maturities of greater than three months from the date of purchase are classified as marketable securities. Investments Investments classified as held to maturity investments are reported at amortized cost and realized gains or losses are reported in earnings. Investments classified as available-for-sale debt securities are carried at estimated fair value with unrealized gains and losses recorded as a component of accumulated other comprehensive income. Available-for-sale securities available for current operations are classified as current assets otherwise, they are classified as long term. Management determines the appropriate classification of its investment in debt and equity securities at the time of purchase and re-evaluates such determination at each balance sheet date. The Company reviews its investments for impairment and adjusts these investments to fair value through earnings, as required. Property, Plant and Equipment and Depreciation Property, plant and equipment are stated at cost. The Company utilizes the straight-line method of depreciation over the estimated useful lives of the assets: Building and building equipment 20 - 30 years Land and leasehold improvements 10 - 20 years Machinery and equipment 2 - 13 years The Company capitalizes certain computer software and development costs, included in machinery and equipment, when incurred in connection with developing or obtaining computer software for internal use. Capitalized software costs are amortized over the estimated useful lives of the software, which generally range from 3 to 8 years. The Company reviews long-lived assets to assess recoverability using undiscounted cash flows. When certain events or changes in operating or economic conditions occur, an impairment assessment may be performed on the recoverability of the carrying value of these assets. If the asset is determined to be impaired, the loss is measured based on the difference between the asset’s fair value and its carrying value. If quoted market prices are not available, the Company will estimate fair value using a discounted value of estimated future cash flows. Revenue Recognition The Company recognizes revenue from product sales when obligations under the terms of a contract with the customer are satisfied; generally, this occurs with the transfer of control of the goods to customers. The Company's global payment terms are typically between 30 to 90 days. Provisions for certain rebates, sales incentives, trade promotions, coupons, product returns, discounts to customers and governmental clawback provisions are accounted for as variable consideration and recorded as a reduction in sales. The liability is recognized within Accrued Rebates, Returns, and Promotions on the consolidated balance sheet. Product discounts granted are based on the terms of arrangements with direct, indirect and other market participants, as well as market conditions, including consideration of competitor pricing. Rebates are estimated based on contractual terms, historical experience, patient outcomes, trend analysis and projected market conditions in the various markets served. A significant portion of the liability related to rebates is from the sale of the Company's pharmaceutical products within the U.S., primarily t he Managed Care, Medicare and Medicaid programs, which amounted to $7.7 billion and $7.2 billion as of January 2, 2022 and January 3, 2021, respectively. The Company evaluates market conditions for products or groups of products primarily through the analysis of wholesaler and other third-party sell-through and market research data, as well as internally generated information. Sales returns are estimated and recorded based on historical sales and returns information. Products that exhibit unusual sales or return patterns due to dating, competition or other marketing matters are specifically investigated and analyzed as part of the accounting for sales return accruals. Sales returns allowances represent a reserve for products that may be returned due to expiration, destruction in the field, or in specific areas, product recall. The sales returns reserve is based on historical return trends by product and by market as a percent to gross sales. In accordance with the Company’s accounting policies, the Company generally issues credit to customers for returned goods. The Company’s sales returns reserves are accounted for in accordance with the U.S. GAAP guidance for revenue recognition when right of return exists. Sales returns reserves are recorded at full sales value. Sales returns in the Consumer Health and Pharmaceutical segments are almost exclusively not resalable. Sales returns for certain franchises in the Medical Devices segment are typically resalable but are not material. The Company infrequently exchanges products from inventory for returned products. The sales returns reserve for the total Company has been approximately 1.0% of annual net trade sales during each of the fiscal years 2021, 2020 and 2019. Promotional programs, such as product listing allowances and cooperative advertising arrangements, are recorded in the same period as related sales. Continuing promotional programs include coupons and volume-based sales incentive programs. The redemption cost of consumer coupons is based on historical redemption experience by product and value. Volume-based incentive programs are based on the estimated sales volumes for the incentive period and are recorded as products are sold. These arrangements are evaluated to determine the appropriate amounts to be deferred or recorded as a reduction of revenue. The Company also earns profit-share payments through collaborative arrangements for certain products, which are included in sales to customers. For all years presented, profit-share payments were less than 3.0% of the total revenues and are included in sales to customers. See Note 17 to the Consolidated Financial Statements for further disaggregation of revenue. Shipping and Handling Shipping and handling costs incurred were $1.1 billion, $1.0 billion and $1.0 billion in fiscal years 2021, 2020 and 2019, respectively, and are included in selling, marketing and administrative expense. The amount of revenue received for shipping and handling is less than 0.5% of sales to customers for all periods presented. Inventories Inventories are stated at the lower of cost or net realizable value determined by the first-in, first-out method. Intangible Assets and Goodwill The authoritative literature on U.S. GAAP requires that goodwill and intangible assets with indefinite lives be assessed annually for impairment. The Company completed its annual impairment test for 2021 in the fiscal fourth quarter. Future impairment tests will be performed annually in the fiscal fourth quarter, or sooner if warranted. Purchased in-process research and development is accounted for as an indefinite lived intangible asset until the underlying project is completed, at which point the intangible asset will be accounted for as a definite lived intangible asset, or abandoned, at which point the intangible asset will be written off or partially impaired. Intangible assets that have finite useful lives continue to be amortized over their useful lives, and are reviewed for impairment when warranted by economic conditions. See Note 5 for further details on Intangible Assets and Goodwill. Financial Instruments As required by U.S. GAAP, all derivative instruments are recorded on the balance sheet at fair value. Fair value is the exit price that would be received to sell an asset or paid to transfer a liability. Fair value is a market-based measurement determined using assumptions that market participants would use in pricing an asset or liability. The authoritative literature establishes a three-level hierarchy to prioritize the inputs used in measuring fair value, with Level 1 having the highest priority and Level 3 having the lowest. Changes in the fair value of derivatives are recorded each period in current earnings or other comprehensive income, depending on whether the derivative is designated as part of a hedge transaction, and if so, the type of hedge transaction. The Company documents all relationships between hedged items and derivatives. The overall risk management strategy includes reasons for undertaking hedge transactions and entering into derivatives. The objectives of this strategy are: (1) minimize foreign currency exposure’s impact on the Company’s financial performance; (2) protect the Company’s cash flow from adverse movements in foreign exchange rates; (3) ensure the appropriateness of financial instruments; and (4) manage the enterprise risk associated with financial institutions. See Note 6 for additional information on Financial Instruments. Leases The Company determines whether an arrangement is a lease at contract inception by establishing if the contract conveys the right to control the use of identified property, plant, or equipment for a period of time in exchange for consideration. Right of Use (ROU) Assets and Lease Liabilities for operating leases are included in Other assets Accrued liabilities Other liabilities ROU Assets and Lease Liabilities are recognized at the lease commencement date based on the present value of all minimum lease payments over the lease term. The Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments, when the implicit rate is not readily determinable. Lease terms may include options to extend or terminate the lease. These options are included in the lease term when it is reasonably certain that the Company will exercise that option. Operating lease expense is recognized on a straight-line basis over the lease term. The Company has elected the following policy elections on adoption: use of portfolio approach on leases of assets under master service agreements, exclusion of short term leases on the balance sheet, and not separating lease and non-lease components. The Company primarily has operating lease for space, vehicles, manufacturing equipment and data processing equipment. The ROU asset pertaining to operating leases was $0.9 billion and $1.0 billion in 2021 and 2020, respectively. The lease liability was $1.0 billion and $1.1 billion in 2021and 2020, respectively. The operating lease costs were $0.3 billion, $0.3 billion and $0.3 billion in 2021, 2020 and 2019, respectively. Cash paid for amounts included in the measurement of lease liabilities were $0.3 billion, $0.3 billion and $0.3 billion in 2021, 2020 and 2019, respectively. Product Liability Accruals for product liability claims are recorded, on an undiscounted basis, when it is probable that a liability has been incurred and the amount of the liability can be reasonably estimated based on existing information and actuarially determined estimates where applicable. The accruals are adjusted periodically as additional information becomes available. The Company accrues an estimate of the legal defense costs needed to defend each matter when those costs are probable and can be reasonably estimated. To the extent adverse verdicts have been rendered against the Company, the Company does not record an accrual until a loss is determined to be probable and can be reasonably estimated. The Company has self insurance through a wholly-owned captive insurance company. In addition to accruals in the self insurance program, claims that exceed the insurance coverage are accrued when losses are probable and amounts can be reasonably estimated. Research and Development Research and development expenses are expensed as incurred in accordance with ASC 730, Research and Development. Upfront and milestone payments made to third parties in connection with research and development collaborations are expensed as incurred up to the point of regulatory approval. Payments made to third parties subsequent to regulatory approval are capitalized and amortized over the remaining useful life of the related product. Amounts capitalized for such payments are included in other intangibles, net of accumulated amortization. The Company enters into collaborative arrangements, typically with other pharmaceutical or biotechnology companies, to develop and commercialize drug candidates or intellectual property. These arrangements typically involve two (or more) parties who are active participants in the collaboration and are exposed to significant risks and rewards dependent on the commercial success of the activities. These collaborations usually involve various activities by one or more parties, including research and development, marketing and selling and distribution. Often, these collaborations require upfront, milestone and royalty or profit share payments, contingent upon the occurrence of certain future events linked to the success of the asset in development. Amounts due from collaborative partners related to development activities are generally reflected as a reduction of research and development expense because the performance of contract development services is not central to the Company’s operations. In general, the income statement presentation for these collaborations is as follows: Nature/Type of Collaboration Statement of Earnings Presentation Third-party sale of product & profit share payments received Sales to customers Royalties/milestones paid to collaborative partner (post-regulatory approval)* Cost of products sold Royalties received from collaborative partner Other income (expense), net Upfront payments & milestones paid to collaborative partner (pre-regulatory approval) Research and development expense Research and development payments to collaborative partner Research and development expense Research and development payments received from collaborative partner or government entity Reduction of Research and development expense * Milestones are capitalized as intangible assets and amortized to cost of products sold over the useful life. For all years presented, there was no individual project that represented greater than 5% of the total annual consolidated research and development expense. The Company has a number of products and compounds developed in collaboration with strategic partners including XARELTO ® , co-developed with Bayer HealthCare AG and IMBRUVICA ® , developed in collaboration and co-marketed with Pharmacyclics LLC, an AbbVie company. Separately, the Company has a number of licensing arrangements for products and compounds including DARZALEX ® , licensed from Genmab A/S. Advertising Costs associated with advertising are expensed in the year incurred and are included in selling, marketing and administrative expenses. Advertising expenses worldwide, which comprised television, radio, print media and Internet advertising, were $2.7 billion, $2.1 billion and $2.2 billion in fiscal years 2021, 2020 and 2019, respectively. Income Taxes Income taxes are recorded based on amounts refundable or payable for the current year and include the results of any difference between U.S. GAAP accounting and tax reporting, recorded as deferred tax assets or liabilities. The Company estimates deferred tax assets and liabilities based on enacted tax regulations and rates. Future changes in tax laws and rates may affect recorded deferred tax assets and liabilities in the future. The Company has unrecognized tax benefits for uncertain tax positions. The Company follows U.S. GAAP which prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. Management believes that changes in these estimates would not have a material effect on the Company's results of operations, cash flows or financial position. In 2017, the United States enacted into law new U.S. tax legislation, the U.S. Tax Cuts and Jobs Act (TCJA). This law included provisions for a comprehensive overhaul of the corporate income tax code, including a reduction of the statutory corporate tax rate from 35% to 21%, effective on January 1, 2018. The TCJA included a provision for a tax on all previously undistributed earnings of U.S. companies located in foreign jurisdictions. Undistributed earnings in the form of cash and cash equivalents were taxed at a rate of 15.5% and all other earnings were taxed at a rate of 8.0%. This tax is payable over 8 years and will not accrue interest. These payments began in 2018 and will continue through 2025. The remaining balance at the end of the 2021 was approximately $6.9 billion, of which $6.1 billion is classified as noncurrent and reflected as “Long-term taxes payable” on the Company’s balance sheet. The balance of this account is related to receivables from tax authorities not expected to be received in the next 12 months. The TCJA also includes provisions for a tax on global intangible low-taxed income (GILTI). GILTI is described as the excess of a U.S. shareholder’s total net foreign income over a deemed return on tangible assets, as provided by the TCJA. In January 2018, the FASB issued guidance that allows companies to elect as an accounting policy whether to record the tax effects of GILTI in the period the tax liability is generated (i.e., “period cost”) or provide for deferred tax assets and liabilities related to basis differences that exist and are expected to effect the amount of GILTI inclusion in future years upon reversal (i.e., “deferred method”). The Company has elected to account for GILTI under the deferred method. The deferred tax amounts recorded are based on the evaluation of temporary differences that are expected to reverse as GILTI is incurred in future periods. The Company has recorded deferred tax liabilities on all undistributed earnings prior to December 31, 2017 from its international subsidiaries. The Company has not provided deferred taxes on the undistributed earnings subsequent to January 1, 2018 from certain international subsidiaries where the earnings are considered to be indefinitely reinvested. The Company intends to continue to reinvest these earnings in those international operations. If the Company decides at a later date to repatriate these earnings to the U.S., the Company would be required to provide for the net tax effects on these amounts. The Company estimates that the tax effect of this repatriation would be approximately $0.7 billion under currently enacted tax laws and regulations and at current currency exchange rates. This amount does not include the possible benefit of U.S. foreign tax credits, which may substantially offset this cost. See Note 8 to the Consolidated Financial Statements for further information regarding income taxes. Net Earnings Per Share Basic earnings per share is computed by dividing net earnings available to common shareholders by the weighted average number of common shares outstanding for the period. Diluted earnings per share reflects the potential dilution that could occur if securities were exercised or converted into common stock using the treasury stock method. Use of Estimates The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the U.S. requires management to make estimates and assumptions that affect the amounts reported. Estimates are used when accounting for sales discounts, rebates, allowances and incentives, product liabilities, income taxes, withholding taxes, depreciation, amortization, employee benefits, contingencies and intangible asset and liability valuations. Actual results may or may not differ from those estimates. The Company follows the provisions of U.S. GAAP when recording litigation related contingencies. A liability is recorded when a loss is probable and can be reasonably estimated. The best estimate of a loss within a range is accrued; however, if no estimate in the range is better than any other, the minimum amount is accrued. The extent to which COVID-19 impacts the Company’s business and financial results will depend on numerous evolving factors including, but not limited to: the magnitude and duration of COVID-19, the extent to which it will impact worldwide macroeconomic conditions including interest rates, employment rates and health insurance coverage, the speed of the anticipated recovery, and governmental and business reactions to the pandemic. The Company assessed certain accounting matters that generally require consideration of forecasted financial information in context with the information reasonably available to the Company and the unknown future impacts of COVID-19 as of January 2, 2022 and through the date of this report. The accounting matters assessed included, but were not limited to, the Company’s allowance for doubtful accounts and credit losses, inventory and related reserves, accrued rebates and associated reserves, and the carrying value of the goodwill and other long-lived assets along with the Company’s on-going vaccine development and distribution efforts. While there was not a material impact to the Company’s consolidated financial statements as of and for the fiscal year ended January 2, 2022, the Company’s future assessment of the magnitude and duration of COVID-19, as well as other factors, could result in material impacts to the Company’s consolidated financial statements in future reporting periods. Annual Closing Date The Company follows the concept of a fiscal year, which ends on the Sunday nearest to the end of the month of December. Normally each fiscal year consists of 52 weeks, but every five or six years the fiscal year consists of 53 weeks, and therefore includes additional shipping days, as was the case in fiscal year 2020, and will be the case again in fiscal year 2026. Reclassification Certain prior period amounts have been reclassified to conform to current year presentation.

Cash, Cash Equivalents and Curr

Cash, Cash Equivalents and Current Marketable Securities	12 Months Ended
Cash, Cash Equivalents and Current Marketable Securities	Jan. 02, 2022
Cash and Cash Equivalents [Abstract]
Cash, Cash Equivalents and Current Marketable Securities	Cash, Cash Equivalents and Current Marketable Securities At the end of the fiscal year 2021 and 2020, cash, cash equivalents and current marketable securities were comprised of: (Dollars in Millions) 2021 Carrying Amount Unrecognized Loss Estimated Fair Value Cash & Cash Equivalents Current Marketable Securities Cash $ 2,936 — 2,936 2,936 — Non-U.S. Sovereign Securities (1) 1,006 — 1,006 90 916 U.S. Reverse repurchase agreements 1,659 — 1,659 1,659 — Corporate debt securities (1) 3,479 (1) 3,478 200 3,279 Money market funds 1,901 — 1,901 1,901 — Time deposits (1) 900 — 900 900 — Subtotal $ 11,881 (1) 11,880 7,686 4,195 U.S. Gov't Securities $ 19,485 (4) 19,481 6,785 12,696 Other Sovereign Securities 1 — 1 1 — Corporate debt securities 245 — 245 15 230 Subtotal available for sale (2) $ 19,731 (4) 19,727 6,801 12,926 Total cash, cash equivalents and current marketable securities $ 14,487 17,121 (Dollars in Millions) 2020 Carrying Amount Unrecognized Gain Estimated Fair Value Cash & Cash Equivalents Current Marketable Securities Cash $ 2,863 — 2,863 2,863 — Non-U.S. Sovereign Securities (1) 690 — 690 — 690 U.S. Reverse repurchase agreements 1,937 — 1,937 1,937 — Corporate debt securities (1) 2,674 — 2,674 1,451 1,223 Money market funds 2,102 — 2,102 2,102 — Time deposits (1) 877 — 877 877 — Subtotal $ 11,143 — 11,143 9,230 1,913 Gov't Securities $ 13,777 1 13,778 4,731 9,047 Other Sovereign Securities 14 — 14 — 14 Corporate debt securities 250 — 250 24 226 Subtotal available for sale (2) $ 14,041 1 14,042 4,755 9,287 Total cash, cash equivalents and current marketable securities $ 13,985 11,200 (1) Held to maturity investments are reported at amortized cost and realized gains or losses are reported in earnings. (2) Available for sale debt securities are reported at fair value with unrealized gains and losses reported net of taxes in other comprehensive income. Fair value of government securities and obligations and corporate debt securities were estimated using quoted broker prices and significant other observable inputs. The contractual maturities of the available for sale debt securities at January 2, 2022 are as follows: (Dollars in Millions) Cost Basis Fair Value Due within one year $ 19,709 19,705 Due after one year through five years 22 22 Due after five years through ten years — — Total debt securities $ 19,731 19,727 The Company invests its excess cash in both deposits with major banks throughout the world and other high-quality money market instruments. The Company has a policy of making investments only with commercial institutions that have at least an investment grade credit rating.

Inventories

Inventories	12 Months Ended
Inventories	Jan. 02, 2022
Inventory Disclosure [Abstract]
Inventories	Inventories At the end of fiscal years 2021 and 2020, inventories were comprised of: (Dollars in Millions) 2021 2020 Raw materials and supplies $ 1,592 1,410 Goods in process 2,287 2,040 Finished goods 6,508 5,894 Total inventories $ 10,387 9,344

Property, Plant and Equipment

Property, Plant and Equipment	12 Months Ended
Property, Plant and Equipment	Jan. 02, 2022
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment	Property, Plant and Equipment At the end of fiscal years 2021 and 2020, property, plant and equipment at cost and accumulated depreciation were: (Dollars in Millions) 2021 2020 Land and land improvements $ 884 882 Buildings and building equipment 12,882 12,502 Machinery and equipment 29,774 29,104 Construction in progress 4,139 4,316 Total property, plant and equipment, gross $ 47,679 46,804 Less accumulated depreciation 28,717 28,038 Total property, plant and equipment, net (1) $ 18,962 18,766 The Company capitalizes interest expense as part of the cost of construction of facilities and equipment. Interest expense capitalized in fiscal years 2021, 2020 and 2019 was $49 million, $63 million and $70 million, respectively. Depreciation expense, including the amortization of capitalized interest in fiscal years 2021, 2020 and 2019 was $2.7 billion, $2.6 billion and $2.5 billion, respectively. Upon retirement or other disposal of property, plant and equipment, the costs and related amounts of accumulated depreciation or amortization are eliminated from the asset and accumulated depreciation accounts, respectively. The difference, if any, between the net asset value and the proceeds are recorded in earnings.

Intangible Assets and Goodwill

Intangible Assets and Goodwill	12 Months Ended
Intangible Assets and Goodwill	Jan. 02, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets and Goodwill	Intangible Assets and Goodwill At the end of fiscal years 2021 and 2020, the gross and net amounts of intangible assets were: (Dollars in Millions) 2021 2020 Intangible assets with definite lives: Patents and trademarks — gross $ 38,572 39,990 Less accumulated amortization (20,088) (17,618) Patents and trademarks — net $ 18,484 22,372 Customer relationships and other intangibles — gross $ 23,011 22,898 Less accumulated amortization (11,925) (10,912) Customer relationships and other intangibles — net (1) $ 11,086 11,986 Intangible assets with indefinite lives: Trademarks $ 6,985 7,195 Purchased in-process research and development (2) 9,837 11,849 Total intangible assets with indefinite lives $ 16,822 19,044 Total intangible assets — net $ 46,392 53,402 (1) The majority is comprised of customer relationships (2) In fiscal 2021, the Company recorded a partial IPR&D impairment charge of $0.9 billion primarily related to expected development delays in the general surgery digital robotics platform (Ottava) acquired with the Auris Health acquisition in 2019. The impairment charge was calculated based on revisions to the discounted cash flow valuation model reflecting a delay of first in human procedures of approximately two years from the initial acquisition model assumption of the second half of 2022. The remaining reduction was driven by assets that reached commercialization and are now classified as having definite lives. Goodwill as of January 2, 2022 and January 3, 2021, as allocated by segment of business, was as follows: (Dollars in Millions) Consumer Health Pharmaceutical Medical Devices Total Goodwill at December 29, 2019 $ 9,736 9,169 14,734 33,639 Goodwill, related to acquisitions — 1,222 238 1,460 Currency translation/other 600 618 76 1,294 Goodwill at January 3, 2021 $ 10,336 11,009 15,048 36,393 Goodwill, related to acquisitions — — — — Goodwill, related to divestitures (9) — — (9) Currency translation/other (517) (429) (192) (1,138) Goodwill at January 2, 2022 $ 9,810 10,580 14,856 35,246 The weighted average amortization period for patents and trademarks is 12 years. The weighted average amortization period for customer relationships and other intangible assets is 21 years. The amortization expense of amortizable assets included in Cost of products sold was $4.7 billion, $4.7 billion and $4.5 billion before tax, for the fiscal years ended January 2, 2022, January 3, 2021 and December 29, 2019, respectively. Intangible asset write-downs are included in Other (income) expense, net. The estimated amortization expense for approved products, before tax, for the five succeeding years is approximately: (Dollars in Millions) 2022 2023 2024 2025 2026 $4,600 4,600 4,400 3,600 3,000 See Note 18 to the Consolidated Financial Statements for additional details related to acquisitions and divestitures.

Fair Value Measurements

Fair Value Measurements	12 Months Ended
Fair Value Measurements	Jan. 02, 2022
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements The Company uses forward foreign exchange contracts to manage its exposure to the variability of cash flows, primarily related to the foreign exchange rate changes of future intercompany products and third-party purchases of materials denominated in a foreign currency. The Company uses cross currency interest rate swaps to manage currency risk primarily related to borrowings. Both types of derivatives are designated as cash flow hedges. Additionally, the Company uses interest rate swaps as an instrument to manage interest rate risk related to fixed rate borrowings. These derivatives are designated as fair value hedges. The Company uses cross currency interest rate swaps and forward foreign exchange contracts designated as net investment hedges. Additionally, the Company uses forward foreign exchange contracts to offset its exposure to certain foreign currency assets and liabilities. These forward foreign exchange contracts are not designated as hedges and therefore, changes in the fair values of these derivatives are recognized in earnings, thereby offsetting the current earnings effect of the related foreign currency assets and liabilities. The Company does not enter into derivative financial instruments for trading or speculative purposes, or that contain credit risk related contingent features. The Company maintains credit support agreements (CSA) with certain derivative counterparties establishing collateral thresholds based on respective credit ratings and netting agreements. As of January 2, 2022, the total amount of cash collateral paid by the Company under the CSA amounted to $570 million net, related to net investment and cash flow hedges. On an ongoing basis, the Company monitors counter-party credit ratings. The Company considers credit non-performance risk to be low, because the Company primarily enters into agreements with commercial institutions that have at least an investment grade credit rating. Refer to the table on significant financial assets and liabilities measured at fair value contained in this footnote for receivables and payables with these commercial institutions. As of January 2, 2022, the Company had notional amounts outstanding for forward foreign exchange contracts, cross currency interest rate swaps and interest rate swaps of $45.8 billion, $37.4 billion and $10.0 billion, respectively. As of January 3, 2021, the Company had notional amounts outstanding for forward foreign exchange contracts and cross currency interest rate swaps of $37.8 billion and $30.6 billion, respectively. All derivative instruments are recorded on the balance sheet at fair value. Changes in the fair value of derivatives are recorded each period in current earnings or other comprehensive income, depending on whether the derivative is designated as part of a hedge transaction, and if so, the type of hedge transaction. The designation as a cash flow hedge is made at the entrance date of the derivative contract. At inception, all derivatives are expected to be highly effective. Foreign exchange contracts designated as cash flow hedges are accounted for under the forward method and all gains/losses associated with these contracts will be recognized in the income statement when the hedged item impacts earnings. Changes in the fair value of these derivatives are recorded in accumulated other comprehensive income until the underlying transaction affects earnings, and are then reclassified to earnings in the same account as the hedged transaction. Gains and losses associated with interest rate swaps and changes in fair value of hedged debt attributable to changes in interest rates are recorded to interest expense in the period in which they occur. Gains and losses on net investment hedge are accounted through the currency translation account within accumulated other comprehensive income. The portion excluded from effectiveness testing is recorded through interest (income) expense using the spot method. On an ongoing basis, the Company assesses whether each derivative continues to be highly effective in offsetting changes of hedged items. If and when a derivative is no longer expected to be highly effective, hedge accounting is discontinued. The Company designated its Euro denominated notes issued in May 2016 with due dates ranging from 2022 to 2035 as a net investment hedge of the Company's investments in certain of its international subsidiaries that use the Euro as their functional currency in order to reduce the volatility caused by changes in exchange rates. As of January 2, 2022, the balance of deferred net loss on derivatives included in accumulated other comprehensive income was $336 million after-tax. For additional information, see the Consolidated Statements of Comprehensive Income and Note 13. The Company expects that substantially all of the amounts related to forward foreign exchange contracts will be reclassified into earnings over the next 12 months as a result of transactions that are expected to occur over that period. The maximum length of time over which the Company is hedging transaction exposure is 18 months, excluding interest rate contracts and net investment hedges. The amount ultimately realized in earnings may differ as foreign exchange rates change. Realized gains and losses are ultimately determined by actual exchange rates at maturity of the derivative. The following table is a summary of the activity related to derivatives and hedges for the fiscal years ended January 2, 2022 and January 3, 2021, net of tax: January 2, 2022 January 3, 2021 (Dollars in Millions) Sales Cost of Products Sold R&D Expense Interest (Income) Expense Other (Income) Expense Sales Cost of Products Sold R&D Expense Interest (Income) Expense Other (Income) Expense The effects of fair value, net investment and cash flow hedging: Gain (Loss) on fair value hedging relationship: Interest rate swaps contracts: Hedged items $ — — — (109) — — — — — — Derivatives designated as hedging instruments — — — 109 — — — — — — Gain (Loss) on net investment hedging relationship: Cross currency interest rate swaps contracts: Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing $ — — — 174 — — — — 153 — Amount of gain or (loss) recognized in AOCI — — — 174 — — — — 153 — Gain (Loss) on cash flow hedging relationship: Forward foreign exchange contracts: Amount of gain or (loss) reclassified from AOCI into income 17 119 30 — 47 12 (329) (137) — (16) Amount of gain or (loss) recognized in AOCI (94) (557) 123 — 146 44 298 (91) — (52) Cross currency interest rate swaps contracts: Amount of gain or (loss) reclassified from AOCI into income — — — 402 — — — — 370 — Amount of gain or (loss) recognized in AOCI $ — — — 9 — — — — 748 — As of January 2, 2022 and January 3, 2021, the following amounts were recorded on the consolidated balance sheet related to cumulative basis adjustment for fair value hedges Line item in the Consolidated Balance Sheet in which the hedged item is included Carrying Amount of the Hedged Liability Cumulative Amount of Fair Value Hedging Adjustment Included in the Carrying Amount of the Hedged Liability (Dollars in Millions) January 2, 2022 January 3, 2021 January 2, 2022 January 3, 2021 Long-term Debt $ 9,793 $ — $ (142) $ — The following table is the effect of derivatives not designated as hedging instrument for the fiscal years ended January 2, 2022 and January 3, 2021: (Dollars in Millions) Location of Gain /(Loss) Recognized in Income on Derivative Gain/(Loss) Derivatives Not Designated as Hedging Instruments January 2, 2022 January 3, 2021 Foreign Exchange Contracts Other (income) expense $ (70) 24 The following table is the effect of net investment hedges for the fiscal years ended January 2, 2022 and January 3, 2021: Gain/(Loss) Location of Gain or (Loss) Reclassified from Accumulated Other Comprehensive Income Into Income Gain/(Loss) Reclassified From (Dollars in Millions) January 2, 2022 January 3, 2021 January 2, 2022 January 3, 2021 Debt $ 387 (473) Interest (income) expense — — Cross Currency interest rate swaps $ 548 65 Interest (income) expense — — The Company holds equity investments with readily determinable fair values and equity investments without readily determinable fair values. The Company measures equity investments that do not have readily determinable fair values at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer. The following table is a summary of the activity related to equity investments for the fiscal years ended January 2, 2022 and January 3, 2021: January 3, 2021 January 2, 2022 (Dollars in Millions) Carrying Value Changes in Fair Value Reflected in Net Income (1) Sales/ Purchases/Other (2) Carrying Value Non Current Other Assets Equity Investments with readily determinable value $ 1,481 198 205 1,884 1,884 Equity Investments without readily determinable value $ 738 394 (632) 500 500 December 29, 2019 January 3, 2021 (Dollars in Millions) Carrying Value Changes in Fair Value Reflected in Net Income (1) Sales/ Purchases/Other (2) Carrying Value Non Current Other Assets Equity Investments with readily determinable value $ 1,148 527 (194) 1,481 1,481 Equity Investments without readily determinable value $ 712 (55) 81 738 738 (1) Recorded in Other Income/Expense (2) Other includes impact of currency For the fiscal years ended January 2, 2022 and January 3, 2021 for equity investments without readily determinable market values, $28 million and $76 million, respectively, of the changes in fair value reflected in net income were the result of impairments. There were offsetting impacts of $422 million and $21 million, respectively, of changes in fair value reflected in net income due to changes in observable prices and gains on the disposal of investments. The impact in fiscal 2021 was driven by the gain on disposal of the Grail investment. Fair value is the exit price that would be received to sell an asset or paid to transfer a liability. Fair value is a market-based measurement determined using assumptions that market participants would use in pricing an asset or liability. In accordance with ASC 820, a three-level hierarchy to prioritize the inputs used in measuring fair value. The levels within the hierarchy are described below with Level 1 having the highest priority and Level 3 having the lowest. The fair value of a derivative financial instrument (i.e., forward foreign exchange contracts, interest rate contracts) is the aggregation by currency of all future cash flows discounted to its present value at the prevailing market interest rates and subsequently converted to the U.S. Dollar at the current spot foreign exchange rate. The Company does not believe that fair values of these derivative instruments materially differ from the amounts that could be realized upon settlement or maturity, or that the changes in fair value will have a material effect on the Company’s results of operations, cash flows or financial position. The Company also holds equity investments which are classified as Level 1 and debt securities which are classified as Level 2. The Company holds acquisition related contingent liabilities based upon certain regulatory and commercial events, which are classified as Level 3, whose values are determined using discounted cash flow methodologies or similar techniques for which the determination of fair value requires significant judgment or estimations. The following three levels of inputs are used to measure fair value: Level 1 — Quoted prices in active markets for identical assets and liabilities. Level 2 — Significant other observable inputs. Level 3 — Significant unobservable inputs. The Company’s significant financial assets and liabilities measured at fair value as of the fiscal year ended January 2, 2022 and January 3, 2021 were as follows: 2021 2020 (Dollars in Millions) Level 1 Level 2 Level 3 Total Total (1) Derivatives designated as hedging instruments: Assets: Forward foreign exchange contracts $ — 540 — 540 849 Interest rate contracts (2) — 796 — 796 240 Total $ — 1,336 — 1,336 1,089 Liabilities: Forward foreign exchange contracts — 881 — 881 702 Interest rate contracts (2) — 979 — 979 1,569 Total $ — 1,860 — 1,860 2,271 Derivatives not designated as hedging instruments: Assets: Forward foreign exchange contracts $ — 24 — 24 49 Liabilities: Forward foreign exchange contracts — 28 — 28 38 Available For Sale Other Investments: Equity investments (3) 1,884 — — 1,884 1,481 Debt securities (4) — 19,727 — 19,727 14,042 Other Liabilities Contingent Consideration (5) $ 533 533 633 Gross to Net Derivative Reconciliation 2021 2020 (Dollars in Millions) Total Gross Assets $ 1,360 1,138 Credit Support Agreement (CSA) (1,285) (1,107) Total Net Asset 75 31 Total Gross Liabilities 1,888 2,309 Credit Support Agreement (CSA) (1,855) (2,172) Total Net Liabilities $ 33 137 Summarized information about changes in liabilities for contingent consideration is as follows: 2021 2020 2019 (Dollars in Millions) Beginning Balance $ 633 1,715 397 Changes in estimated fair value (6) (52) (1,089) 151 Additions — 106 1,246 Payments (48) (99) (79) Ending Balance $ 533 633 1,715 (1) 2020 assets and liabilities are all classified as Level 2 with the exception of equity investments of $1,481 million, which are classified as Level 1 and contingent consideration of $633 million, classified as Level 3. (2) Includes cross currency interest rate swaps and interest rate swaps. (3) Classified as non-current other assets. (4) Classified as cash equivalents and current marketable securities. (5) Includes $520 million, $594 million and $1,631 million, classified as non-current other liabilities as of January 2, 2022, January 3, 2021 and December 29, 2019, respectively. Includes $13 million, $39 million and $84 million classified as current liabilities as of January 2, 2022, January 3, 2021 and December 29, 2019, respectively. (6) Ongoing fair value adjustment amounts are recorded primarily in Research and Development expense. The Company recorded a contingent consideration reversal of $1,148 million in 2020 related to the timing of certain developmental milestones associated with the Auris Health acquisition. The reversal of the contingent consideration was recorded in Other income and expense. See Notes 2 and 7 for financial assets and liabilities held at carrying amount on the Consolidated Balance Sheet.

Borrowings

Borrowings	12 Months Ended
Borrowings	Jan. 02, 2022
Debt Disclosure [Abstract]
Borrowings	Borrowings The components of long-term debt are as follows: (Dollars in Millions) 2021 Effective Rate % 2020 Effective Rate % 3.55% Notes due 2021 $ — — % $ 450 3.67 % 2.45% Notes due 2021 — — 350 2.48 1.65% Notes due 2021 — — 999 1.65 0.250% Notes due 2022 (1B Euro 1.1311) (2) /(1B Euro 1.2281) (3) 1,131 (2) 0.26 1,227 (3) 0.26 2.25% Notes due 2022 1,000 2.31 999 2.31 6.73% Debentures due 2023 250 6.73 250 6.73 3.375% Notes due 2023 802 3.18 803 3.17 2.05% Notes due 2023 499 2.09 499 2.09 0.650% Notes due 2024 (750MM Euro 1.1311) (2) /(750MM Euro 1.2281) (3) 847 (2) 0.68 919 (3) 0.68 5.50% Notes due 2024 (500MM 1.3485 GBP ) (2) /(500MM GBP 1.3654) (3) 672 (2) 6.75 679 (3) 6.75 2.625% Notes due 2025 749 2.63 748 2.63 0.55% Notes due 2025 983 0.57 996 0.57 2.45% Notes due 2026 1,995 2.47 1,994 2.47 2.95% Notes due 2027 978 2.96 997 2.96 0.95% Notes due 2027 1,478 0.96 1,494 0.96 1.150% Notes due 2028 (750MM Euro 1.1311) (2) /(750MM Euro 1.2281) (3) 843 (2) 1.21 915 (3) 1.21 2.90% Notes due 2028 1,495 2.91 1,495 2.91 6.95% Notes due 2029 298 7.14 297 7.14 1.30% Notes due 2030 1,723 1.30 1,743 1.30 4.95% Debentures due 2033 498 4.95 498 4.95 4.375% Notes due 2033 854 4.24 855 4.24 1.650% Notes due 2035 (1.5B Euro 1.1311) (2) /(1.5B Euro 1.2281) (3) 1,683 (2) 1.68 1,827 (3) 1.68 3.55% Notes due 2036 974 3.59 989 3.59 5.95% Notes due 2037 993 5.99 992 5.99 3.625% Notes due 2037 1,475 3.64 1,488 3.64 5.85% Debentures due 2038 696 5.85 696 5.85 3.400% Notes due 2038 992 3.42 991 3.42 4.50% Debentures due 2040 540 4.63 539 4.63 2.10% Notes due 2040 974 2.14 986 2.14 4.85% Notes due 2041 297 4.89 297 4.89 4.50% Notes due 2043 496 4.52 496 4.52 3.70% Notes due 2046 1,975 3.74 1,974 3.74 3.75% Notes due 2047 971 3.76 991 3.76 3.500% Notes due 2048 743 3.52 742 3.52 2.250% Notes due 2050 983 2.29 984 2.29 2.450% Notes due 2060 1,222 2.49 1,228 2.49 Other 7 — 7 — Subtotal 32,116 (4) 2.89 % (1) 34,434 (4) 2.85 % (1) Less current portion 2,131 1,799 Total long-term debt $ 29,985 $ 32,635 (1) Weighted average effective rate. (2) Translation rate at January 2, 2022. (3) Translation rate at January 3, 2021. (4) The excess of the fair value over the carrying value of debt was $3.2 billion at the end of fiscal year 2021 and $5.4 billion at the end of fiscal year 2020. Fair value of the long-term debt was estimated using market prices, which were corroborated by quoted broker prices and significant other observable inputs. The Company has access to substantial sources of funds at numerous banks worldwide. In September 2021, the Company secured a new 364-day Credit Facility. Total credit available to the Company approximates $10 billion, which expires on September 8, 2022. Interest charged on borrowings under the credit line agreement is based on either the Term SOFR Reference Rate or other applicable market rates as allowed under the terms of the agreement, plus applicable margins. Commitment fees under the agreements are not material. Throughout fiscal years 2021 and 2020, the Company continued to have access to liquidity through the commercial paper market. Short-term borrowings and the current portion of long-term debt amounted to approximately $3.8 billion and $2.6 billion at the end of fiscal years 2021 and 2020, respectively. The current portion of the long term debt was $2.1 billion and $1.8 billion in 2021 and 2020, respectively, and the remainder is commercial paper and local borrowing by international subsidiaries. The current debt balance as of January 2, 2022 includes $1.6 billion of commercial paper which has a weighted average interest rate of 0.11% and a weighted average maturity of approximately three months. Aggregate maturities of long-term debt obligations commencing in 2022 are: (Dollars in Millions) 2022 2023 2024 2025 2026 After 2026 $2,131 1,551 1,518 1,732 1,995 23,189

Income Taxes

Income Taxes	12 Months Ended
Income Taxes	Jan. 03, 2021
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes The provision for taxes on income consists of: (Dollars in Millions) 2021 2020 2019 Currently payable: U.S. taxes $ 1,525 1,026 1,941 International taxes 2,452 1,898 2,744 Total currently payable 3,977 2,924 4,685 Deferred: U.S. taxes 583 (76) (814) International taxes (2,662) (1,065) (1,662) Total deferred (2,079) (1,141) (2,476) Provision for taxes on income $ 1,898 1,783 2,209 A comparison of income tax expense at the U.S. statutory rate of 21% in fiscal years 2021, 2020 and 2019, to the Company’s effective tax rate is as follows: (Dollars in Millions) 2021 2020 2019 U.S. $ 6,110 4,312 3,543 International 16,666 12,185 13,785 Earnings before taxes on income: $ 22,776 16,497 17,328 Tax rates: U.S. statutory rate 21.0 % 21.0 21.0 International operations (1) (16.4) (9.9) (5.9) U.S. taxes on international income (2) 6.7 2.7 1.8 Tax benefits from loss on capital assets (1.3) (1.2) (0.3) Tax benefits on share-based compensation (1.0) (1.5) (0.5) TCJA and related impacts (0.5) 0.7 (3.9) (3) All other (0.2) (1.0) 0.5 Effective Rate 8.3 % 10.8 12.7 (1) For all periods presented the Company has subsidiaries operating in Puerto Rico under various tax incentives. International operations reflects the impacts of operations in jurisdictions with statutory tax rates different than the U.S., particularly Ireland, Switzerland and Puerto Rico, which is a favorable impact on the effective tax rate as compared with the U.S. statutory rate. The 2021 amounts include the reorganization of international subsidiaries; the 2020 and 2019 amounts include the impact of the new tax legislation enactment in Switzerland, both of which are further described below. (2) Includes the impact of the GILTI tax, the Foreign-Derived Intangible Income deduction and other foreign income that is taxable under the U.S. tax code. The 2021 amounts include the reorganization of international subsidiaries; the 2020 and 2019 amounts include the impact of the new tax legislation enactment in Switzerland, both of which is further described below. (3) Represents impact of adjustments to balances originally recorded as part of the 2017 TCJA provisional tax charge. Further information provided below. The fiscal year 2021 tax rate decreased by 2.5% compared to the fiscal year 2020 tax rate, which was primarily driven by the following items. In fiscal year 2021, the Company reorganized the ownership structure of certain wholly-owned international subsidiaries. As part of this reorganization, the Company increased the tax basis of certain assets to fair value in accordance with applicable local regulations. The net impact of this restructuring was approximately $0.6 billion net benefit or 2.7% benefit to the Company’s annual effective tax rate, comprised of the following items: • approximately $2.3 billion of local deferred tax assets to record the remeasurement of the tax basis of these assets to fair value, this benefit has been reflected as “International Operations” on the Company’s effective tax rate reconciliation. • approximately $1.7 billion of U.S. deferred tax expense relating to the GILTI deferred tax liability resulting from the remeasurement of these deferred tax assets. This expense has been reflected as “U.S. tax on international income” on the Company’s effective tax rate reconciliation. Also, in the fiscal fourth quarter of 2021, the Company recognized a loss on certain U.S. affiliates related to the previously impaired book value of certain intangibles, which reduced the 2021 tax rate by approximately 1.3% which is reflected as a “Tax benefits from loss on capital assets” on the effective tax rate reconciliation. Additionally other fiscal 2021 impacts to the rate were primarily driven by litigation and acquisition related items as follows: • the Company accrued additional legal expenses, of approximately $1.6 billion for talc at an effective tax rate of 23.5% and $0.8 billion for Risperdal settlements at an effective tax rate of 16.4% (See Note 19 to the Consolidated Financial Statements for more details). • the Company recorded a partial IPR&D charge of $0.9 billion for the Ottava intangible asset (acquired with the Auris Health acquisition in 2019) at an effective rate of 22.4% (See Notes 5 and 18 to the Consolidated Financial Statements for more details). The fiscal year 2020 tax rate decreased by 1.9% compared to the fiscal year 2019 tax rate. which was primarily driven by the following items. In fiscal year 2019, Switzerland enacted the Federal Act on Tax Reform and AHV Financing (TRAF) which became effective on January 1, 2020. The Federal transitional provisions of TRAF allow companies, under certain conditions, to adjust the tax basis in certain assets to fair value (i.e., “step-up”) to be depreciated and amortized resulting in an incremental Swiss tax deduction over the transitional period. TRAF also provides for parameters which enable the Swiss cantons to establish localized tax rates and regulations for companies. The new cantonal tax parameters include favorable tax benefits for patents and additional research and development tax deductions. The cantonal transitional provisions of TRAF allowed companies to elect either 1) tax basis step-up similar to the Federal transition benefit or 2) alternative statutory tax rate for a period not to exceed 5 years. The Company currently has operations located in various Swiss cantons. During the fiscal year 2019, as described in further detail below, the Company recorded the impacts of the TRAF that were enacted in that period. During the fiscal year 2020, the final canton where the Company maintains significant operations enacted TRAF legislation. Additionally, the Company received rulings from the Swiss Federal and cantonal tax authorities in the remaining jurisdictions where it has significant operations. These rulings resulted in the Company revising its estimate on the tax basis adjustment (i.e., “step-up”) for its assets and as a result, the Company recorded additional deferred tax benefits in 2020. The Company recognized a net benefit in the fiscal year 2020 for Swiss Tax Reform of approximately $0.4 billion or 2.6% benefit to the Company’s annual effective tax rate, comprised of the following items: • approximately $0.3 billion tax benefit relating to the remeasurement of Swiss deferred tax assets and liabilities for the change in the Federal and cantonal tax rates, where enactment occurred in the fiscal year 2020; this benefit has been reflected as “International Operations” on the Company’s effective tax rate reconciliation. • a $450 million deferred tax asset related to the estimated value of a Federal tax basis step-up of the Company’s Swiss subsidiaries’ assets as described above; this benefit has been reflected as “International Operations” on the Company’s effective tax rate reconciliation. • approximately $0.3 billion of U.S. deferred tax expense relating to the GILTI deferred tax liability resulting from the remeasurement of the Swiss deferred tax assets and liabilities in the fiscal year 2020. This benefit has been reflected as “U.S. tax on international income” on the Company’s effective tax rate reconciliation. The Company does not expect to receive future rulings regarding the transitional provisions of TRAF. Also, in the fiscal year 2020, the Company recognized a capital loss on certain U.S. affiliates related to the previously impaired book value of certain intangibles, which reduced the 2020 tax rate by approximately 1.2% which is reflected as a “Tax benefits from loss on capital assets” on the effective tax rate reconciliation. In addition, in the fiscal year 2020, the Company had lower income in higher tax jurisdictions, primarily driven by: • the impact of the accrual of litigation costs related to talc for $4.0 billion which reduced the U.S. earnings before taxes at an effective tax rate of 23.5%; • the accrual of additional legal costs, including an additional $1.0 billion associated with a revised agreement in principle to settle opioid litigation at an effective tax rate of 21.4% The Company also reduced the contingent consideration liability related to the Auris Health acquisition (see Note 18) and reversed of some of its unrecognized tax benefits due to the completion of several years of tax examinations in certain jurisdictions during the fiscal year 2020. In fiscal year 2019, the Company reorganized the ownership structure of certain wholly-owned international subsidiaries in the fiscal fourth quarter of 2019, which resulted in a reduction of certain withholding and local taxes that it had previously recognized as part of the provisional Tax Cuts and Jobs Act (TCJA) tax charge in the fiscal year 2017 and finalized in the fiscal year 2018. Following the completion of this restructuring and approval by the applicable local authorities, the Company reversed a deferred tax liability of $0.6 billion and a related deferred tax asset of $0.2 billion for U.S. foreign tax credits, for a net deferred tax benefit of $0.4 billion decreasing the annual effective tax rate by 2.2%. This benefit has been reflected as “TCJA and related impacts” on the Company’s effective tax rate reconciliation. The following items also impacted the fiscal year 2019 effective tax rate: • The impact of the agreement in principle to settle opioid litigation for $4 billion (see Note 19 to the Consolidated Financial Statements) which reduced the U.S. earnings before taxes at an effective tax rate of 23.5% and decreased the Company’s annual effective tax rate by approximately 2.1%. • In December of fiscal year 2019, the U.S. Treasury issued final foreign tax credit regulations, which resulted in the Company revising the amount of foreign tax credits that were initially recorded in the fiscal year 2017 as part of the provisional TCJA tax charge. As a result, the Company recorded an increased deferred tax asset related to these foreign tax credits of approximately $0.3 billion or 1.7% to the annual effective tax rate. This benefit has been reflected as “TCJA and related impacts” on the Company’s effective tax rate reconciliation. • The Company reassessed its uncertain tax positions related to the current IRS audit and increased its unrecognized tax benefit by $0.3 billion liability which increased the annual effective tax rate by approximately 1.5% (see section on Unrecognized Tax Benefits for additional information). As these positions were related to uncertain tax regarding international transfer pricing, this expense has been classified as “International Operations” on the Company’s effective tax rate reconciliation. As described above for the Swiss tax legislation, in the fiscal year 2019, the Company recorded a net tax expense of $0.1 billion which increased the effective tax rate for the fiscal year 2019 by approximately 0.6%. This net tax expense related to federal and certain cantonal enactments in the fiscal year 2019 consisting of the following provisions: • approximately $0.6 billion tax expense relating to the remeasurement of Swiss deferred tax assets and liabilities for the change in the Federal and cantonal tax rates, where enactment occurred by December 29, 2019; this expense has been reflected as “International Operations” on the Company’s effective tax rate reconciliation. • a $0.9 billion deferred tax asset related to the estimated value of a Federal tax basis step-up of the Company’s Swiss subsidiaries’ assets; this benefit has been reflected as “International Operations” on the Company’s effective tax rate reconciliation. • approximately $450 million of U.S. deferred tax expense relating to the GILTI deferred tax liability resulting from the remeasurement of the Swiss deferred tax assets and liabilities and the new deferred tax asset for the Federal step-up. This benefit has been reflected as “U.S. tax on international income” on the Company’s effective tax rate reconciliation. Temporary differences and carryforwards at the end of fiscal years 2021 and 2020 were as follows: 2021 Deferred Tax 2020 Deferred Tax (1) (Dollars in Millions) Asset Liability Asset Liability Employee related obligations $ 1,244 2,434 Stock based compensation 679 627 Depreciation of property, plant and equipment (876) (823) Goodwill and intangibles (2,659) (2) (5,023) R&D capitalized for tax 1,664 1,517 Reserves & liabilities 2,882 3,466 Income reported for tax purposes 2,566 1,777 Net realizable operating loss carryforward 1,073 990 Undistributed foreign earnings 1,015 (1,461) 812 (1,435) Global intangible low-taxed income (4,853) (3,606) Miscellaneous international 1,006 (39) 854 (211) Miscellaneous U.S. 495 (59) Total deferred income taxes $ 12,624 (9,888) 12,477 (11,157) ( 1) Certain prior year amounts have been reclassified to conform to current year presentation (2) Amount is inclusive of the $2.3 billion deferred tax asset established as part of the reorganized ownership structure of certain wholly-owned international subsidiaries, as previously described. The Company has wholly-owned international subsidiaries that have cumulative net losses. The Company believes that it is more likely than not that these subsidiaries will generate future taxable income sufficient to utilize these deferred tax assets. However, in certain jurisdictions, valuation allowances have been recorded against deferred tax assets for loss carryforwards that are not more likely than not to be realized. Such valuation allowances are not material. The following table summarizes the activity related to unrecognized tax benefits: (Dollars in Millions) 2021 2020 2019 Beginning of year $ 3,373 3,853 3,326 Increases related to current year tax positions 242 265 249 Increases related to prior period tax positions 23 668 408 Decreases related to prior period tax positions (128) (551) (105) Settlements (187) (839) (9) Lapse of statute of limitations 0 (23) (16) End of year $ 3,323 3,373 3,853 The unrecognized tax benefits of $3.3 billion at January 2, 2022, if recognized, would affect the Company’s annual effective tax rate. The Company conducts business and files tax returns in numerous countries and currently has tax audits in progress with a number of tax authorities. With respect to the United States, the IRS has completed its audit for the tax years through 2012 and is currently auditing tax years 2013 through 2016. In the fiscal year 2020, the Company made its final payments for approximately$0.7 billion to the U.S. Treasury related to the final settlement of 2010-2012 tax audit liability. In other major jurisdictions where the Company conducts business, the years that remain open to tax audit go back to the year 2008. The Company believes it is possible that tax audits may be completed over the next twelve months by taxing authorities in some jurisdictions outside of the United States. However, the Company is not able to provide a reasonably reliable estimate of the timing of any other future tax payments relating to uncertain tax positions. The Company classifies liabilities for unrecognized tax benefits and related interest and penalties as long-term liabilities, except as previously noted on amounts related to the current United States IRS audit. Interest expense and penalties related to unrecognized tax benefits are classified as income tax expense. The Company recognized after tax interest expense of $44 million, $32 million and $50 million in fiscal years 2021, 2020 and 2019, respectively. The total amount of accrued interest was $512 million and $468 million in fiscal years 2021 and 2020, respectively.

Employee Related Obligations

Employee Related Obligations	12 Months Ended
Employee Related Obligations	Jan. 02, 2022
Compensation Related Costs [Abstract]
Employee Related Obligations	Employee Related Obligations At the end of fiscal 2021 and fiscal 2020, employee related obligations recorded on the Consolidated Balance Sheets were: (Dollars in Millions) 2021 2020 Pension benefits $ 4,088 5,761 Postretirement benefits 2,069 2,229 Postemployment benefits 3,117 3,078 Deferred compensation 181 250 Total employee obligations 9,455 11,318 Less current benefits payable 557 547 Employee related obligations — non-current $ 8,898 10,771 Prepaid employee related obligations of $4,436 million and $656 million for 2021 and 2020, respectively, are included in Other assets on the Consolidated Balance Sheets.

Pensions and Other Benefit Plan

Pensions and Other Benefit Plans	12 Months Ended
Pensions and Other Benefit Plans	Jan. 02, 2022
Retirement Benefits [Abstract]
Pensions and Other Benefit Plans	Pensions and Other Benefit Plans The Company sponsors various retirement and pension plans, including defined benefit, defined contribution and termination indemnity plans, which cover most employees worldwide. The Company also provides post-retirement benefits, primarily healthcare, to all eligible U.S. retired employees and their dependents. Many international employees are covered by government-sponsored programs and the cost to the Company is not significant. In the U.S, non-union pension benefits for employees hired before January 1, 2015 are primarily based on the employee’s compensation during the last five years before retirement and the number of years of service (the Final Average Pay formula). U.S. pension benefits for employees hired after 2014, are calculated using a different formula based on employee compensation over total years of service (the Retirement Value formula). In January 2021, the Company announced that, effective on January 1, 2026, all eligible U.S. non-union employees, regardless of hire date, will earn benefits under the Retirement Value formula. This amendment does not affect the benefits accrued under the Final Average Pay formula for service before January 1, 2026. The impact of this change decreases the Projected Benefit Obligation as of January 3, 2021 by approximately $1.8 billion and is included in the “Amendments” line in the Change in Benefit Obligation. International subsidiaries have plans under which funds are deposited with trustees, annuities are purchased under group contracts, or reserves are provided. The Company does not fund retiree healthcare benefits in advance and has the right to modify these plans in the future. In 2021 and 2020 the Company used December 31, 2021 and December 31, 2020, respectively, as the measurement date for all U.S. and international retirement and other benefit plans. Net periodic benefit costs for the Company’s defined benefit retirement plans and other benefit plans for 2021, 2020 and 2019 include the following components: Retirement Plans Other Benefit Plans (Dollars in Millions) 2021 2020 2019 2021 2020 2019 Service cost $ 1,421 1,380 1,163 309 287 274 Interest cost 770 955 1,096 81 133 185 Expected return on plan assets (2,645) (2,461) (2,322) (7) (7) (6) Amortization of prior service cost (181) 2 4 (31) (31) (31) Recognized actuarial losses (gains) 1,257 891 579 151 142 129 Curtailments and settlements 1 23 73 — — — Net periodic benefit cost $ 623 790 593 503 524 551 The service cost component of net periodic benefit cost is presented in the same line items on the Consolidated Statement of Earnings where other employee compensation costs are reported, including Cost of products sold, Research and development expense, and Selling, marketing and administrative expenses. All other components of net periodic benefit cost are presented as part of Other (income) expense, net on the Consolidated Statement of Earnings. Unrecognized gains and losses for the U.S. pension plans are amortized over the average remaining future service for each plan. For plans with no active employees, they are amortized over the average life expectancy. The amortization of gains and losses for the other U.S. benefit plans is determined by using a 10% corridor of the greater of the market value of assets or the accumulated postretirement benefit obligation. Total unamortized gains and losses in excess of the corridor are amortized over the average remaining future service. Prior service costs/benefits for the U.S. pension plans are amortized over the average remaining future service of plan participants at the time of the plan amendment. Prior service cost/benefit for the other U.S. benefit plans is amortized over the average remaining service to full eligibility age of plan participants at the time of the plan amendment. The following table represents the weighted-average actuarial assumptions: Retirement Plans Other Benefit Plans Worldwide Benefit Plans 2021 2020 2019 2021 2020 2019 Net Periodic Benefit Cost Service cost discount rate 2.14 % 2.82 3.63 2.09 3.04 4.45 Interest cost discount rate 2.34 % 3.13 4.13 2.33 3.08 4.25 Rate of increase in compensation levels 4.01 % 4.00 3.99 4.25 4.25 4.29 Expected long-term rate of return on plan assets 7.71 % 8.12 8.31 Benefit Obligation Discount rate 2.49 % 2.14 2.91 2.68 2.23 3.39 Rate of increase in compensation levels 4.01 % 4.00 4.01 4.21 4.27 4.29 The Company’s discount rates are determined by considering current yield curves representing high quality, long-term fixed income instruments. The resulting discount rates are consistent with the duration of plan liabilities. The Company's methodology in determining service and interest cost uses duration specific spot rates along that yield curve to the plans' liability cash flows. The expected rates of return on plan asset assumptions represent the Company's assessment of long-term returns on diversified investment portfolios globally. The assessment is determined using projections from external financial sources, long-term historical averages, actual returns by asset class and the various asset class allocations by market. The following table displays the assumed healthcare cost trend rates, for all individuals: Healthcare Plans 2021 2020 Healthcare cost trend rate assumed for next year 5.33 % 5.68 % Rate to which the cost trend rate is assumed to decline (ultimate trend) 3.73 % 4.49 % Year the rate reaches the ultimate trend rate 2046 2040 The following table sets forth information related to the benefit obligation and the fair value of plan assets at fiscal year-end 2021 and 2020 for the Company’s defined benefit retirement plans and other post-retirement plans: Retirement Plans Other Benefit Plans (Dollars in Millions) 2021 2020 2021 2020 Change in Benefit Obligation Projected benefit obligation — beginning of year $ 43,300 37,188 5,028 5,076 Service cost 1,421 1,380 309 287 Interest cost 770 955 81 133 Plan participant contributions 67 61 — — Amendments (1) 5 (1,780) — — Actuarial (gains) losses (2) (2,132) 5,716 (188) (75) Divestitures & acquisitions (2) (88) — — Curtailments, settlements & restructuring (7) (24) — — Benefits paid from plan (1,157) (1,111) (348) (396) Effect of exchange rates (683) 1,003 (4) 3 Projected benefit obligation — end of year $ 41,582 43,300 4,878 5,028 Change in Plan Assets Plan assets at fair value — beginning of year $ 38,195 32,201 90 115 Actual return on plan assets 4,439 5,524 17 14 Company contributions 969 870 343 357 Plan participant contributions 67 61 — — Settlements (7) (13) — — Divestitures & acquisitions (2) (84) — — Benefits paid from plan assets (1,157) (1,111) (348) (396) Effect of exchange rates (574) 747 — — Plan assets at fair value — end of year $ 41,930 38,195 102 90 Funded status — end of year $ 348 (5,105) (4,776) (4,938) Amounts Recognized in the Company’s Balance Sheet consist of the following: Non-current assets $ 4,436 656 — — Current liabilities (115) (125) (438) (418) Non-current liabilities (3,973) (5,636) (4,338) (4,520) Total recognized in the consolidated balance sheet — end of year $ 348 (5,105) (4,776) (4,938) Amounts Recognized in Accumulated Other Comprehensive Income consist of the following: Net actuarial loss $ 5,539 10,860 1,113 1,463 Prior service cost (credit) (1) (1,610) (1,797) (13) (44) Unrecognized net transition obligation — — — — Total before tax effects $ 3,929 9,063 1,100 1,419 Accumulated Benefit Obligations — end of year $ 39,049 40,356 (1) In January 2021, the Company announced that, effective on January 1, 2026, all eligible U.S. non-union employees, regardless of hire date, will earn benefits under the Retirement Value formula. This amendment does not affect the benefits accrued under the Final Average Pay formula for service before January 1, 2026. (2) The actuarial gain for retirement plans in 2021 was primarily related to increases in discount rates; the actuarial losses for retirement plans in 2020 were primarily related to decreases in discount rates. Retirement Plans Other Benefit Plans (Dollars in Millions) 2021 2020 2021 2020 Amounts Recognized in Net Periodic Benefit Cost and Other Comprehensive Income Net periodic benefit cost $ 623 790 503 524 Net actuarial (gain) loss (3,927) 2,616 (199) (81) Amortization of net actuarial loss (1,257) (891) (151) (142) Prior service cost (credit) 5 (1,780) — — Amortization of prior service (cost) credit 181 (2) 31 31 Effect of exchange rates (136) 293 — 1 Total loss/(income) recognized in other comprehensive income, before tax $ (5,134) 236 (319) (191) Total recognized in net periodic benefit cost and other comprehensive income $ (4,511) 1,026 184 333 The Company plans to continue to fund its U.S. Qualified Plans to comply with the Pension Protection Act of 2006. International Plans are funded in accordance with local regulations. Additional discretionary contributions are made when deemed appropriate to meet the long-term obligations of the plans. For certain plans, funding is not a common practice, as funding provides no economic benefit. Consequently, the Company has several pension plans that are not funded. In 2021, the Company contributed $102 million and $867 million to its U.S. and international pension plans, respectively. The following table displays the funded status of the Company's U.S. Qualified & Non-Qualified pension plans and international funded and unfunded pension plans at December 31, 2021 and December 31, 2020, respectively: U.S. Plans International Plans Qualified Plans Non-Qualified Plans Funded Plans Unfunded Plans (Dollars in Millions) 2021 2020 2021 2020 2021 2020 2021 2020 Plan Assets $ 27,944 25,554 — — 13,986 12,641 — — Projected Benefit Obligation 25,041 25,466 2,703 2,748 13,428 14,541 410 545 Accumulated Benefit Obligation 23,985 24,158 2,479 2,495 12,212 13,210 373 493 Over (Under) Funded Status Projected Benefit Obligation $ 2,903 88 (2,703) (2,748) 558 (1,900) (410) (545) Accumulated Benefit Obligation 3,959 1,396 (2,479) (2,495) 1,774 (569) (373) (493) Plans with accumulated benefit obligations in excess of plan assets have an accumulated benefit obligation, projected benefit obligation and plan assets of $3.9 billion, $4.2 billion and $0.3 billion, respectively, at the end of 2021, and $8.8 billion, $9.8 billion and $4.4 billion, respectively, at the end of 2020. The following table displays the projected future benefit payments from the Company’s retirement and other benefit plans: (Dollars in Millions) 2022 2023 2024 2025 2026 2027-2031 Projected future benefit payments Retirement plans $ 1,317 1,386 1,421 1,496 1,572 9,279 Other benefit plans $ 447 459 472 485 434 2,379 The following table displays the projected future minimum contributions to the unfunded retirement plans. These amounts do not include any discretionary contributions that the Company may elect to make in the future. (Dollars in Millions) 2022 2023 2024 2025 2026 2027-2031 Projected future contributions $ 114 119 126 133 139 794 Each pension plan is overseen by a local committee or board that is responsible for the overall administration and investment of the pension plans. In determining investment policies, strategies and goals, each committee or board considers factors including, local pension rules and regulations; local tax regulations; availability of investment vehicles (separate accounts, commingled accounts, insurance funds, etc.); funded status of the plans; ratio of actives to retirees; duration of liabilities; and other relevant factors including: diversification, liquidity of local markets and liquidity of base currency. A majority of the Company’s pension funds are open to new entrants and are expected to be on-going plans. Permitted investments are primarily liquid and/or listed, with little reliance on illiquid and non-traditional investments such as hedge funds. The Company’s retirement plan asset allocation at the end of 2021 and 2020 and target allocations for 2022 are as follows: Percent of Target 2021 2020 2022 Worldwide Retirement Plans Equity securities 65 % 66 % 61 % Debt securities 35 34 39 Total plan assets 100 % 100 % 100 % Determination of Fair Value of Plan Assets The Plan has an established and well-documented process for determining fair values. Fair value is based upon quoted market prices, where available. If listed prices or quotes are not available, fair value is based upon models that primarily use, as inputs, market-based or independently sourced market parameters, including yield curves, interest rates, volatilities, equity or debt prices, foreign exchange rates and credit curves. While the Plan believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different estimate of fair value at the reporting date. Valuation Hierarchy The authoritative literature establishes a three-level hierarchy to prioritize the inputs used in measuring fair value. The levels within the hierarchy are described in the table below with Level 1 having the highest priority and Level 3 having the lowest. The Net Asset Value (NAV) is based on the value of the underlying assets owned by the fund, minus its liabilities, and then divided by the number of shares outstanding. A financial instrument’s categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. Following is a description of the valuation methodologies used for the investments measured at fair value. • Short-term investment funds — Cash and quoted short-term instruments are valued at the closing price or the amount held on deposit by the custodian bank. Other investments are through investment vehicles valued using the NAV provided by the administrator of the fund. The NAV is a quoted price in a market that is not active and classified as Level 2. • Government and agency securities — A limited number of these investments are valued at the closing price reported on the major market on which the individual securities are traded. Where quoted prices are available in an active market, the investments are classified within Level 1 of the valuation hierarchy. If quoted market prices are not available for the specific security, then fair values are estimated by using pricing models, quoted prices of securities with similar characteristics or discounted cash flows. When quoted market prices for a security are not available in an active market, they are classified as Level 2. • Debt instruments — A limited number of these investments are valued at the closing price reported on the major market on which the individual securities are traded. Where quoted prices are available in an active market, the investments are classified as Level 1. If quoted market prices are not available for the specific security, then fair values are estimated by using pricing models, quoted prices of securities with similar characteristics or discounted cash flows and are classified as Level 2. Level 3 debt instruments are priced based on unobservable inputs. • Equity securities — Equity securities are valued at the closing price reported on the major market on which the individual securities are traded. Substantially all equity securities are classified within Level 1 of the valuation hierarchy. • Commingled funds — These investment vehicles are valued using the NAV provided by the fund administrator. Assets in the Level 2 category have a quoted market price. • Other assets — Other assets are represented primarily by limited partnerships. These investment vehicles are valued using the NAV provided by the fund administrator. Other assets that are exchange listed and actively traded are classified as Level 1, while inactively traded assets are classified as Level 2. The following table sets forth the Retirement Plans' investments measured at fair value as of December 31, 2021 and December 31, 2020: Quoted Prices Significant Significant Unobservable Inputs (1) Investments Measured at Net Asset Value (Level 1) (Level 2) (Level 3) Total Assets (Dollars in Millions) 2021 2020 2021 2020 2021 2020 2021 2020 2021 2020 Short-term investment funds $ 102 127 1,033 763 — — — — 1,135 890 Government and agency securities — — 7,016 5,023 — — — — 7,016 5,023 Debt instruments — — 3,505 3,931 — — — — 3,505 3,931 Equity securities 14,107 14,375 2 2 — — — — 14,109 14,377 Commingled funds — — 5,496 4,690 105 160 8,708 8,236 14,309 13,086 Other assets — — 34 11 15 21 1,807 856 1,856 888 Investments at fair value $ 14,209 14,502 17,086 14,420 120 181 10,515 9,092 41,930 38,195 (1) The activity for the Level 3 assets is not significant for all years presented. The Company's Other Benefit Plans are unfunded except for U.S. commingled funds (Level 2) of $102 million and $90 million at December 31, 2021 and December 31, 2020, respectively.

Savings Plan

Savings Plan	12 Months Ended
Savings Plan	Jan. 02, 2022
Savings Plan [Abstract]
Savings Plan	Savings PlanThe Company has voluntary 401(k) savings plans designed to enhance the existing retirement programs covering eligible employees. The Company matches a percentage of each employee’s contributions consistent with the provisions of the plan for which he/she is eligible. Total Company matching contributions to the plans were $256 million, $243 million and $235 million in fiscal years 2021, 2020 and 2019, respectively.

Capital and Treasury Stock

Capital and Treasury Stock	12 Months Ended
Capital and Treasury Stock	Jan. 02, 2022
Equity [Abstract]
Capital and Treasury Stock	Capital and Treasury Stock Changes in treasury stock were: Treasury Stock (Amounts in Millions Except Treasury Stock Shares in Thousands) Shares Amount Balance at December 30, 2018 457,519 $ 34,362 Employee compensation and stock option plans (20,053) (2,691) Repurchase of common stock 49,870 6,746 Balance at December 29, 2019 487,336 38,417 Employee compensation and stock option plans (21,765) (3,148) Repurchase of common stock 21,760 3,221 Balance at January 3, 2021 487,331 38,490 Employee compensation and stock option plans (17,399) (2,847) Repurchase of common stock 20,946 3,456 Balance at January 2, 2022 490,878 $ 39,099 Aggregate shares of common stock issued were approximately 3,119,843,000 shares at the end of fiscal years 2021, 2020 and 2019. Cash dividends paid were $4.19 per share in fiscal year 2021, compared with dividends of $3.98 per share in fiscal year 2020, and $3.75 per share in fiscal year 2019. On January 4, 2022, the Board of Directors declared a regular cash dividend of $1.06 per share, payable on March 8, 2022 to shareholders of record as of February 22, 2022. On December 17, 2018, the Company announced that its Board of Directors approved a share repurchase program, authorizing the Company to purchase up to $5.0 billion of the Company's shares of common stock. This share repurchase program was completed as of September 29, 2019.

Accumulated Other Comprehensive

Accumulated Other Comprehensive Income (Loss)	12 Months Ended
Accumulated Other Comprehensive Income (Loss)	Jan. 02, 2022
Equity [Abstract]
Accumulated Other Comprehensive Income (Loss)	Accumulated Other Comprehensive Income (Loss) Components of other comprehensive income (loss) consist of the following: (Dollars in Millions) Foreign Gain/(Loss) On Securities Employee Benefit Plans Gain/ Total December 30, 2018 $ (8,869) — (6,158) (195) (15,222) Net 2019 changes 164 — (733) (100) (669) December 29, 2019 (8,705) — (6,891) (295) (15,891) Net 2020 changes (233) 1 (66) 947 649 January 3, 2021 (8,938) 1 (6,957) 652 (15,242) Net 2021 changes (1,079) (4) 4,255 (988) 2,184 January 2, 2022 $ (10,017) (3) (2,702) (336) (13,058) Amounts in accumulated other comprehensive income are presented net of the related tax impact. Foreign currency translation is not adjusted for income taxes where it relates to permanent investments in international subsidiaries. For additional details on comprehensive income see the Consolidated Statements of Comprehensive Income. Details on reclassifications out of Accumulated Other Comprehensive Income: Gain/(Loss) On Securities - reclassifications released to Other (income) expense, net. Employee Benefit Plans - reclassifications are included in net periodic benefit cost. See Note 10 for additional details. Gain/(Loss) On Derivatives & Hedges - reclassifications to earnings are recorded in the same account as the hedged transaction. See Note 6 for additional details.

International Currency Translat

International Currency Translation	12 Months Ended
International Currency Translation	Jan. 02, 2022
Foreign Currency Translation [Abstract]
International Currency Transalation	International Currency Translation For translation of its subsidiaries operating in non-U.S. Dollar currencies, the Company has determined that the local currencies of its international subsidiaries are the functional currencies except those in highly inflationary economies, which are defined as those which have had compound cumulative rates of inflation of 100% or more during the past three years, or where a substantial portion of its cash flows are not in the local currency. For the majority of the Company's subsidiaries the local currency is the functional currency. In consolidating international subsidiaries, balance sheet currency effects are recorded as a component of accumulated other comprehensive income. The other current and non-current assets line within the Statement of Cash flows includes the impact of foreign currency translation. This equity account includes the results of translating certain balance sheet assets and liabilities at current exchange rates and some accounts at historical rates, except for those located in highly inflationary economies, (Argentina and Venezuela). The translation of balance sheet accounts for highly inflationary economies are reflected in the operating results. A rollforward of the changes during fiscal years 2021, 2020 and 2019 for foreign currency translation adjustments is included in Note 13. Net currency transaction gains and losses included in Other (income) expense were losses of $236 million, $209 million and $267 million in fiscal years 2021, 2020 and 2019, respectively.

Earnings Per Share

Earnings Per Share	12 Months Ended
Earnings Per Share	Jan. 02, 2022
Earnings Per Share [Abstract]
Earnings Per Share	Earnings Per Share The following is a reconciliation of basic net earnings per share to diluted net earnings per share for the fiscal years ended January 2, 2022, January 3, 2021 and December 29, 2019: (In Millions Except Per Share Amounts) 2021 2020 2019 Basic net earnings per share $ 7.93 5.59 5.72 Average shares outstanding — basic 2,632.1 2,632.8 2,645.1 Potential shares exercisable under stock option plans 138.0 118.3 136.3 Less: shares repurchased under treasury stock method (96.1) (80.4) (97.8) Convertible debt shares — — 0.7 Adjusted average shares outstanding — diluted 2,674.0 2,670.7 2,684.3 Diluted net earnings per share $ 7.81 5.51 5.63 The diluted net earnings per share calculation for fiscal year 2021 included all shares related to stock options, as the exercise price of these options was less than the average market value of the Company's stock. As of January 2, 2022, the Company did not have convertible debt. The diluted net earnings per share calculation for fiscal year 2020 excluded 18 million shares related to stock options, as the exercise price of these options was greater than the average market value of the Company's stock. As of January 3, 2021, the Company did not have convertible debt. The diluted net earnings per share calculation for fiscal year 2019 excluded an insignificant number of shares related to stock options, as the exercise price of these options was greater than the average market value of the Company’s stock. The diluted net earnings per share calculation for fiscal year 2019 included the dilutive effect of convertible debt that was offset by the related reduction in interest expense of $1 million after-tax.

Common Stock, Stock Option Plan

Common Stock, Stock Option Plans and Stock Compensation Agreements	12 Months Ended
	Jan. 02, 2022
Share-based Payment Arrangement [Abstract]
Common Stock, Stock Option Plans and Stock Compensation Agreements	Common Stock, Stock Option Plans and Stock Compensation Agreements At January 2, 2022, the Company had 2 stock-based compensation plans. The shares outstanding are for contracts under the Company's 2005 Long-Term Incentive Plan and the 2012 Long-Term Incentive Plan. The 2005 Long-Term Incentive Plan expired April 26, 2012. All options and restricted shares granted subsequent to that date were under the 2012 Long-Term Incentive Plan. Under the 2012 Long-Term Incentive Plan, the Company may issue up to 650 million shares of common stock, plus any shares canceled, expired, forfeited, or not issued from the 2005 Long-Term Incentive Plan subsequent to April 26, 2012. Shares available for future grants under the 2012 Long-Term Incentive Plan were 240 million at the end of fiscal year 2021. The compensation cost that has been charged against income for these plans was $1,135 million, $1,005 million and $977 million for fiscal years 2021, 2020 and 2019, respectively. The total income tax benefit recognized in the income statement for share-based compensation costs was $218 million, $210 million and $227 million for fiscal years 2021, 2020 and 2019, respectively. The Company also recognized additional income tax benefits of $223 million, $248 million and $209 million for fiscal years 2021, 2020 and 2019, respectively, for which options were exercised or restricted shares were vested. The total unrecognized compensation cost was $862 million, $804 million and $823 million for fiscal years 2021, 2020 and 2019, respectively. The weighted average period for this cost to be recognized was 1.78 years, 1.76 years and 1.71 years for fiscal years 2021, 2020, and 2019, respectively. Share-based compensation costs capitalized as part of inventory were insignificant in all periods. The Company settles employee benefit equity issuances with treasury shares. Treasury shares are replenished through market purchases throughout the year for the number of shares used to settle employee benefit equity issuances. Stock Options Stock options expire 10 years from the date of grant and vest over service periods that range from 6 months to 4 years. All options are granted at the average of the high and low prices of the Company’s Common Stock on the New York Stock Exchange on the date of grant. The fair value of each option award was estimated on the date of grant using the Black-Scholes option valuation model that uses the assumptions noted in the following table. For 2021, 2020 and 2019 grants, expected volatility represents a blended rate of 10-year weekly historical overall volatility rate, and a 5-week average implied volatility rate based on at-the-money traded Johnson & Johnson options with a life of 2 years. For all grants, historical data is used to determine the expected life of the option. The risk-free rate was based on the U.S. Treasury yield curve in effect at the time of grant. The average fair value of options granted was $20.86, $16.42 and $17.80, in fiscal years 2021, 2020 and 2019, respectively. The fair value was estimated based on the weighted average assumptions of: 2021 2020 2019 Risk-free rate 0.83 % 1.47 % 2.56 % Expected volatility 18.59 % 15.33 % 16.27 % Expected life (in years) 7.0 7.0 7.0 Expected dividend yield 2.50 % 2.60 % 2.80 % A summary of option activity under the Plan as of January 2, 2022, January 3, 2021 and December 29, 2019, and changes during the years ending on those dates is presented below: (Shares in Thousands) Outstanding Shares Weighted Aggregate Shares at December 30, 2018 109,652 $ 98.29 $ 3,214 Options granted 19,745 131.94 Options exercised (14,785) 82.43 Options canceled/forfeited (2,975) 125.11 Shares at December 29, 2019 111,637 105.63 4,478 Options granted 20,723 151.41 Options exercised (16,275) 86.05 Options canceled/forfeited (1,835) 137.62 Shares at January 3, 2021 114,250 116.22 4,703 Options granted 18,525 164.62 Options exercised (13,248) 97.48 Options canceled/forfeited (2,166) 149.75 Shares at January 2, 2022 117,361 $ 125.36 $ 5,364 The total intrinsic value of options exercised was $919 million, $1,021 million and $807 million in fiscal years 2021, 2020 and 2019, respectively. The following table summarizes stock options outstanding and exercisable at January 2, 2022: (Shares in Thousands) Outstanding Exercisable Exercise Price Range Options Average Life (1) Weighted Average Exercise Price Options Weighted Average Exercise Price $65.08-$90.44 16,007 1.6 $81.92 16,007 $81.92 $100.06-$101.87 22,647 3.6 $101.07 22,647 $101.07 $115.67-$129.51 24,543 5.6 $122.59 23,972 $122.43 $131.94-$151.41 36,304 7.6 $142.23 100 $140.72 $151.42-$164.62 17,860 9.1 $164.62 16 $164.62 117,361 5.8 $125.36 62,742 $104.42 (1) Average contractual life remaining in years. Stock options outstanding at January 3, 2021 and December 29, 2019 were 114,250 and an average life of 6.0 years and 111,637 and an average life of 6.0 years, respectively. Stock options exercisable at January 3, 2021 and December 29, 2019 were 61,289 at an average price of $96.97 and 60,761 at an average price of $88.88, respectively. Restricted Share Units and Performance Share Units The Company grants restricted share units which vest over service periods that range from 6 months to 3 years. The Company also grants performance share units, which are paid in shares of Johnson & Johnson Common Stock after the end of a three-year performance period. Whether any performance share units vest, and the amount that does vest, is tied to the completion of service periods that range from 6 months to 3 years and the achievement, over a three-year period, of three equally-weighted goals that directly align with or help drive long-term total shareholder return: operational sales, adjusted operational earnings per share, and relative total shareholder return. Beginning in fiscal 2020, performance shares were granted with two equally-weighted goals that directly align with or help drive long-term total shareholder return: adjusted operational earnings per share and relative total shareholder return. The number of shares actually earned at the end of the three-year period will vary, based only on actual performance, from 0% to 200% of the target number of performance share units granted . A summary of the restricted share units and performance share units activity under the Plans as of January 2, 2022 is presented below: (Shares in Thousands) Outstanding Restricted Share Units Outstanding Performance Share Units Shares at January 3, 2021 14,998 2,236 Granted 4,981 741 Issued (5,101) (610) Canceled/forfeited/adjusted (756) (55) Shares at January 2, 2022 14,122 2,312 The average fair value of the restricted share units granted was $152.62, $139.58 and $121.31 in fiscal years 2021, 2020 and 2019, respectively, using the fair market value at the date of grant. The fair value of restricted share units was discounted for dividends, which are not paid on the restricted share units during the vesting period. The fair value of restricted share units issued was $611 million, $650 million and $586 million in 2021, 2020 and 2019, respectively. The weighted average fair value of the performance share units granted was $179.35, $160.54 and $124.67 in fiscal years 2021, 2020 and 2019, calculated using the weighted average fair market value for each of the component goals at the date of grant.

Segments of Business and Geogra

Segments of Business and Geographic Areas	12 Months Ended
Segments of Business and Geographic Areas	Jan. 03, 2021
Segment Reporting [Abstract]
Segments of Business and Geographic Areas	Segments of Business* and Geographic Areas Sales to Customers % Change (Dollars in Millions) 2021 2020 2019 ’21 vs. ’20 ’20 vs. ’19 Consumer Health OTC U.S. $ 2,594 2,460 2,010 5.4 % 22.4 International 2,634 2,364 2,434 11.4 (2.9) Worldwide 5,227 4,824 4,444 8.4 8.5 Skin Health/Beauty U.S. 2,400 2,350 2,392 2.1 (1.7) International 2,141 2,100 2,201 1.9 (4.6) Worldwide 4,541 4,450 4,593 2.0 (3.1) Oral Care U.S. 637 683 621 (6.7) 9.9 International 1,008 958 906 5.1 5.7 Worldwide 1,645 1,641 1,528 0.2 7.4 Baby Care U.S. 378 376 362 0.5 3.7 International 1,188 1,141 1,313 4.1 (13.1) Worldwide 1,566 1,517 1,675 3.2 (9.4) Women's Health U.S. 13 13 12 (1.6) 8.2 International 905 888 974 1.8 (8.8) Worldwide 917 901 986 1.8 (8.6) Wound Care/Other U.S. 495 480 441 3.1 8.9 International 243 240 230 1.7 4.1 Worldwide 739 720 671 2.6 7.2 TOTAL CONSUMER HEALTH U.S. 6,516 6,362 5,839 2.4 9.0 International 8,119 7,691 8,059 5.6 (4.6) Worldwide 14,635 14,053 13,898 4.1 1.1 PHARMACEUTICAL Immunology U.S. 10,843 10,175 9,641 6.6 5.5 International 5,907 4,880 4,309 21.0 13.2 Worldwide 16,750 15,055 13,950 11.3 7.9 REMICADE ® U.S. 2,019 2,508 3,079 (19.5) (18.5) U.S. Exports 236 346 294 (31.9) 18.0 International 935 893 1,007 4.8 (11.4) Worldwide 3,190 3,747 4,380 (14.9) (14.4) SIMPONI / SIMPONI ARIA ® U.S. 1,127 1,155 1,159 (2.4) (0.3) International 1,148 1,088 1,029 5.5 5.8 Worldwide 2,276 2,243 2,188 1.4 2.6 STELARA ® U.S. 5,938 5,240 4,346 13.3 20.6 International 3,196 2,467 2,015 29.6 22.4 Worldwide 9,134 7,707 6,361 18.5 21.1 TREMFYA ® U.S. 1,503 926 764 62.3 21.3 International 624 421 248 48.2 69.9 Worldwide 2,127 1,347 1,012 57.9 33.2 OTHER IMMUNOLOGY U.S. 21 — — — International 3 11 10 (73.3) 6.4 Worldwide 24 11 10 6.4 Infectious Diseases U.S. 2,249 1,735 1,597 29.7 8.6 International 3,612 1,839 1,815 96.3 1.3 Worldwide 5,861 3,574 3,413 64.0 4.7 COVID-19 VACCINE U.S. 634 — — International 1,751 — — Worldwide 2,385 — — EDURANT ® / rilpivirine U.S. 41 44 50 (7.6) (11.2) International 953 920 812 3.6 13.3 Worldwide 994 964 861 3.1 11.9 PREZISTA ® / PREZCOBIX ® / REZOLSTA ® / SYMTUZA ® U.S. 1,508 1,587 1,422 (4.9) 11.6 International 575 597 689 (3.6) (13.4) Worldwide 2,083 2,184 2,110 (4.6) 3.5 OTHER INFECTIOUS DISEASES U.S. 66 104 126 (36.0) (17.6) International 333 323 315 3.0 2.6 Worldwide 399 427 441 (6.5) (3.2) Neuroscience U.S. 3,347 3,091 2,919 8.3 5.9 International 3,664 3,457 3,409 6.0 1.4 Worldwide 7,011 6,548 6,328 7.1 3.5 CONCERTA ® / methylphenidate U.S. 172 183 233 (5.8) (21.4) International 495 439 463 12.8 (5.1) Worldwide 667 622 696 7.3 (10.6) INVEGA SUSTENNA ® / XEPLION ® / INVEGA TRINZA ® / TREVICTA ® U.S. 2,550 2,314 2,107 10.2 9.8 International 1,472 1,339 1,224 10.0 9.4 Worldwide 4,022 3,653 3,330 10.1 9.7 RISPERDAL CONSTA ® U.S. 287 296 314 (2.9) (5.9) International 305 346 374 (11.8) (7.5) Worldwide 592 642 688 (7.7) (6.8) OTHER NEUROSCIENCE U.S. 338 298 266 13.3 12.4 International 1,391 1,334 1,349 4.3 (1.1) Worldwide 1,729 1,632 1,614 6.0 1.1 Oncology U.S. 5,958 5,092 4,299 17.0 18.5 International 8,590 7,275 6,393 18.1 13.8 Worldwide 14,548 12,367 10,692 17.6 15.7 DARZALEX ® U.S. 3,169 2,232 1,567 42.0 42.4 International 2,854 1,958 1,430 45.8 36.9 Worldwide 6,023 4,190 2,998 43.8 39.8 ERLEADA ® U.S. 813 583 297 39.3 96.1 International 478 176 35 * * * * Worldwide 1,291 760 332 70.0 * * IMBRUVICA ® U.S. 1,747 1,821 1,555 (4.0) 17.1 International 2,622 2,307 1,856 13.6 24.3 Worldwide 4,369 4,128 3,411 5.8 21.0 ZYTIGA ® / abiraterone acetate U.S. 119 373 810 (68.1) (54.0) International 2,178 2,097 1,985 3.9 5.6 Worldwide 2,297 2,470 2,795 (7.0) (11.6) OTHER ONCOLOGY U.S. 110 83 70 31.7 18.6 International 458 738 1,087 (37.9) (32.1) Worldwide 568 821 1,158 (30.8) (29.1) Pulmonary Hypertension U.S. 2,365 2,133 1,684 10.9 26.6 International 1,085 1,015 939 6.9 8.2 Worldwide 3,450 3,148 2,623 9.6 20.0 OPSUMIT ® U.S. 1,147 1,008 766 13.7 31.7 International 672 631 562 6.6 12.3 Worldwide 1,819 1,639 1,327 11.0 23.5 UPTRAVI ® U.S. 1,056 955 714 10.5 33.8 International 181 138 105 31.1 30.9 Worldwide 1,237 1,093 819 13.1 33.5 OTHER U.S. 163 169 205 (3.7) (17.6) International 232 247 272 (5.9) (9.2) Worldwide 395 416 476 (5.0) (12.8) Cardiovascular / Metabolism / Other U.S. 3,192 3,509 3,734 (9.0) (6.0) International 1,268 1,369 1,458 (7.4) (6.1) Worldwide 4,460 4,878 5,192 (8.6) (6.0) XARELTO ® U.S. 2,438 2,345 2,313 4.0 1.4 International — — — — — Worldwide 2,438 2,345 2,313 4.0 1.4 INVOKANA ® / INVOKAMET ® U.S. 308 564 536 (45.4) 5.2 International 254 231 199 9.9 16.3 Worldwide 563 795 735 (29.3) 8.2 PROCRIT ® / EPREX ® U.S. 223 277 505 (19.7) (45.1) International 256 274 285 (6.8) (3.8) Worldwide 479 552 790 (13.3) (30.2) OTHER U.S. 223 323 380 (31.0) (15.1) International 758 864 974 (12.2) (11.3) Worldwide 981 1,186 1,353 (17.3) (12.4) TOTAL PHARMACEUTICAL U.S. 27,954 25,735 23,874 8.6 7.8 International 24,126 19,837 18,324 21.6 8.3 Worldwide 52,080 45,572 42,198 14.3 8.0 MEDICAL DEVICES Interventional Solutions U.S. 1,836 1,452 1,443 26.4 0.6 International 2,135 1,594 1,554 34.0 2.6 Worldwide 3,971 3,046 2,997 30.4 1.6 Orthopaedics U.S. 5,126 4,779 5,319 7.3 (10.2) International 3,462 2,984 3,520 16.0 (15.2) Worldwide 8,588 7,763 8,839 10.6 (12.2) HIPS U.S. 883 793 863 11.4 (8.2) International 602 487 575 23.6 (15.3) Worldwide 1,485 1,280 1,438 16.0 (11.0) KNEES U.S. 787 743 889 5.9 (16.4) International 538 427 591 26.1 (27.8) Worldwide 1,325 1,170 1,480 13.3 (21.0) TRAUMA U.S. 1,819 1,648 1,652 10.4 (0.2) International 1,066 966 1,068 10.4 (9.6) Worldwide 2,885 2,614 2,720 10.4 (3.9) SPINE, SPORTS & OTHER U.S. 1,637 1,595 1,915 2.6 (16.7) International 1,256 1,104 1,286 13.8 (14.1) Worldwide 2,893 2,699 3,201 7.2 (15.7) Surgery U.S. 3,867 3,249 3,828 19.0 (15.1) International 5,945 4,983 5,673 19.3 (12.2) Worldwide 9,812 8,232 9,501 19.2 (13.4) ADVANCED U.S. 1,761 1,535 1,637 14.9 (6.2) International 2,861 2,304 2,458 24.1 (6.2) Worldwide 4,622 3,839 4,095 20.4 (6.2) GENERAL U.S. 2,105 1,714 2,192 22.7 (21.8) International 3,085 2,679 3,215 15.2 (16.7) Worldwide 5,190 4,392 5,406 18.1 (18.8) Vision U.S. 1,857 1,557 1,794 19.3 (13.2) International 2,831 2,362 2,830 19.8 (16.5) Worldwide 4,688 3,919 4,624 19.6 (15.2) CONTACT LENSES / OTHER U.S. 1,398 1,213 1,304 15.2 (7.0) International 2,043 1,781 2,088 14.7 (14.7) Worldwide 3,440 2,994 3,392 14.9 (11.7) SURGICAL U.S. 459 344 490 33.5 (29.7) International 788 581 742 35.7 (21.7) Worldwide 1,248 925 1,232 34.9 (24.9) TOTAL MEDICAL DEVICES U.S. 12,686 11,036 12,384 14.9 (10.9) International 14,374 11,923 13,579 20.6 (12.2) Worldwide 27,060 22,959 25,963 17.9 (11.6) WORLDWIDE U.S. 47,156 43,133 42,097 9.3 2.5 International 46,619 39,451 39,962 18.2 (1.3) Worldwide $ 93,775 82,584 82,059 13.6 % 0.6 Certain prior year amounts have been reclassified to conform to current year presentation *Percentage greater than 100% or not meaningful Income (Loss) Before Tax Identifiable Assets (Dollars in Millions) 2021 (3) 2020 (4) 2019 (5) 2021 2020 Consumer Health $ 1,294 (1,064) 2,061 $ 25,081 27,355 Pharmaceutical 18,181 15,462 8,816 64,376 66,158 Medical Devices 4,373 3,044 7,286 53,372 49,578 Total 23,848 17,442 18,163 142,829 143,091 Less: Expense not allocated to segments (1) 1,072 945 835 General corporate (2) 39,189 31,803 Worldwide total $ 22,776 16,497 17,328 $ 182,018 174,894 Additions to Property, Depreciation and (Dollars in Millions) 2021 2020 2019 2021 2020 2019 Consumer Health $ 331 248 328 $ 759 785 765 Pharmaceutical 1,198 863 950 4,029 4,006 3,910 Medical Devices 1,933 1,980 1,912 2,286 2,140 2,014 Segments total 3,462 3,091 3,190 7,074 6,931 6,689 General corporate 190 256 308 316 300 320 Worldwide total $ 3,652 3,347 3,498 $ 7,390 7,231 7,009 Sales to Customers Long-Lived Assets (6) (Dollars in Millions) 2021 2020 2019 2021 2020 United States $ 47,156 43,133 42,097 $ 48,586 49,951 Europe 23,594 18,980 18,466 43,257 49,363 Western Hemisphere excluding U.S. 5,750 5,335 5,941 2,708 2,734 Asia-Pacific, Africa 17,275 15,136 15,555 5,035 5,484 Segments total 93,775 82,584 82,059 99,586 107,532 General corporate 1,014 1,029 Other non long-lived assets 81,418 66,333 Worldwide total $ 93,775 82,584 82,059 $ 182,018 174,894 See Note 1 for a description of the segments in which the Company operates. Export sales are not significant. In fiscal year 2021, the Company utilized three wholesalers distributing products for all three segments that represented approximately 14.0%, 11.0% and 11.0% of the total consolidated revenues. In fiscal year 2020, the Company had three wholesalers distributing products for all three segments that represented approximately 16.0%, 12.0% and 12.0% of the total consolidated revenues. In fiscal year 2019, the Company had three wholesalers distributing products for all three segments that represented approximately 15.0%, 12.0%, and 11.0% of the total consolidated revenues. (1) Amounts not allocated to segments include interest (income) expense and general corporate (income) expense. (2) General corporate includes cash, cash equivalents and marketable securities. (3) Consumer Health includes: • Litigation expense of $1.6 billion, primarily talc related reserves • A restructuring related charge of $0.1 billion Pharmaceutical includes: • Litigation expense of $0.6 billion, primarily related to Risperdal • Divestiture gains of $0.6 billion • Gains on securities of $0.5 billion • A restructuring related charge of $0.1 billion Medical Devices includes: • A restructuring related charge of $0.3 billion • An in-process research and development expense of $0.9 billion • A Medical Device Regulation charge of $0.2 billion • Litigation expense of $0.1 billion (4) Consumer Health includes: • Litigation expense of $3.9 billion, primarily talc related reserves and certain settlements. Pharmaceutical includes: • Litigation expense of $0.8 billion, primarily related to the agreement in principle to settle opioid litigation • An unrealized gain on securities of $0.5 billion • A restructuring related charge of $0.1 billion Medical Devices includes: • A contingent consideration reversal of $1.1 billion related to the timing of certain developmental milestones associated with the Auris Health acquisition. • Litigation expense of $0.3 billion • A restructuring related charge of $0.3 billion • An in-process research and development expense of $0.2 billion • A Medical Device Regulation charge of $0.1 billion (5) Consumer Health includes: • A gain of $0.3 billion related to the Company's previously held equity investment in DR. CI:LABO • Litigation expense of $0.4 billion • A restructuring related charge of $0.1 billion Pharmaceutical includes: • Litigation expense of $4.3 billion of which $4.0 billion is related to the agreement in principle to settle opioid litigation • An in-process research and development expense of $0.9 billion related to the Alios asset • A research and development expense of $0.3 billion for an upfront payment related to argenx • An unrealized gain on securities of $0.6 billion • Actelion acquisition and integration related costs of $0.2 billion • A restructuring charge of $0.1 billion Medical Devices includes: • A gain of $2.0 billion from the divestiture of the ASP business • A restructuring related charge of $0.4 billion • Litigation expense of $0.4 billion • Auris Health acquisition and integration related costs of $0.1 billion (6) Long-lived assets include property, plant and equipment, net for fiscal years 2021, and 2020 of $18,962 and $18,766, respectively, and intangible assets and goodwill, net for fiscal years 2021 and 2020 of $81,638 and $89,795, respectively.

Acquisitions and Divestitures

Acquisitions and Divestitures	12 Months Ended
Acquisitions and Divestitures	Jan. 03, 2021
Business Combination and Asset Acquisition [Abstract]
Acquisitions and Divestitures	Acquisitions and Divestitures During fiscal year 2021, the Company did not make any material acquisitions. During fiscal year 2020, certain businesses were acquired for $7.3 billion in cash and $0.4 billion of liabilities assumed. These acquisitions were accounted for using the acquisition method and, accordingly, results of operations have been included in the financial statements from their respective dates of acquisition. The excess of purchase price over the estimated fair value of tangible assets acquired amounted to $7.5 billion and has been assigned to identifiable intangible assets, with any residual recorded to goodwill. The fiscal year 2020 acquisitions primarily included: all rights to the investigational compound bermekimab, which has multiple dermatological indications, along with certain employees from XBiotech Inc. (XBiotech), Momenta Pharmaceuticals, Inc. (Momenta), a company that discovers and develops novel therapies for immune-mediated diseases and the outstanding shares in Verb Surgical Inc., a company with significant robotics and data science capabilities. During the fiscal first quarter of 2020, the Company completed the acquisition of all rights to the investigational compound bermekimab, which has multiple dermatological indications, along with certain employees from XBiotech Inc., for a purchase price of $0.8 billion. The fair value of the acquisition was allocated primarily to non-amortizable intangible assets, primarily IPR&D, for $0.8 billion applying a probability of success factor that ranged from 20% to 60% to reflect inherent development, regulatory and commercial risk for the different indications. The discount rate applied was approximately 16%. XBiotech may be eligible to receive additional payments upon the receipt of certain commercialization authorizations. The transaction was accounted for as a business combination and included in the Pharmaceutical segment. On January 28, 2022, subsequent to the fiscal year 2021, additional information regarding efficacy became available which led the Company to the decision to terminate the development of bermekimab for Atopic Dermatitis (AD). The Company recorded an intangible asset impairment charge of approximately $0.6 billion related to an in-process research and development asset, bermekimab (JnJ-77474462), an investigational drug for the treatment of AD and Hidradenitis Suppurativa (HS). The impairment charge is related to the AD indication and is a nonrecognized subsequent event and will be reflected in the first quarter 2022 financial statements. The Company acquired all rights to bermekimab from XBiotech, Inc. in fiscal year 2020. Additionally, in the fiscal first quarter of 2020, the Company completed the acquisition of all outstanding shares in Verb Surgical Inc., a company with significant robotics and data science capabilities, including those shares previously held by Verily. The transaction was accounted for as a business combination and included in the Medical Devices segment. The fair value of the acquisition was allocated primarily to non-amortizable intangible assets, primarily IPR&D, for $0.4 billion, goodwill for $0.2 billion, other assets of $0.2 billion and liabilities assumed of $0.3 billion. The fair value of the Company's previously held equity investment in Verb Surgical Inc. was $0.4 billion. On October 1, 2020, the Company completed the acquisition of Momenta for a purchase price of approximately $6.1 billion, net of cash acquired. The fair value of the acquisition was allocated primarily to non-amortizable intangible assets (IPR&D) of $6.0 billion, goodwill of $1.2 billion, other assets of $0.5 billion and liabilities of $1.6 billion. The assets acquired are intended to address substantial unmet medical need in maternal-fetal disorders, neuro-inflammatory disorders, rheumatology, dermatology and autoimmune hematology. Depending on the asset, probability of success factors ranging from 20% to 77% were used in the fair value calculation to reflect inherent development and regulatory risk of the IPR&D. The discount rate applied was approximately 13%. The goodwill is primarily attributable to synergies expected to arise from the business acquisition and is not expected to be deductible for tax purposes. The transaction was accounted for as a business combination and included in the Pharmaceutical segment. During fiscal year 2019 certain businesses were acquired for $5.8 billion in cash and $1.4 billion of liabilities assumed. These acquisitions were accounted for using the acquisition method and, accordingly, results of operations have been included in the financial statements from their respective dates of acquisition. The excess of purchase price over the estimated fair value of tangible assets acquired amounted to $6.8 billion and has been assigned to identifiable intangible assets, with any residual recorded to goodwill. The fiscal year 2019 acquisitions primarily included DR. CI:LABO, a Japanese company focused on the marketing, development and distribution of a broad range of dermocosmetic, cosmetic and skincare products and Auris Health, Inc. a privately held developer of robotic technologies, initially focused in lung cancer, with an U.S. FDA-cleared platform currently used in bronchoscopic diagnostic and therapeutic procedures. On January 17, 2019, the Company acquired DR. CI:LABO, a Japanese company focused on the marketing, development and distribution of a broad range of dermocosmetic, cosmetic and skincare products for a total purchase price of approximately ¥230 billion, which equates to approximately $2.1 billion, using the exchange rate of 109.06 Japanese Yen to each U.S. Dollar on January 16, 2019. Additionally, in the fiscal first quarter of 2019, the Company recognized a pre-tax gain recorded in Other (income) expense, net, of approximately $0.3 billion related to the Company's previously held equity investment in DR. CI:LABO. The Company treated this transaction as a business combination and included it in the Consumer Health segment. During the fiscal first quarter of 2020, the Company finalized the purchase price allocation. The final fair value of the acquisition was allocated primarily to amortizable intangible assets for $1.5 billion, goodwill for $1.2 billion and liabilities of $0.4 billion. The amortizable intangible assets were comprised of brand/trademarks and customer relationships with a weighted average life of 15.3 years. The goodwill is primarily attributable to synergies expected to arise from the business acquisition and is not expected to be deductible for tax purposes. On April 1, 2019 the Company completed the acquisition of Auris Health, Inc. for approximately $3.4 billion, net of cash acquired. Additional contingent payments of up to $2.35 billion, in the aggregate, may be payable upon reaching certain predetermined milestones. Auris Health was a privately held developer of robotic technologies, initially focused in lung cancer, with a U.S. FDA-cleared platform currently used in bronchoscopic diagnostic and therapeutic procedures. The Company treated this transaction as a business combination and included it in the Medical Devices segment. The fair value of the acquisition was allocated primarily to amortizable and non-amortizable intangible assets, primarily IPR&D for $3.0 billion, goodwill for $2.0 billion, marketable securities of $0.2 billion and liabilities assumed of $1.8 billion, which includes the fair value of the contingent payments mentioned above. The goodwill is primarily attributable to synergies expected to arise from the business acquisition and is not expected to be deductible for tax purposes. During the fiscal second quarter of 2020, the Company finalized the purchase price allocation. During fiscal 2020, the Company recorded Other income of approximately $1.1 billion for the reversal of all of the contingent consideration related to the timing of certain developmental and commercial milestones, which are not expected to be met based on the Company’s current timelines. During the fiscal third quarter of 2020, the Company recorded a partial IPR&D impairment charge of $0.1 billion related to timing and progression of the digital surgery platforms. In the fiscal third quarter of 2021, the Company recorded a partial IPR&D charge of $0.9 billion primarily related to expected development delays in the general surgery digital robotics platform (Ottava). A probability of success factor ranging from 18% to 66% across Ottava sub-platforms, was used in the fair value calculation to reflect inherent regulatory and commercial risk of the contingent payments and IPR&D. The discount rate applied was approximately 9.5%. In accordance with U.S. GAAP standards related to business combinations, and goodwill and other intangible assets, supplemental pro forma information for fiscal years 2021, 2020 and 2019 is not provided, as the impact of the aforementioned acquisitions did not have a material effect on the Company’s results of operations, cash flows or financial position. Divestitures During fiscal year 2021, in separate transactions, the Company divested two brands outside the U.S. within the Pharmaceutical segment. The Company recognized a pre-tax gain recorded in Other (income) expense, net, of approximately $0.6 billion. During fiscal year 2020, the Company sold 11.8 million shares of Idorsia LTD (Idorsia), or its 8.3% ownership in the company at that time. The transaction resulted in gross proceeds of approximately CHF 337 million ($357 million) based on a sales price of CHF 28.55/share and resulted in an immaterial net loss. At the end of fiscal 2020, the Company had rights to approximately 38.7 million shares through a convertible loan with a principal amount of CHF 445 million (due June 2027). During fiscal year 2021, the Company converted CHF 110 million ($120 million) of this loan into approximately 9.6 million shares of Idorsia which were reflected at fair value as of January 2, 2022. During the fiscal third quarter of 2021, the Company's undrawn credit facility with Idorsia was terminated.

Legal Proceedings

Legal Proceedings	12 Months Ended
Legal Proceedings	Jan. 02, 2022
Commitments and Contingencies Disclosure [Abstract]
Legal Proceedings	Legal ProceedingsJohnson & Johnson and certain of its subsidiaries are involved in various lawsuits and claims regarding product liability; intellectual property; commercial; indemnification and other matters; governmental investigations; and other legal proceedings that arise from time to time in the ordinary course of their business. Due to the ongoing impacts of the COVID-19 pandemic, certain trials have been rescheduled or delayed. The Company continues to monitor its legal proceedings as the situation evolves and in person trials resume. The Company records accruals for loss contingencies associated with these legal matters when it is probable that a liability will be incurred, and the amount of the loss can be reasonably estimated. As of January 2, 2022, the Company has determined that the liabilities associated with certain litigation matters are probable and can be reasonably estimated. The Company has accrued for these matters and will continue to monitor each related legal issue and adjust accruals as might be warranted based on new information and further developments in accordance with ASC 450-20-25. For these and other litigation and regulatory matters discussed below for which a loss is probable or reasonably possible, the Company is unable to estimate the possible loss or range of loss beyond the amounts accrued. Amounts accrued for legal contingencies often result from a complex series of judgments about future events and uncertainties that rely heavily on estimates and assumptions including timing of related payments. The ability to make such estimates and judgments can be affected by various factors including, among other things, whether damages sought in the proceedings are unsubstantiated or indeterminate; scientific and legal discovery has not commenced or is not complete; proceedings are in early stages; matters present legal uncertainties; there are significant facts in dispute; procedural or jurisdictional issues; the uncertainty and unpredictability of the number of potential claims; ability to achieve comprehensive multi-party settlements; complexity of related cross-claims and counterclaims; and/or there are numerous parties involved. To the extent adverse awards, judgments or verdicts have been rendered against the Company, the Company does not record an accrual until a loss is determined to be probable and can be reasonably estimated. In the Company’s opinion, based on its examination of these matters, its experience to date and discussions with counsel, the ultimate outcome of legal proceedings, net of liabilities accrued in the Company’s balance sheet, is not expected to have a material adverse effect on the Company’s financial position. However, the resolution of, or increase in accruals for, one or more of these matters in any reporting period may have a material adverse effect on the Company’s results of operations and cash flows for that period. PRODUCT LIABILITY Johnson & Johnson and certain of its subsidiaries are involved in numerous product liability claims and lawsuits involving multiple products. Claimants in these cases seek substantial compensatory and, where available, punitive damages. While the Company believes it has substantial defenses, it is not feasible to predict the ultimate outcome of litigation. From time to time, even if it has substantial defenses, the Company considers isolated settlements based on a variety of circumstances. The Company has established accruals for product liability claims and lawsuits in compliance with ASC 450-20 based on currently available information, which in some cases may be limited. The Company accrues an estimate of the legal defense costs needed to defend each matter when those costs are probable and can be reasonably estimated. For certain of these matters, the Company has accrued additional amounts such as estimated costs associated with settlements, damages and other losses. Product liability accruals can represent projected product liability for thousands of claims around the world, each in different litigation environments and with different fact patterns. Changes to the accruals may be required in the future as additional information becomes available. The most significant of these cases include: the DePuy ASR™ XL Acetabular System and DePuy ASR™ Hip Resurfacing System; the PINNACLE ® Acetabular Cup System; pelvic meshes; RISPERDAL ® ; XARELTO ® ; body powders containing talc, primarily JOHNSON'S ® Baby Powder; INVOKANA ® ; and ETHICON PHYSIOMESH ® Flexible Composite Mesh. As of January 2, 2022, in the United States there were approximately 250 plaintiffs with direct claims in pending lawsuits regarding injuries allegedly due to the DePuy ASR™ XL Acetabular System and DePuy ASR™ Hip Resurfacing System; 5,300 with respect to the PINNACLE ® Acetabular Cup System; 10,100 with respect to pelvic meshes; 8,800 with respect to RISPERDAL ® ; 5,500 with respect to XARELTO ® ; 40,400 with respect to body powders containing talc; 100 with respect to INVOKANA ® ; and 4,700 with respect to ETHICON PHYSIOMESH ® Flexible Composite Mesh. The number of pending lawsuits is expected to fluctuate as certain lawsuits are settled or dismissed and additional lawsuits are filed. In August 2010, DePuy Orthopaedics, Inc. (DePuy) announced a worldwide voluntary recall of its ASR ™ XL Acetabular System and DePuy ASR ™ Hip Resurfacing System (ASR Hip) used in hip replacement surgery. Claims for personal injury have been made against DePuy and Johnson & Johnson. Cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Northern District of Ohio. Litigation has also been filed in countries outside of the United States, primarily in the United Kingdom, Canada, Australia, Ireland, Germany, India and Italy. In November 2013, DePuy reached an agreement with a Court-appointed committee of lawyers representing ASR Hip plaintiffs to establish a program to settle claims with eligible ASR Hip patients in the United States who had surgery to replace their ASR Hips, known as revision surgery, as of August 2013. DePuy reached additional agreements in February 2015 and March 2017, which further extended the settlement program to include ASR Hip patients who had revision surgeries after August 2013 and prior to February 15, 2017. This settlement program has resolved more than 10,000 claims, thereby bringing to resolution significant ASR Hip litigation activity in the United States. However, lawsuits in the United States remain, and the settlement program does not address litigation outside of the United States. In Australia, a class action settlement was reached that resolved the claims of the majority of ASR Hip patients in that country. In Canada, the Company has reached agreements to settle the class actions filed in that country . The Company continues to receive information with respect to potential additional costs associated with this recall on a worldwide basis. The Company has established accruals for the costs associated with the United States settlement program and ASR Hip-related product liability litigation. Claims for personal injury have also been made against DePuy Orthopaedics, Inc. and Johnson & Johnson (collectively, DePuy) relating to the PINNACLE ® Acetabular Cup System used in hip replacement surgery. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. Cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Northern District of Texas. Litigation also has been filed in some state courts and in countries outside of the United States. Several adverse verdicts have been rendered against DePuy, one of which was reversed on appeal and remanded for retrial. During the first quarter of 2019, DePuy established a United States settlement program to resolve these cases. As part of the settlement program, adverse verdicts have been settled. The Company has established an accrual for product liability litigation associated with the PINNACLE ® Acetabular Cup System and the related settlement program. Claims for personal injury have been made against Ethicon, Inc. (Ethicon) and Johnson & Johnson arising out of Ethicon’s pelvic mesh devices used to treat stress urinary incontinence and pelvic organ prolapse. The Company continues to receive information with respect to potential costs and additional cases. Cases filed in federal courts in the United States had been organized as a multi-district litigation (MDL) in the United States District Court for the Southern District of West Virginia. In March 2021, the MDL Court entered an order closing the MDL. The MDL Court has remanded cases for trial to the jurisdictions where the case was originally filed and additional pelvic mesh lawsuits have been filed, and remain, outside of the MDL. The Company has settled or otherwise resolved the majority of the United States cases and the estimated costs associated with these settlements and the remaining cases are reflected in the Company’s accruals. In addition, class actions and individual personal injury cases or claims seeking damages for alleged injury resulting from Ethicon’s pelvic mesh devices have been commenced in various countries outside of the United States, including claims and cases in the United Kingdom, the Netherlands and class actions in Israel, Australia and Canada. In November 2019, the Federal Court of Australia issued a judgment regarding its findings with respect to liability in relation to the three Lead Applicants and generally in relation to the design, manufacture, pre and post-market assessments and testing, and supply and promotion of the devices in Australia used to treat stress urinary incontinence and pelvic organ prolapse. In March 2020, the Court issued a decision and entered damages awards to the three Lead Applicants. The Company appealed the decision to the intermediate appellate court, the Full Court. The appeal was heard in February 2021 and, in March 2021, the Full Court entered a judgment dismissing the appeal. An application for special leave to the High Court of Australia was filed in April 2021, and the High Court heard oral argument on the application in November 2021. Special leave was refused. While this brings an end to the appellate process, there will now be an individual case assessment process for the remaining group member claims. The parties currently are in discussions with the Court to determine the form and mechanism of that individual case assessment process. The next hearing is scheduled for late February 2022. The class actions in Canada were discontinued in 2020 as a result of a settlement of a group of cases and an agreement to resolve the Israeli class action was reached in May 2021. The parties in the Israeli class action are currently negotiating the wording and some of the terms thereof and once finalized, the settlement will be subject to court approval. The parties are due to update the court on the status of the finalization of the settlement negotiations by the end of February 2022. The Company has established accruals with respect to product liability litigation associated with Ethicon’s pelvic mesh products. Following a June 2016 worldwide market withdrawal of ETHICON PHYSIOMESH ® Flexible Composite Mesh (Physiomesh), claims for personal injury have been made against Ethicon, Inc. (Ethicon) and Johnson & Johnson alleging personal injury arising out of the use of this hernia mesh device. Cases filed in federal courts in the United States have been organized as a multi-district litigation (MDL) in the United States District Court for the Northern District of Georgia. A multi-county litigation (MCL) also has been formed in New Jersey state court and assigned to Atlantic County for cases pending in New Jersey. In addition to the matters in the MDL and MCL, there are additional lawsuits pending in the United States District Court for the Southern District of Ohio, which are part of the MDL for polypropylene mesh devices manufactured by C.R. Bard, Inc., one multi-plaintiff lawsuit pending in Oklahoma state court and lawsuits pending outside the United States. In May 2021, Ethicon and lead counsel for the plaintiffs entered into a term sheet to resolve approximately 3,600 Physiomesh cases (covering approximately 4,300 plaintiffs) pending in the MDL and MCL at that time. A master settlement agreement (MSA) was entered into in September 2021 and includes 3,729 cases in the MDL and MCL. All deadlines and trial settings in those proceedings are currently stayed pending the completion of the settlement agreement. The deadline for issuance of Individual Allocation amounts by the Special Master is March 2022. The costs associated with this proposed settlement are reflected in the Company’s accruals. Post-Settlement cases in the Physiomesh MDL and MCL are subject to docket control orders requiring early expert reports and discovery requirements. As of February 2022, there are approximately 90 active cases subject to these orders which are being reviewed and evaluated. Claims have also been filed against Ethicon and Johnson & Johnson alleging personal injuries arising from the PROCEED ® Mesh and PROCEED ® Ventral Patch hernia mesh products. In March 2019, the New Jersey Supreme Court entered an order consolidating these cases pending in New Jersey as an MCL in Atlantic County Superior Court. Additional cases have been filed in various federal and state courts in the United States, and in jurisdictions outside the United States. Discovery is underway in the MCL proceedings. Ethicon and Johnson & Johnson also have been subject to claims for personal injuries arising from the PROLENE™ Polypropylene Hernia System. In January 2020, the New Jersey Supreme Court created an MCL in Atlantic County Superior Court to handle such cases. Cases involving this product have also been filed in other federal and state courts in the United States. The Company has established accruals with respect to product liability litigation associated with ETHICON PHYSIOMESH ® Flexible Composite Mesh, PROCEED ® Mesh and PROCEED ® Ventral Patch, and PROLENE™ Polypropylene Hernia System products. Claims for personal injury have been made against Janssen Pharmaceuticals, Inc. and Johnson & Johnson arising out of the use of RISPERDAL ® , and related compounds, indicated for the treatment of schizophrenia, acute manic or mixed episodes associated with bipolar I disorder and irritability associated with autism. Lawsuits primarily have been filed in state courts in Pennsylvania, California, and Missouri. Other actions are pending in various courts in the United States and Canada. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. The Company has successfully defended a number of these cases but there have been verdicts against the Company, including a verdict in October 2019 of $8.0 billion of punitive damages related to one plaintiff, which the trial judge reduced to $6.8 million in January 2020. In September 2021, the Company entered into a settlement in principle with the counsel representing plaintiffs in this matter and in substantially all of the outstanding cases in the United States. The costs associated with this and other settlements are reflected in the Company’s accruals. Claims for personal injury arising out of the use of XARELTO ® , an oral anticoagulant, have been made against Janssen Pharmaceuticals, Inc. (JPI); Johnson & Johnson; and JPI’s collaboration partner for XARELTO ® , Bayer Healthcare AG, and certain of its affiliates. Cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Eastern District of Louisiana. In addition, cases have been filed in state courts across the United States. Many of these cases were consolidated into a state mass tort litigation in Philadelphia, Pennsylvania and in a coordinated proceeding in Los Angeles, California. Class action lawsuits also have been filed in Canada. In March 2019, JPI and Johnson & Johnson announced an agreement in principle to settle the XARELTO ® cases in the United States; the settlement agreement was executed in May 2019, the settlement became final in December 2019, and the settlement was funded in January 2020. This resolved the majority of cases pending in the United States. The Company has established accruals for its costs associated with the United States settlement program and XARELTO ® related product liability litigation. A significant number of personal injury claims alleging that talc causes cancer were made against Johnson & Johnson Consumer Inc. and Johnson & Johnson arising out of the use of body powders containing talc, primarily JOHNSON’S ® Baby Powder. The number of these personal injury lawsuits, filed in state and federal courts in the United States as well as outside of the United States, continued to increase through fiscal year 2021. In talc cases that previously have gone to trial, the Company has obtained a number of defense verdicts, but there also have been verdicts against the Company, many of which have been reversed on appeal. In June 2020, the Missouri Court of Appeals reversed in part and affirmed in part a July 2018 verdict of $4.7 billion in Ingham v. Johnson & Johnson, et al., No. ED 207476 (Mo. App.), reducing the overall award to $2.1 billion. An application for transfer of the case to the Missouri Supreme Court was subsequently denied and in June 2021, a petition for certiorari, seeking a review of the Ingham decision by the United States Supreme Court, was denied. In June 2021, the Company paid the award, which, including interest, totaled approximately $2.5 billion. The facts and circumstances, including the terms of the award, were unique to the Ingham decision and not representative of other claims brought against the Company. The Company continues to believe that it has strong legal grounds to contest the other talc verdicts that it has appealed. Notwithstanding the Company’s confidence in the safety of its talc products, in certain circumstances the Company has settled cases. In October 2021, Johnson & Johnson Consumer Inc. (Old JJCI) implemented a corporate restructuring (the 2021 Corporate Restructuring). As a result of that restructuring, Old JJCI ceased to exist and three new entities were created: (a) LTL Management LLC, a North Carolina limited liability company (LTL or Debtor); (b) Royalty A&M LLC, a North Carolina limited liability company and a direct subsidiary of LTL (RAM); and (c) the Debtor’s direct parent, Johnson & Johnson Consumer Inc., a New Jersey company (New JJCI). The Debtor received certain of Old JJCI’s assets and became solely responsible for the talc-related liabilities of Old JJCI, including all liabilities related in any way to injury or damage, or alleged injury or damage, sustained or incurred in the purchase or use of, or exposure to, talc, including talc contained in any product, or to the risk of, or responsibility for, any such damage or injury, except for any liabilities for which the exclusive remedy is provided under a workers’ compensation statute or act (the Talc-Related Liabilities). In October 2021, notwithstanding the Company’s confidence in the safety of its talc products, the Debtor filed a voluntary petition with the United States Bankruptcy Court for the Western District of North Carolina, Charlotte Division, seeking relief under chapter 11 of the Bankruptcy Code (the LTL Bankruptcy Case). As a result of the LTL Bankruptcy Case, the Court entered a temporary restraining order staying all litigation against LTL and Old JJCI. On November 15, 2021, the North Carolina Bankruptcy Court confirmed the scope of the stay, issuing a Preliminary Injunction (PI) prohibiting and enjoining the commencement and prosecution of talc-related claims against LTL, Old JJCI, New JJCI, Johnson & Johnson, other of their corporate affiliates, identified retailers, insurance companies, and certain other parties. The LTL Bankruptcy Case was transferred to the United States Bankruptcy Court for the District of New Jersey in November 2021, and that court subsequently extended the PI through the end of February 2022. Claimants have filed a motion to dismiss the LTL Bankruptcy Case. The court commenced a hearing on February 14, 2022 regarding the motion to dismiss and on whether the PI should be extended. While the PI effectively stays all of the Company’s talc-related personal injury litigation, LTL has agreed to lift the automatic stay on a small number of appeals where appeal bonds have been filed. The Company has agreed to provide funding to LTL for the payment of amounts the Bankruptcy Court determines are owed by LTL through the establishment of a $2 billion trust in furtherance of this purpose. The Company has established a reserve for approximately $2 billion in connection with the aforementioned trust. Subsequent to the fiscal third quarter of 2021, the Company de-consolidated LTL, which is a related party, as a result of the bankruptcy filing. The impact of the de-consolidation is not material to the Company. The parties have not yet been able to reach a resolution of all matters related to talc, and while certain amounts under various scenarios have recently been referred to in testimony as part of the LTL bankruptcy proceedings, the Company is unable to estimate the possible loss or range of loss beyond the amount accrued. In February 2019, the Company’s talc supplier, Imerys Talc America, Inc. and two of its affiliates, Imerys Talc Vermont, Inc. and Imerys Talc Canada, Inc. (collectively, Imerys) filed a voluntary petition under chapter 11 of the United States Code (the Bankruptcy Code) in the United States Bankruptcy Court for the District of Delaware (Imerys Bankruptcy). The Imerys Bankruptcy relates to Imerys’s potential liability for personal injury from exposure to talcum powder sold by Imerys (Talc Claims). In its bankruptcy, Imerys alleges it has claims against the Company for indemnification and rights to joint insurance proceeds. In May 2020, Imerys, its parent Imerys S.A., the Tort Claimants’ Committee (TCC), and the Future Claimants’ Representative (FCR) (collectively, the Plan Proponents) filed their Plan of Reorganization (the Plan) and the Disclosure Statement related thereto. The Plan Proponents have since filed numerous amendments to the Plan and Disclosure Statement. A hearing on the Plan Proponent’s Disclosure Statement was held in January 2021, and the Court entered an order approving the Disclosure Statement, allowing Imerys to proceed with soliciting votes on the Plan. In March 2021, the Company voted to reject the Plan and opted out of the consensual releases in the Plan. In April 2021, the Plan Proponents announced the Plan had received the requisite number of accepting votes to confirm the Plan. The Company challenged certain improprieties with respect to portions of the vote and sought to disqualify those votes. In October 2021, the Bankruptcy Court issued a ruling deeming thousands of votes as withdrawn as improperly voted. In October 2021, Imerys cancelled the confirmation hearing on the Plan. Imerys, the TCC, the FCR, and certain of Imerys’s insurers (the Mediation Parties) have since agreed to engage in mediation. In July 2021, Imerys commenced an adversary proceeding against the Company in the Imerys Bankruptcy (the Imerys adversary proceeding). The Imerys adversary proceeding sought, among other things, certain declarations with respect to the indemnification obligations allegedly owed by the Company to Imerys. The TCC and FCR simultaneously filed a motion for temporary restraining order and preliminary injunction seeking to enjoin the Company from undergoing a corporate restructuring that would separate the Company’s talc liabilities from its other assets. The Bankruptcy Court denied the motion. The Company thereafter filed a motion to dismiss the adversary proceeding. The Bankruptcy Court has not yet decided the motion to dismiss. In October 2021, the Company filed a Notice of Bankruptcy Filing and Stay of Proceedings clarifying that the automatic stay arising upon the filing of the LTL Bankruptcy Case should apply to the Imerys adversary proceeding. In June 2020, Cyprus Mines Corporation and its parent (together, Cyprus), which had owned certain Imerys talc mines, filed an adversary proceeding against the Company and Imerys in the Imerys Bankruptcy seeking a declaration of indemnity rights under certain contractual agreements (the Cyprus adversary proceeding). The Company denies such indemnification is owed, and filed a motion to dismiss the adversary complaint. In February 2021, Cyprus filed a voluntary petition for relief under chapter 11 of the Bankruptcy Code and filed its Disclosure Statement and Plan. The Plan contemplates a settlement with Imerys and talc claimants where Cyprus would make a monetary contribution to a trust established under the Imerys Plan in exchange for an injunction against Talc Claims asserted against it. Cyprus has not yet sought approval of its Disclosure Statement and Plan. Cyprus, along with the TCC and FCR appointed in the Cyprus chapter 11 case, have agreed to participate in the mediation with the Mediation Parties. In October 2021, the Company filed a Notice of Bankruptcy Filing and Stay of Proceedings clarifying that the automatic stay arising upon the filing of the LTL Bankruptcy Case should apply to the Cyprus adversary proceeding. In February 2021, several of the Company’s insurers involved in coverage litigation in New Jersey State Court (the Coverage Action) filed a motion in the Imerys Bankruptcy Court proceeding seeking a determination that the automatic stay does not apply to the Coverage Action and, in the alternative, seeking relief from the automatic stay to allow them to continue to litigate their claims in the Coverage Action. In March 2021, the Company filed a limited response and reservation of rights with respect to the motion. The Court entered an agreed order modifying the stay to allow the litigation in the Coverage Action to continue. In October 2021, LTL filed a Notice of Bankruptcy Filing and Stay of Proceedings clarifying that the automatic stay arising upon the filing of the LTL Bankruptcy Case should apply to the Coverage Action. In February 2018, a securities class action lawsuit was filed against Johnson & Johnson and certain named officers in the United States District Court for the District of New Jersey, alleging that Johnson & Johnson violated the federal securities laws by failing to disclose alleged asbestos contamination in body powders containing talc, primarily JOHNSON’S ® Baby Powder, and that purchasers of Johnson & Johnson’s shares suffered losses as a result. Plaintiff is seeking damages. In April 2019, the Company moved to dismiss the complaint and briefing on the motion was complete as of August 2019. In December 2019, the Court denied, in part, the motion to dismiss. In March 2020, the Company answered the complaint. In April 2021, briefing on Plaintiffs’ motion for class certification was completed. In July 2021, the Company filed a notice of supplemental authority in opposition to Plaintiff’s motion for class certification, and Plaintiff filed a response. In December 2021, the Company filed a motion to supplement the class certification record, and in January 2022, Plaintiff responded. Discovery is ongoing. In June 2019, a shareholder filed a complaint initiating a summary proceeding in New Jersey state court for a books and records inspection. In August 2019, Johnson & Johnson responded to the books and records complaint and filed a cross motion to dismiss. In September 2019, Plaintiff replied and the Court heard oral argument. In February 2022, the Court granted Johnson & Johnson's cross motion to dismiss. In October 2019, December 2019, and January 2020, four shareholders filed four separate derivative lawsuits against Johnson & Johnson as the nominal defendant and its current directors and certain officers as defendants in the United States District Court for the District of New Jersey, alleging a breach of fiduciary duties related to the alleged asbestos contamination in body powders containing talc, primarily JOHNSON’S ® Baby Powder, and that Johnson & Johnson has suffered damages as a result of those alleged breaches. In February 2020, the four cases were consolidated into a single action under the caption In re Johnson & Johnson Talc Stockholder Derivative Litigation . In July 2020, a report was delivered to the Company’s Board of Directors by independent counsel retained by the Board to investigate the allegations in the derivative lawsuits and in a series of shareholder letters that the Board received raising similar issues and demanding that suit be brought against certain Directors. Four of the shareholders who sent demands are plaintiffs in th e In re Johnson & Johnson Talc Stockholder Derivative Litigation . The independent counsel recommended that the Company reject the shareholder demands and take the steps that are necessary or appropriate to secure dismissal of the derivative lawsuits. The Board unanimously adopted the recommendations of the independent counsel’s report. In October 2020, the shareholders filed a consolidated complaint, and in January 2021, Johnson & Johnson moved to dismiss the consolidated complaint. In March 2021, Plaintiffs filed a motion for discovery. The Court temporarily terminated Johnson & Johnson’s motion to dismiss pending a decision on Plaintiff’s motion for discovery. In November 2021, at the Court’s request, the parties submitted supplemental briefing on Plaintiff’s motion for discovery. In January 2019, two ERISA class action lawsuits were filed by participants in the Johnson & Johnson Savings Plan against Johnson & Johnson, its Pension and Benefits Committee, and certain named officers in the United States District Court for the District of New Jersey, alleging that the defendants breached their fiduciary duties by offering Johnson & Johnson stock as a Johnson & Johnson Savings Plan investment option when it was imprudent to do so because of failures to disclose alleged asbestos contamination in body powders containing talc, primarily JOHNSON’S ® Baby Powder. Plaintiffs are seeking damages and injunctive relief. In September 2019, Defendants filed a motion to dismiss. In April 2020, the Court granted Defendants’ motion but granted leave to amend. In June 2020, Plaintiffs filed an amended complaint, and in July 2020, Defendants moved to dismiss the amended complaint. As of October 2020, briefing on Defendants’ motion was complete. In February 2021, the Court granted Defendants’ motion, and granted Plaintiffs leave to amend. In April 2021, Plaintiffs informed the Court that they did not intend to file an amended complaint, and the Court dismissed the case with prejudice. In May 2021, Plaintiffs filed a notice of appeal with the Third Circuit. In July 2021, Plaintiffs filed their opening brief in the Third Circuit and in September 2021, Defendants filed their response brief, and in October 2021, Plaintiffs filed their reply brief. In January 2022, the Third Circuit heard oral argument. A lawsuit was brought against the Company in the Superior Court of California for the County of San Diego alleging violations of California’s Consumer Legal Remedies Act (CLRA) relating to JOHNSON’S ® Baby Powder. In that lawsuit, the plaintiffs allege that Johnson & Johnson violated the CLRA by failing to provide required Proposition 65 warnings. In July 2019, the Company filed a notice of removal to the United States District Court for the Southern District of California and plaintiffs filed a second amended complaint shortly thereafter. In October 2019, the Company moved to dismiss the second amended complaint for failure to state a claim upon which relief may be granted. In response to those motions, plaintiffs filed a third amended complaint. In December 2019, the Company moved to dismiss the third amended complaint for failure to state a claim upon which relief may be granted. In April 2020, the Court granted the motion to dismiss but granted leave to amend. In May 2020, plaintiffs filed a Fourth Amended Complaint but indicated that they would be filing a motion for leave to file a fifth amended

Restructuring

Restructuring	12 Months Ended
Restructuring	Jan. 02, 2022
Restructuring and Related Activities [Abstract]
Restructuring	Restructuring In the fiscal second quarter of 2018, the Company announced plans to implement a series of actions across its Global Supply Chain that are intended to focus resources and increase investments in the critical capabilities, technologies and solutions necessary to manufacture and supply its product portfolio, enhance agility and drive growth. The Global Supply Chain actions include expanding the use of strategic collaborations and bolstering initiatives to reduce complexity, improve cost-competitiveness, enhance capabilities and optimize the Supply Chain network. In fiscal year 2021, the Company recorded a pre-tax charge of $0.5 billion, which is included on the following lines of the Consolidated Statement of Earnings, $0.3 billion in restructuring, $0.1 billion in other (income) expense and $0.1 billion in cost of products sold. Total project costs of approximately $1.8 billion have been recorded since the restructuring was announced. See the following table for additional details on the restructuring program. In total, the Company expects the Global Supply Chain actions to generate approximately $0.6 billion to $0.8 billion in annual pre-tax cost savings that will be substantially delivered by the end of 2022. The program is set to be completed at the end of 2022. The Company expects to record pre-tax restructuring charges of approximately $2.1 billion to $2.3 billion, over the 4 to 5 year period of this activity. These costs are associated with network optimizations, exit costs and accelerated depreciation and amortization. The following table summarizes the severance charges and the associated spending under these initiatives through the fiscal year ended 2021: (Dollars in Millions) Severance Asset Write-offs/Sales Other (2) Total Reserve balance, December 29, 2019 $ 164 — 16 180 2020 activity (29) — (7) (36) Reserve balance, January 3, 2021 135 — 9 144 Current year activity: Charges — 53 420 473 Cash settlements (23) (404) (427) Settled non cash — (53) (53) Reserve balance, January 2, 2022 (1) $ 112 — 25 137 (1) Cash outlays for severance are expected to be substantially paid out over the next year in accordance with the Company's plans and local laws. (2) Other includes project expense such as salaries for employees supporting these initiatives and consulting expenses.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
Summary of Significant Accounting Policies (Policies)	Jan. 02, 2022
Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation The consolidated financial statements include the accounts of Johnson & Johnson and its subsidiaries (the Company). Intercompany accounts and transactions are eliminated. Columns and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures.
Description of the Company And Business Segments	Description of the Company and Business Segments The Company has approximately 141,700 employees worldwide engaged in the research and development, manufacture and sale of a broad range of products in the healthcare field. The Company conducts business in virtually all countries of the world and its primary focus is on products related to human health and well-being. The Company is organized into three business segments: Consumer Health, Pharmaceutical and Medical Devices. The Consumer Health segment includes a broad range of products used in the Baby Care, Oral Care, Skin Health/Beauty, Over-the-Counter pharmaceutical, Women’s Health and Wound Care markets. These products are marketed to the general public and sold online (eCommerce) and to retail outlets and distributors throughout the world. The Pharmaceutical segment is focused on six therapeutic areas, including Immunology, Infectious diseases, Neuroscience, Oncology, Pulmonary Hypertension, and Cardiovascular and Metabolic diseases. Products in this segment are distributed directly to retailers, wholesalers, distributors, hospitals and healthcare professionals for prescription use. The Medical Devices segment includes a broad range of products used in the Orthopaedic, Surgery, Interventional Solutions (cardiovascular and neurovascular) and Vision fields. These products are distributed to wholesalers, hospitals and retailers, and used principally in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. In November 2021, the Company announced its intention to separate the Company’s Consumer Health business, with the intention to create a new, publicly traded company. The Company is targeting completion of the planned separation in 18 to 24 months after initial announcement.
New Accounting Standards	New Accounting Standards Recently Adopted Accounting Standards There were no new material accounting standards adopted in fiscal 2021. Recently Issued Accounting Standards Not Adopted as of January 2, 2022 The Company assesses the adoption impacts of recently issued accounting standards by the Financial Accounting Standards Board on the Company's financial statements as well as material updates to previous assessments, if any, from the Company’s Annual Report on Form 10-K for the fiscal year ended January 3, 2021. There were no new material accounting standards issued in fiscal 2021 that impacted the Company. ASU 2021-01: Reference Rate Reform
Cash Equivalents	Cash Equivalents The Company classifies all highly liquid investments with stated maturities of three months or less from date of purchase as cash equivalents and all highly liquid investments with stated maturities of greater than three months from the date of purchase as current marketable securities. The Company has a policy of making investments only with commercial institutions that have at least an investment grade credit rating. The Company invests its cash primarily in government securities and obligations, corporate debt securities, money market funds and reverse repurchase agreements (RRAs). RRAs are collateralized by deposits in the form of Government Securities and Obligations for an amount not less than 102% of their value. The Company does not record an asset or liability as the Company is not permitted to sell or repledge the associated collateral. The Company has a policy that the collateral has at least an A (or equivalent) credit rating. The Company utilizes a third party custodian to manage the exchange of funds and ensure that collateral received is maintained at 102% of the value of the RRAs on a daily basis. RRAs with stated maturities of greater than three months from the date of purchase are classified as marketable securities.
Investments	InvestmentsInvestments classified as held to maturity investments are reported at amortized cost and realized gains or losses are reported in earnings. Investments classified as available-for-sale debt securities are carried at estimated fair value with unrealized gains and losses recorded as a component of accumulated other comprehensive income. Available-for-sale securities available for current operations are classified as current assets otherwise, they are classified as long term. Management determines the appropriate classification of its investment in debt and equity securities at the time of purchase and re-evaluates such determination at each balance sheet date. The Company reviews its investments for impairment and adjusts these investments to fair value through earnings, as required.
Property, Plant and Equipment and Depreciation	Property, Plant and Equipment and Depreciation Property, plant and equipment are stated at cost. The Company utilizes the straight-line method of depreciation over the estimated useful lives of the assets: Building and building equipment 20 - 30 years Land and leasehold improvements 10 - 20 years Machinery and equipment 2 - 13 years The Company capitalizes certain computer software and development costs, included in machinery and equipment, when incurred in connection with developing or obtaining computer software for internal use. Capitalized software costs are amortized over the estimated useful lives of the software, which generally range from 3 to 8 years. The Company reviews long-lived assets to assess recoverability using undiscounted cash flows. When certain events or changes in operating or economic conditions occur, an impairment assessment may be performed on the recoverability of the carrying value of these assets. If the asset is determined to be impaired, the loss is measured based on the difference between the asset’s fair value and its carrying value. If quoted market prices are not available, the Company will estimate fair value using a discounted value of estimated future cash flows.
Revenue Recognition	Revenue Recognition The Company recognizes revenue from product sales when obligations under the terms of a contract with the customer are satisfied; generally, this occurs with the transfer of control of the goods to customers. The Company's global payment terms are typically between 30 to 90 days. Provisions for certain rebates, sales incentives, trade promotions, coupons, product returns, discounts to customers and governmental clawback provisions are accounted for as variable consideration and recorded as a reduction in sales. The liability is recognized within Accrued Rebates, Returns, and Promotions on the consolidated balance sheet. Product discounts granted are based on the terms of arrangements with direct, indirect and other market participants, as well as market conditions, including consideration of competitor pricing. Rebates are estimated based on contractual terms, historical experience, patient outcomes, trend analysis and projected market conditions in the various markets served. A significant portion of the liability related to rebates is from the sale of the Company's pharmaceutical products within the U.S., primarily t he Managed Care, Medicare and Medicaid programs, which amounted to $7.7 billion and $7.2 billion as of January 2, 2022 and January 3, 2021, respectively. The Company evaluates market conditions for products or groups of products primarily through the analysis of wholesaler and other third-party sell-through and market research data, as well as internally generated information. Sales returns are estimated and recorded based on historical sales and returns information. Products that exhibit unusual sales or return patterns due to dating, competition or other marketing matters are specifically investigated and analyzed as part of the accounting for sales return accruals. Sales returns allowances represent a reserve for products that may be returned due to expiration, destruction in the field, or in specific areas, product recall. The sales returns reserve is based on historical return trends by product and by market as a percent to gross sales. In accordance with the Company’s accounting policies, the Company generally issues credit to customers for returned goods. The Company’s sales returns reserves are accounted for in accordance with the U.S. GAAP guidance for revenue recognition when right of return exists. Sales returns reserves are recorded at full sales value. Sales returns in the Consumer Health and Pharmaceutical segments are almost exclusively not resalable. Sales returns for certain franchises in the Medical Devices segment are typically resalable but are not material. The Company infrequently exchanges products from inventory for returned products. The sales returns reserve for the total Company has been approximately 1.0% of annual net trade sales during each of the fiscal years 2021, 2020 and 2019. Promotional programs, such as product listing allowances and cooperative advertising arrangements, are recorded in the same period as related sales. Continuing promotional programs include coupons and volume-based sales incentive programs. The redemption cost of consumer coupons is based on historical redemption experience by product and value. Volume-based incentive programs are based on the estimated sales volumes for the incentive period and are recorded as products are sold. These arrangements are evaluated to determine the appropriate amounts to be deferred or recorded as a reduction of revenue. The Company also earns profit-share payments through collaborative arrangements for certain products, which are included in sales to customers. For all years presented, profit-share payments were less than 3.0% of the total revenues and are included in sales to customers. See Note 17 to the Consolidated Financial Statements for further disaggregation of revenue.
Shipping and Handling	Shipping and Handling Shipping and handling costs incurred were $1.1 billion, $1.0 billion and $1.0 billion in fiscal years 2021, 2020 and 2019, respectively, and are included in selling, marketing and administrative expense. The amount of revenue received for shipping and handling is less than 0.5% of sales to customers for all periods presented.
Inventories	Inventories Inventories are stated at the lower of cost or net realizable value determined by the first-in, first-out method.
Intangible Assets and Goodwill	Intangible Assets and Goodwill The authoritative literature on U.S. GAAP requires that goodwill and intangible assets with indefinite lives be assessed annually for impairment. The Company completed its annual impairment test for 2021 in the fiscal fourth quarter. Future impairment tests will be performed annually in the fiscal fourth quarter, or sooner if warranted. Purchased in-process research and development is accounted for as an indefinite lived intangible asset until the underlying project is completed, at which point the intangible asset will be accounted for as a definite lived intangible asset, or abandoned, at which point the intangible asset will be written off or partially impaired. Intangible assets that have finite useful lives continue to be amortized over their useful lives, and are reviewed for impairment when warranted by economic conditions. See Note 5 for further details on Intangible Assets and Goodwill.
Financial Instruments	Financial Instruments As required by U.S. GAAP, all derivative instruments are recorded on the balance sheet at fair value. Fair value is the exit price that would be received to sell an asset or paid to transfer a liability. Fair value is a market-based measurement determined using assumptions that market participants would use in pricing an asset or liability. The authoritative literature establishes a three-level hierarchy to prioritize the inputs used in measuring fair value, with Level 1 having the highest priority and Level 3 having the lowest. Changes in the fair value of derivatives are recorded each period in current earnings or other comprehensive income, depending on whether the derivative is designated as part of a hedge transaction, and if so, the type of hedge transaction. The Company documents all relationships between hedged items and derivatives. The overall risk management strategy includes reasons for undertaking hedge transactions and entering into derivatives. The objectives of this strategy are: (1) minimize foreign currency exposure’s impact on the Company’s financial performance; (2) protect the Company’s cash flow from adverse movements in foreign exchange rates; (3) ensure the appropriateness of financial instruments; and (4) manage the enterprise risk associated with financial institutions. See Note 6 for additional information on Financial Instruments.
Leases	Leases The Company determines whether an arrangement is a lease at contract inception by establishing if the contract conveys the right to control the use of identified property, plant, or equipment for a period of time in exchange for consideration. Right of Use (ROU) Assets and Lease Liabilities for operating leases are included in Other assets Accrued liabilities Other liabilities ROU Assets and Lease Liabilities are recognized at the lease commencement date based on the present value of all minimum lease payments over the lease term. The Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments, when the implicit rate is not readily determinable. Lease terms may include options to extend or terminate the lease. These options are included in the lease term when it is reasonably certain that the Company will exercise that option. Operating lease expense is recognized on a straight-line basis over the lease term. The Company has elected the following policy elections on adoption: use of portfolio approach on leases of assets under master service agreements, exclusion of short term leases on the balance sheet, and not separating lease and non-lease components. The Company primarily has operating lease for space, vehicles, manufacturing equipment and data processing equipment. The ROU asset pertaining to operating leases was $0.9 billion and $1.0 billion in 2021 and 2020, respectively. The lease liability was $1.0 billion and $1.1 billion in 2021and 2020, respectively. The operating lease costs were $0.3 billion, $0.3 billion and $0.3 billion in 2021, 2020 and 2019, respectively. Cash paid for amounts included in the measurement of lease liabilities were $0.3 billion, $0.3 billion and $0.3 billion in 2021, 2020 and 2019, respectively.
Product Liability	Product Liability Accruals for product liability claims are recorded, on an undiscounted basis, when it is probable that a liability has been incurred and the amount of the liability can be reasonably estimated based on existing information and actuarially determined estimates where applicable. The accruals are adjusted periodically as additional information becomes available. The Company accrues an estimate of the legal defense costs needed to defend each matter when those costs are probable and can be reasonably estimated. To the extent adverse verdicts have been rendered against the Company, the Company does not record an accrual until a loss is determined to be probable and can be reasonably estimated.
Research and Development	Research and Development Research and development expenses are expensed as incurred in accordance with ASC 730, Research and Development. Upfront and milestone payments made to third parties in connection with research and development collaborations are expensed as incurred up to the point of regulatory approval. Payments made to third parties subsequent to regulatory approval are capitalized and amortized over the remaining useful life of the related product. Amounts capitalized for such payments are included in other intangibles, net of accumulated amortization. The Company enters into collaborative arrangements, typically with other pharmaceutical or biotechnology companies, to develop and commercialize drug candidates or intellectual property. These arrangements typically involve two (or more) parties who are active participants in the collaboration and are exposed to significant risks and rewards dependent on the commercial success of the activities. These collaborations usually involve various activities by one or more parties, including research and development, marketing and selling and distribution. Often, these collaborations require upfront, milestone and royalty or profit share payments, contingent upon the occurrence of certain future events linked to the success of the asset in development. Amounts due from collaborative partners related to development activities are generally reflected as a reduction of research and development expense because the performance of contract development services is not central to the Company’s operations. In general, the income statement presentation for these collaborations is as follows: Nature/Type of Collaboration Statement of Earnings Presentation Third-party sale of product & profit share payments received Sales to customers Royalties/milestones paid to collaborative partner (post-regulatory approval)* Cost of products sold Royalties received from collaborative partner Other income (expense), net Upfront payments & milestones paid to collaborative partner (pre-regulatory approval) Research and development expense Research and development payments to collaborative partner Research and development expense Research and development payments received from collaborative partner or government entity Reduction of Research and development expense * Milestones are capitalized as intangible assets and amortized to cost of products sold over the useful life. For all years presented, there was no individual project that represented greater than 5% of the total annual consolidated research and development expense. The Company has a number of products and compounds developed in collaboration with strategic partners including XARELTO ® , co-developed with Bayer HealthCare AG and IMBRUVICA ® , developed in collaboration and co-marketed with Pharmacyclics LLC, an AbbVie company. Separately, the Company has a number of licensing arrangements for products and compounds including DARZALEX ® , licensed from Genmab A/S.
Advertising	Advertising Costs associated with advertising are expensed in the year incurred and are included in selling, marketing and administrative expenses. Advertising expenses worldwide, which comprised television, radio, print media and Internet advertising, were $2.7 billion, $2.1 billion and $2.2 billion in fiscal years 2021, 2020 and 2019, respectively.
Income Taxes	Income Taxes Income taxes are recorded based on amounts refundable or payable for the current year and include the results of any difference between U.S. GAAP accounting and tax reporting, recorded as deferred tax assets or liabilities. The Company estimates deferred tax assets and liabilities based on enacted tax regulations and rates. Future changes in tax laws and rates may affect recorded deferred tax assets and liabilities in the future. The Company has unrecognized tax benefits for uncertain tax positions. The Company follows U.S. GAAP which prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. Management believes that changes in these estimates would not have a material effect on the Company's results of operations, cash flows or financial position. In 2017, the United States enacted into law new U.S. tax legislation, the U.S. Tax Cuts and Jobs Act (TCJA). This law included provisions for a comprehensive overhaul of the corporate income tax code, including a reduction of the statutory corporate tax rate from 35% to 21%, effective on January 1, 2018. The TCJA included a provision for a tax on all previously undistributed earnings of U.S. companies located in foreign jurisdictions. Undistributed earnings in the form of cash and cash equivalents were taxed at a rate of 15.5% and all other earnings were taxed at a rate of 8.0%. This tax is payable over 8 years and will not accrue interest. These payments began in 2018 and will continue through 2025. The remaining balance at the end of the 2021 was approximately $6.9 billion, of which $6.1 billion is classified as noncurrent and reflected as “Long-term taxes payable” on the Company’s balance sheet. The balance of this account is related to receivables from tax authorities not expected to be received in the next 12 months. The TCJA also includes provisions for a tax on global intangible low-taxed income (GILTI). GILTI is described as the excess of a U.S. shareholder’s total net foreign income over a deemed return on tangible assets, as provided by the TCJA. In January 2018, the FASB issued guidance that allows companies to elect as an accounting policy whether to record the tax effects of GILTI in the period the tax liability is generated (i.e., “period cost”) or provide for deferred tax assets and liabilities related to basis differences that exist and are expected to effect the amount of GILTI inclusion in future years upon reversal (i.e., “deferred method”). The Company has elected to account for GILTI under the deferred method. The deferred tax amounts recorded are based on the evaluation of temporary differences that are expected to reverse as GILTI is incurred in future periods. The Company has recorded deferred tax liabilities on all undistributed earnings prior to December 31, 2017 from its international subsidiaries. The Company has not provided deferred taxes on the undistributed earnings subsequent to January 1, 2018 from certain international subsidiaries where the earnings are considered to be indefinitely reinvested. The Company intends to continue to reinvest these earnings in those international operations. If the Company decides at a later date to repatriate these earnings to the U.S., the Company would be required to provide for the net tax effects on these amounts. The Company estimates that the tax effect of this repatriation would be approximately $0.7 billion under currently enacted tax laws and regulations and at current currency exchange rates. This amount does not include the possible benefit of U.S. foreign tax credits, which may substantially offset this cost. See Note 8 to the Consolidated Financial Statements for further information regarding income taxes.
Net Earnings Per Share	Net Earnings Per Share Basic earnings per share is computed by dividing net earnings available to common shareholders by the weighted average number of common shares outstanding for the period. Diluted earnings per share reflects the potential dilution that could occur if securities were exercised or converted into common stock using the treasury stock method.
Use of Estimates	Use of Estimates The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the U.S. requires management to make estimates and assumptions that affect the amounts reported. Estimates are used when accounting for sales discounts, rebates, allowances and incentives, product liabilities, income taxes, withholding taxes, depreciation, amortization, employee benefits, contingencies and intangible asset and liability valuations. Actual results may or may not differ from those estimates. The Company follows the provisions of U.S. GAAP when recording litigation related contingencies. A liability is recorded when a loss is probable and can be reasonably estimated. The best estimate of a loss within a range is accrued; however, if no estimate in the range is better than any other, the minimum amount is accrued. The extent to which COVID-19 impacts the Company’s business and financial results will depend on numerous evolving factors including, but not limited to: the magnitude and duration of COVID-19, the extent to which it will impact worldwide macroeconomic conditions including interest rates, employment rates and health insurance coverage, the speed of the anticipated recovery, and governmental and business reactions to the pandemic. The Company assessed certain accounting matters that generally require consideration of forecasted financial information in context with the information reasonably available to the Company and the unknown future impacts of COVID-19 as of January 2, 2022 and through the date of this report. The accounting matters assessed included, but were not limited to, the Company’s allowance for doubtful accounts and credit losses, inventory and related reserves, accrued rebates and associated reserves, and the carrying value of the goodwill and other long-lived assets along with the Company’s on-going vaccine development and distribution efforts. While there was not a material impact to the Company’s consolidated financial statements as of and for the fiscal year ended January 2, 2022, the Company’s future assessment of the magnitude and duration of COVID-19, as well as other factors, could result in material impacts to the Company’s consolidated financial statements in future reporting periods.
Annual Closing Date	Annual Closing Date The Company follows the concept of a fiscal year, which ends on the Sunday nearest to the end of the month of December. Normally each fiscal year consists of 52 weeks, but every five or six years the fiscal year consists of 53 weeks, and therefore includes additional shipping days, as was the case in fiscal year 2020, and will be the case again in fiscal year 2026.
Reclassification	Reclassification Certain prior period amounts have been reclassified to conform to current year presentation.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	12 Months Ended
Summary of Significant Accounting Policies (Tables)	Jan. 02, 2022
Accounting Policies [Abstract]
Estimated Useful Lives of Assets	Property, plant and equipment are stated at cost. The Company utilizes the straight-line method of depreciation over the estimated useful lives of the assets: Building and building equipment 20 - 30 years Land and leasehold improvements 10 - 20 years Machinery and equipment 2 - 13 years

Cash, Cash Equivalents and Cu_2

Cash, Cash Equivalents and Current Marketable Securities (Tables)	12 Months Ended
	Jan. 02, 2022
Cash and Cash Equivalents [Abstract]
Cash and Cash Equivalent Composition	At the end of the fiscal year 2021 and 2020, cash, cash equivalents and current marketable securities were comprised of: (Dollars in Millions) 2021 Carrying Amount Unrecognized Loss Estimated Fair Value Cash & Cash Equivalents Current Marketable Securities Cash $ 2,936 — 2,936 2,936 — Non-U.S. Sovereign Securities (1) 1,006 — 1,006 90 916 U.S. Reverse repurchase agreements 1,659 — 1,659 1,659 — Corporate debt securities (1) 3,479 (1) 3,478 200 3,279 Money market funds 1,901 — 1,901 1,901 — Time deposits (1) 900 — 900 900 — Subtotal $ 11,881 (1) 11,880 7,686 4,195 U.S. Gov't Securities $ 19,485 (4) 19,481 6,785 12,696 Other Sovereign Securities 1 — 1 1 — Corporate debt securities 245 — 245 15 230 Subtotal available for sale (2) $ 19,731 (4) 19,727 6,801 12,926 Total cash, cash equivalents and current marketable securities $ 14,487 17,121 (Dollars in Millions) 2020 Carrying Amount Unrecognized Gain Estimated Fair Value Cash & Cash Equivalents Current Marketable Securities Cash $ 2,863 — 2,863 2,863 — Non-U.S. Sovereign Securities (1) 690 — 690 — 690 U.S. Reverse repurchase agreements 1,937 — 1,937 1,937 — Corporate debt securities (1) 2,674 — 2,674 1,451 1,223 Money market funds 2,102 — 2,102 2,102 — Time deposits (1) 877 — 877 877 — Subtotal $ 11,143 — 11,143 9,230 1,913 Gov't Securities $ 13,777 1 13,778 4,731 9,047 Other Sovereign Securities 14 — 14 — 14 Corporate debt securities 250 — 250 24 226 Subtotal available for sale (2) $ 14,041 1 14,042 4,755 9,287 Total cash, cash equivalents and current marketable securities $ 13,985 11,200 (1) Held to maturity investments are reported at amortized cost and realized gains or losses are reported in earnings. (2) Available for sale debt securities are reported at fair value with unrealized gains and losses reported net of taxes in other comprehensive income.
Contractual Maturities of Available for Sale Securities	The contractual maturities of the available for sale debt securities at January 2, 2022 are as follows: (Dollars in Millions) Cost Basis Fair Value Due within one year $ 19,709 19,705 Due after one year through five years 22 22 Due after five years through ten years — — Total debt securities $ 19,731 19,727

Inventories (Tables)

Inventories (Tables)	12 Months Ended
Inventories (Tables)	Jan. 02, 2022
Inventory Disclosure [Abstract]
Summary of Inventories	At the end of fiscal years 2021 and 2020, inventories were comprised of: (Dollars in Millions) 2021 2020 Raw materials and supplies $ 1,592 1,410 Goods in process 2,287 2,040 Finished goods 6,508 5,894 Total inventories $ 10,387 9,344

Property, Plant and Equipment (

Property, Plant and Equipment (Tables)	12 Months Ended
Property, Plant and Equipment (Tables)	Jan. 02, 2022
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment at Cost and Accumulated Depreciation	At the end of fiscal years 2021 and 2020, property, plant and equipment at cost and accumulated depreciation were: (Dollars in Millions) 2021 2020 Land and land improvements $ 884 882 Buildings and building equipment 12,882 12,502 Machinery and equipment 29,774 29,104 Construction in progress 4,139 4,316 Total property, plant and equipment, gross $ 47,679 46,804 Less accumulated depreciation 28,717 28,038 Total property, plant and equipment, net (1) $ 18,962 18,766

Intangible Assets and Goodwill

Intangible Assets and Goodwill (Tables)	12 Months Ended
Intangible Assets and Goodwill (Tables)	Jan. 02, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Intangible Assets and Goodwill	At the end of fiscal years 2021 and 2020, the gross and net amounts of intangible assets were: (Dollars in Millions) 2021 2020 Intangible assets with definite lives: Patents and trademarks — gross $ 38,572 39,990 Less accumulated amortization (20,088) (17,618) Patents and trademarks — net $ 18,484 22,372 Customer relationships and other intangibles — gross $ 23,011 22,898 Less accumulated amortization (11,925) (10,912) Customer relationships and other intangibles — net (1) $ 11,086 11,986 Intangible assets with indefinite lives: Trademarks $ 6,985 7,195 Purchased in-process research and development (2) 9,837 11,849 Total intangible assets with indefinite lives $ 16,822 19,044 Total intangible assets — net $ 46,392 53,402 (1) The majority is comprised of customer relationships (2) In fiscal 2021, the Company recorded a partial IPR&D impairment charge of $0.9 billion primarily related to expected development delays in the general surgery digital robotics platform (Ottava) acquired with the Auris Health acquisition in 2019. The impairment charge was calculated based on revisions to the discounted cash flow valuation model reflecting a delay of first in human procedures of approximately two years from the initial acquisition model assumption of the second half of 2022. The remaining reduction was driven by assets that reached commercialization and are now classified as having definite lives.
Goodwill	Goodwill as of January 2, 2022 and January 3, 2021, as allocated by segment of business, was as follows: (Dollars in Millions) Consumer Health Pharmaceutical Medical Devices Total Goodwill at December 29, 2019 $ 9,736 9,169 14,734 33,639 Goodwill, related to acquisitions — 1,222 238 1,460 Currency translation/other 600 618 76 1,294 Goodwill at January 3, 2021 $ 10,336 11,009 15,048 36,393 Goodwill, related to acquisitions — — — — Goodwill, related to divestitures (9) — — (9) Currency translation/other (517) (429) (192) (1,138) Goodwill at January 2, 2022 $ 9,810 10,580 14,856 35,246
Intangible Asset Amortization Expense	The estimated amortization expense for approved products, before tax, for the five succeeding years is approximately: (Dollars in Millions) 2022 2023 2024 2025 2026 $4,600 4,600 4,400 3,600 3,000

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	12 Months Ended
Fair Value Measurements (Tables)	Jan. 02, 2022
Fair Value Disclosures [Abstract]
Summary of Derivative Activity	The following table is a summary of the activity related to derivatives and hedges for the fiscal years ended January 2, 2022 and January 3, 2021, net of tax: January 2, 2022 January 3, 2021 (Dollars in Millions) Sales Cost of Products Sold R&D Expense Interest (Income) Expense Other (Income) Expense Sales Cost of Products Sold R&D Expense Interest (Income) Expense Other (Income) Expense The effects of fair value, net investment and cash flow hedging: Gain (Loss) on fair value hedging relationship: Interest rate swaps contracts: Hedged items $ — — — (109) — — — — — — Derivatives designated as hedging instruments — — — 109 — — — — — — Gain (Loss) on net investment hedging relationship: Cross currency interest rate swaps contracts: Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing $ — — — 174 — — — — 153 — Amount of gain or (loss) recognized in AOCI — — — 174 — — — — 153 — Gain (Loss) on cash flow hedging relationship: Forward foreign exchange contracts: Amount of gain or (loss) reclassified from AOCI into income 17 119 30 — 47 12 (329) (137) — (16) Amount of gain or (loss) recognized in AOCI (94) (557) 123 — 146 44 298 (91) — (52) Cross currency interest rate swaps contracts: Amount of gain or (loss) reclassified from AOCI into income — — — 402 — — — — 370 — Amount of gain or (loss) recognized in AOCI $ — — — 9 — — — — 748 — As of January 2, 2022 and January 3, 2021, the following amounts were recorded on the consolidated balance sheet related to cumulative basis adjustment for fair value hedges Line item in the Consolidated Balance Sheet in which the hedged item is included Carrying Amount of the Hedged Liability Cumulative Amount of Fair Value Hedging Adjustment Included in the Carrying Amount of the Hedged Liability (Dollars in Millions) January 2, 2022 January 3, 2021 January 2, 2022 January 3, 2021 Long-term Debt $ 9,793 $ — $ (142) $ —
Schedule of Effect of Derivatives not Designated as Hedging Instruments	The following table is the effect of derivatives not designated as hedging instrument for the fiscal years ended January 2, 2022 and January 3, 2021: (Dollars in Millions) Location of Gain /(Loss) Recognized in Income on Derivative Gain/(Loss) Derivatives Not Designated as Hedging Instruments January 2, 2022 January 3, 2021 Foreign Exchange Contracts Other (income) expense $ (70) 24
Schedule of Effect of Net Investment Hedges	The following table is the effect of net investment hedges for the fiscal years ended January 2, 2022 and January 3, 2021: Gain/(Loss) Location of Gain or (Loss) Reclassified from Accumulated Other Comprehensive Income Into Income Gain/(Loss) Reclassified From (Dollars in Millions) January 2, 2022 January 3, 2021 January 2, 2022 January 3, 2021 Debt $ 387 (473) Interest (income) expense — — Cross Currency interest rate swaps $ 548 65 Interest (income) expense — —
Summary of Activity Related to Equity Investments	The following table is a summary of the activity related to equity investments for the fiscal years ended January 2, 2022 and January 3, 2021: January 3, 2021 January 2, 2022 (Dollars in Millions) Carrying Value Changes in Fair Value Reflected in Net Income (1) Sales/ Purchases/Other (2) Carrying Value Non Current Other Assets Equity Investments with readily determinable value $ 1,481 198 205 1,884 1,884 Equity Investments without readily determinable value $ 738 394 (632) 500 500 December 29, 2019 January 3, 2021 (Dollars in Millions) Carrying Value Changes in Fair Value Reflected in Net Income (1) Sales/ Purchases/Other (2) Carrying Value Non Current Other Assets Equity Investments with readily determinable value $ 1,148 527 (194) 1,481 1,481 Equity Investments without readily determinable value $ 712 (55) 81 738 738 (1) Recorded in Other Income/Expense (2) Other includes impact of currency
Financial Assets and Liabilities at Fair Value	The Company’s significant financial assets and liabilities measured at fair value as of the fiscal year ended January 2, 2022 and January 3, 2021 were as follows: 2021 2020 (Dollars in Millions) Level 1 Level 2 Level 3 Total Total (1) Derivatives designated as hedging instruments: Assets: Forward foreign exchange contracts $ — 540 — 540 849 Interest rate contracts (2) — 796 — 796 240 Total $ — 1,336 — 1,336 1,089 Liabilities: Forward foreign exchange contracts — 881 — 881 702 Interest rate contracts (2) — 979 — 979 1,569 Total $ — 1,860 — 1,860 2,271 Derivatives not designated as hedging instruments: Assets: Forward foreign exchange contracts $ — 24 — 24 49 Liabilities: Forward foreign exchange contracts — 28 — 28 38 Available For Sale Other Investments: Equity investments (3) 1,884 — — 1,884 1,481 Debt securities (4) — 19,727 — 19,727 14,042 Other Liabilities Contingent Consideration (5) $ 533 533 633 Gross to Net Derivative Reconciliation 2021 2020 (Dollars in Millions) Total Gross Assets $ 1,360 1,138 Credit Support Agreement (CSA) (1,285) (1,107) Total Net Asset 75 31 Total Gross Liabilities 1,888 2,309 Credit Support Agreement (CSA) (1,855) (2,172) Total Net Liabilities $ 33 137 Summarized information about changes in liabilities for contingent consideration is as follows: 2021 2020 2019 (Dollars in Millions) Beginning Balance $ 633 1,715 397 Changes in estimated fair value (6) (52) (1,089) 151 Additions — 106 1,246 Payments (48) (99) (79) Ending Balance $ 533 633 1,715 (1) 2020 assets and liabilities are all classified as Level 2 with the exception of equity investments of $1,481 million, which are classified as Level 1 and contingent consideration of $633 million, classified as Level 3. (2) Includes cross currency interest rate swaps and interest rate swaps. (3) Classified as non-current other assets. (4) Classified as cash equivalents and current marketable securities. (5) Includes $520 million, $594 million and $1,631 million, classified as non-current other liabilities as of January 2, 2022, January 3, 2021 and December 29, 2019, respectively. Includes $13 million, $39 million and $84 million classified as current liabilities as of January 2, 2022, January 3, 2021 and December 29, 2019, respectively. (6) Ongoing fair value adjustment amounts are recorded primarily in Research and Development expense. The Company recorded a contingent consideration reversal of $1,148 million in 2020 related to the timing of certain developmental milestones associated with the Auris Health acquisition. The reversal of the contingent consideration was recorded in Other income and expense.

Borrowings (Tables)

Borrowings (Tables)	12 Months Ended
Borrowings (Tables)	Jan. 02, 2022
Debt Disclosure [Abstract]
Schedule of Long-term Debt Instruments	The components of long-term debt are as follows: (Dollars in Millions) 2021 Effective Rate % 2020 Effective Rate % 3.55% Notes due 2021 $ — — % $ 450 3.67 % 2.45% Notes due 2021 — — 350 2.48 1.65% Notes due 2021 — — 999 1.65 0.250% Notes due 2022 (1B Euro 1.1311) (2) /(1B Euro 1.2281) (3) 1,131 (2) 0.26 1,227 (3) 0.26 2.25% Notes due 2022 1,000 2.31 999 2.31 6.73% Debentures due 2023 250 6.73 250 6.73 3.375% Notes due 2023 802 3.18 803 3.17 2.05% Notes due 2023 499 2.09 499 2.09 0.650% Notes due 2024 (750MM Euro 1.1311) (2) /(750MM Euro 1.2281) (3) 847 (2) 0.68 919 (3) 0.68 5.50% Notes due 2024 (500MM 1.3485 GBP ) (2) /(500MM GBP 1.3654) (3) 672 (2) 6.75 679 (3) 6.75 2.625% Notes due 2025 749 2.63 748 2.63 0.55% Notes due 2025 983 0.57 996 0.57 2.45% Notes due 2026 1,995 2.47 1,994 2.47 2.95% Notes due 2027 978 2.96 997 2.96 0.95% Notes due 2027 1,478 0.96 1,494 0.96 1.150% Notes due 2028 (750MM Euro 1.1311) (2) /(750MM Euro 1.2281) (3) 843 (2) 1.21 915 (3) 1.21 2.90% Notes due 2028 1,495 2.91 1,495 2.91 6.95% Notes due 2029 298 7.14 297 7.14 1.30% Notes due 2030 1,723 1.30 1,743 1.30 4.95% Debentures due 2033 498 4.95 498 4.95 4.375% Notes due 2033 854 4.24 855 4.24 1.650% Notes due 2035 (1.5B Euro 1.1311) (2) /(1.5B Euro 1.2281) (3) 1,683 (2) 1.68 1,827 (3) 1.68 3.55% Notes due 2036 974 3.59 989 3.59 5.95% Notes due 2037 993 5.99 992 5.99 3.625% Notes due 2037 1,475 3.64 1,488 3.64 5.85% Debentures due 2038 696 5.85 696 5.85 3.400% Notes due 2038 992 3.42 991 3.42 4.50% Debentures due 2040 540 4.63 539 4.63 2.10% Notes due 2040 974 2.14 986 2.14 4.85% Notes due 2041 297 4.89 297 4.89 4.50% Notes due 2043 496 4.52 496 4.52 3.70% Notes due 2046 1,975 3.74 1,974 3.74 3.75% Notes due 2047 971 3.76 991 3.76 3.500% Notes due 2048 743 3.52 742 3.52 2.250% Notes due 2050 983 2.29 984 2.29 2.450% Notes due 2060 1,222 2.49 1,228 2.49 Other 7 — 7 — Subtotal 32,116 (4) 2.89 % (1) 34,434 (4) 2.85 % (1) Less current portion 2,131 1,799 Total long-term debt $ 29,985 $ 32,635 (1) Weighted average effective rate. (2) Translation rate at January 2, 2022. (3) Translation rate at January 3, 2021. (4) The excess of the fair value over the carrying value of debt was $3.2 billion at the end of fiscal year 2021 and $5.4 billion at the end of fiscal year 2020.
Aggregate Maturities of Long Term Obligations	Aggregate maturities of long-term debt obligations commencing in 2022 are: (Dollars in Millions) 2022 2023 2024 2025 2026 After 2026 $2,131 1,551 1,518 1,732 1,995 23,189

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
Income Taxes (Tables)	Jan. 02, 2022
Income Tax Disclosure [Abstract]
Provision for Income Taxes	The provision for taxes on income consists of: (Dollars in Millions) 2021 2020 2019 Currently payable: U.S. taxes $ 1,525 1,026 1,941 International taxes 2,452 1,898 2,744 Total currently payable 3,977 2,924 4,685 Deferred: U.S. taxes 583 (76) (814) International taxes (2,662) (1,065) (1,662) Total deferred (2,079) (1,141) (2,476) Provision for taxes on income $ 1,898 1,783 2,209
Comparison of Income Taxes at Statutory Rate and Company's Effective Tax Rate	A comparison of income tax expense at the U.S. statutory rate of 21% in fiscal years 2021, 2020 and 2019, to the Company’s effective tax rate is as follows: (Dollars in Millions) 2021 2020 2019 U.S. $ 6,110 4,312 3,543 International 16,666 12,185 13,785 Earnings before taxes on income: $ 22,776 16,497 17,328 Tax rates: U.S. statutory rate 21.0 % 21.0 21.0 International operations (1) (16.4) (9.9) (5.9) U.S. taxes on international income (2) 6.7 2.7 1.8 Tax benefits from loss on capital assets (1.3) (1.2) (0.3) Tax benefits on share-based compensation (1.0) (1.5) (0.5) TCJA and related impacts (0.5) 0.7 (3.9) (3) All other (0.2) (1.0) 0.5 Effective Rate 8.3 % 10.8 12.7 (1) For all periods presented the Company has subsidiaries operating in Puerto Rico under various tax incentives. International operations reflects the impacts of operations in jurisdictions with statutory tax rates different than the U.S., particularly Ireland, Switzerland and Puerto Rico, which is a favorable impact on the effective tax rate as compared with the U.S. statutory rate. The 2021 amounts include the reorganization of international subsidiaries; the 2020 and 2019 amounts include the impact of the new tax legislation enactment in Switzerland, both of which are further described below. (2) Includes the impact of the GILTI tax, the Foreign-Derived Intangible Income deduction and other foreign income that is taxable under the U.S. tax code. The 2021 amounts include the reorganization of international subsidiaries; the 2020 and 2019 amounts include the impact of the new tax legislation enactment in Switzerland, both of which is further described below.
Temporary Differences and Carryforwards	Temporary differences and carryforwards at the end of fiscal years 2021 and 2020 were as follows: 2021 Deferred Tax 2020 Deferred Tax (1) (Dollars in Millions) Asset Liability Asset Liability Employee related obligations $ 1,244 2,434 Stock based compensation 679 627 Depreciation of property, plant and equipment (876) (823) Goodwill and intangibles (2,659) (2) (5,023) R&D capitalized for tax 1,664 1,517 Reserves & liabilities 2,882 3,466 Income reported for tax purposes 2,566 1,777 Net realizable operating loss carryforward 1,073 990 Undistributed foreign earnings 1,015 (1,461) 812 (1,435) Global intangible low-taxed income (4,853) (3,606) Miscellaneous international 1,006 (39) 854 (211) Miscellaneous U.S. 495 (59) Total deferred income taxes $ 12,624 (9,888) 12,477 (11,157) ( 1) Certain prior year amounts have been reclassified to conform to current year presentation
Summary of Activity Related to Unrecognized Tax Benefits	The following table summarizes the activity related to unrecognized tax benefits: (Dollars in Millions) 2021 2020 2019 Beginning of year $ 3,373 3,853 3,326 Increases related to current year tax positions 242 265 249 Increases related to prior period tax positions 23 668 408 Decreases related to prior period tax positions (128) (551) (105) Settlements (187) (839) (9) Lapse of statute of limitations 0 (23) (16) End of year $ 3,323 3,373 3,853

Employee Related Obligations (T

Employee Related Obligations (Tables)	12 Months Ended
Employee Related Obligations (Tables)	Jan. 02, 2022
Compensation Related Costs [Abstract]
Employee Related Obligations	At the end of fiscal 2021 and fiscal 2020, employee related obligations recorded on the Consolidated Balance Sheets were: (Dollars in Millions) 2021 2020 Pension benefits $ 4,088 5,761 Postretirement benefits 2,069 2,229 Postemployment benefits 3,117 3,078 Deferred compensation 181 250 Total employee obligations 9,455 11,318 Less current benefits payable 557 547 Employee related obligations — non-current $ 8,898 10,771

Pensions and Other Benefit Pl_2

Pensions and Other Benefit Plans (Tables)	12 Months Ended
Pensions and Other Benefit Plans (Tables)	Jan. 02, 2022
Retirement Benefits [Abstract]
Components of Net Periodic Benefit Cost	Net periodic benefit costs for the Company’s defined benefit retirement plans and other benefit plans for 2021, 2020 and 2019 include the following components: Retirement Plans Other Benefit Plans (Dollars in Millions) 2021 2020 2019 2021 2020 2019 Service cost $ 1,421 1,380 1,163 309 287 274 Interest cost 770 955 1,096 81 133 185 Expected return on plan assets (2,645) (2,461) (2,322) (7) (7) (6) Amortization of prior service cost (181) 2 4 (31) (31) (31) Recognized actuarial losses (gains) 1,257 891 579 151 142 129 Curtailments and settlements 1 23 73 — — — Net periodic benefit cost $ 623 790 593 503 524 551
Rates Used to Develop Actuarial Present Value of Projected Benefit Obligation	The following table represents the weighted-average actuarial assumptions: Retirement Plans Other Benefit Plans Worldwide Benefit Plans 2021 2020 2019 2021 2020 2019 Net Periodic Benefit Cost Service cost discount rate 2.14 % 2.82 3.63 2.09 3.04 4.45 Interest cost discount rate 2.34 % 3.13 4.13 2.33 3.08 4.25 Rate of increase in compensation levels 4.01 % 4.00 3.99 4.25 4.25 4.29 Expected long-term rate of return on plan assets 7.71 % 8.12 8.31 Benefit Obligation Discount rate 2.49 % 2.14 2.91 2.68 2.23 3.39 Rate of increase in compensation levels 4.01 % 4.00 4.01 4.21 4.27 4.29
Assumed Health Care Cost Trend Rates	The following table displays the assumed healthcare cost trend rates, for all individuals: Healthcare Plans 2021 2020 Healthcare cost trend rate assumed for next year 5.33 % 5.68 % Rate to which the cost trend rate is assumed to decline (ultimate trend) 3.73 % 4.49 % Year the rate reaches the ultimate trend rate 2046 2040
Schedule of Net Funded Status	The following table sets forth information related to the benefit obligation and the fair value of plan assets at fiscal year-end 2021 and 2020 for the Company’s defined benefit retirement plans and other post-retirement plans: Retirement Plans Other Benefit Plans (Dollars in Millions) 2021 2020 2021 2020 Change in Benefit Obligation Projected benefit obligation — beginning of year $ 43,300 37,188 5,028 5,076 Service cost 1,421 1,380 309 287 Interest cost 770 955 81 133 Plan participant contributions 67 61 — — Amendments (1) 5 (1,780) — — Actuarial (gains) losses (2) (2,132) 5,716 (188) (75) Divestitures & acquisitions (2) (88) — — Curtailments, settlements & restructuring (7) (24) — — Benefits paid from plan (1,157) (1,111) (348) (396) Effect of exchange rates (683) 1,003 (4) 3 Projected benefit obligation — end of year $ 41,582 43,300 4,878 5,028 Change in Plan Assets Plan assets at fair value — beginning of year $ 38,195 32,201 90 115 Actual return on plan assets 4,439 5,524 17 14 Company contributions 969 870 343 357 Plan participant contributions 67 61 — — Settlements (7) (13) — — Divestitures & acquisitions (2) (84) — — Benefits paid from plan assets (1,157) (1,111) (348) (396) Effect of exchange rates (574) 747 — — Plan assets at fair value — end of year $ 41,930 38,195 102 90 Funded status — end of year $ 348 (5,105) (4,776) (4,938) Amounts Recognized in the Company’s Balance Sheet consist of the following: Non-current assets $ 4,436 656 — — Current liabilities (115) (125) (438) (418) Non-current liabilities (3,973) (5,636) (4,338) (4,520) Total recognized in the consolidated balance sheet — end of year $ 348 (5,105) (4,776) (4,938) Amounts Recognized in Accumulated Other Comprehensive Income consist of the following: Net actuarial loss $ 5,539 10,860 1,113 1,463 Prior service cost (credit) (1) (1,610) (1,797) (13) (44) Unrecognized net transition obligation — — — — Total before tax effects $ 3,929 9,063 1,100 1,419 Accumulated Benefit Obligations — end of year $ 39,049 40,356 (1) In January 2021, the Company announced that, effective on January 1, 2026, all eligible U.S. non-union employees, regardless of hire date, will earn benefits under the Retirement Value formula. This amendment does not affect the benefits accrued under the Final Average Pay formula for service before January 1, 2026. (2) The actuarial gain for retirement plans in 2021 was primarily related to increases in discount rates; the actuarial losses for retirement plans in 2020 were primarily related to decreases in discount rates. Retirement Plans Other Benefit Plans (Dollars in Millions) 2021 2020 2021 2020 Amounts Recognized in Net Periodic Benefit Cost and Other Comprehensive Income Net periodic benefit cost $ 623 790 503 524 Net actuarial (gain) loss (3,927) 2,616 (199) (81) Amortization of net actuarial loss (1,257) (891) (151) (142) Prior service cost (credit) 5 (1,780) — — Amortization of prior service (cost) credit 181 (2) 31 31 Effect of exchange rates (136) 293 — 1 Total loss/(income) recognized in other comprehensive income, before tax $ (5,134) 236 (319) (191) Total recognized in net periodic benefit cost and other comprehensive income $ (4,511) 1,026 184 333
Information Related to the Benefit Obligation and the Fair Value of Plan Assets	The following table displays the funded status of the Company's U.S. Qualified & Non-Qualified pension plans and international funded and unfunded pension plans at December 31, 2021 and December 31, 2020, respectively: U.S. Plans International Plans Qualified Plans Non-Qualified Plans Funded Plans Unfunded Plans (Dollars in Millions) 2021 2020 2021 2020 2021 2020 2021 2020 Plan Assets $ 27,944 25,554 — — 13,986 12,641 — — Projected Benefit Obligation 25,041 25,466 2,703 2,748 13,428 14,541 410 545 Accumulated Benefit Obligation 23,985 24,158 2,479 2,495 12,212 13,210 373 493 Over (Under) Funded Status Projected Benefit Obligation $ 2,903 88 (2,703) (2,748) 558 (1,900) (410) (545) Accumulated Benefit Obligation 3,959 1,396 (2,479) (2,495) 1,774 (569) (373) (493)
Projected Future Benefit Payments from Company's Retirement and Other Benefit Plans	The following table displays the projected future benefit payments from the Company’s retirement and other benefit plans: (Dollars in Millions) 2022 2023 2024 2025 2026 2027-2031 Projected future benefit payments Retirement plans $ 1,317 1,386 1,421 1,496 1,572 9,279 Other benefit plans $ 447 459 472 485 434 2,379
Projected Future Minimum Contributions to the Company's U.S. and International Unfunded Retirement Plans	The following table displays the projected future minimum contributions to the unfunded retirement plans. These amounts do not include any discretionary contributions that the Company may elect to make in the future. (Dollars in Millions) 2022 2023 2024 2025 2026 2027-2031 Projected future contributions $ 114 119 126 133 139 794
Company' Retirement Plan Asset Allocation and Target Allocations	The Company’s retirement plan asset allocation at the end of 2021 and 2020 and target allocations for 2022 are as follows: Percent of Target 2021 2020 2022 Worldwide Retirement Plans Equity securities 65 % 66 % 61 % Debt securities 35 34 39 Total plan assets 100 % 100 % 100 %
Schedule of Defined Benefit Plans Disclosures	The following table sets forth the Retirement Plans' investments measured at fair value as of December 31, 2021 and December 31, 2020: Quoted Prices Significant Significant Unobservable Inputs (1) Investments Measured at Net Asset Value (Level 1) (Level 2) (Level 3) Total Assets (Dollars in Millions) 2021 2020 2021 2020 2021 2020 2021 2020 2021 2020 Short-term investment funds $ 102 127 1,033 763 — — — — 1,135 890 Government and agency securities — — 7,016 5,023 — — — — 7,016 5,023 Debt instruments — — 3,505 3,931 — — — — 3,505 3,931 Equity securities 14,107 14,375 2 2 — — — — 14,109 14,377 Commingled funds — — 5,496 4,690 105 160 8,708 8,236 14,309 13,086 Other assets — — 34 11 15 21 1,807 856 1,856 888 Investments at fair value $ 14,209 14,502 17,086 14,420 120 181 10,515 9,092 41,930 38,195 (1) The activity for the Level 3 assets is not significant for all years presented.

Capital and Treasury Stock (Tab

Capital and Treasury Stock (Tables)	12 Months Ended
Capital and Treasury Stock (Tables)	Jan. 02, 2022
Equity [Abstract]
Changes in Treasury Stock	Changes in treasury stock were: Treasury Stock (Amounts in Millions Except Treasury Stock Shares in Thousands) Shares Amount Balance at December 30, 2018 457,519 $ 34,362 Employee compensation and stock option plans (20,053) (2,691) Repurchase of common stock 49,870 6,746 Balance at December 29, 2019 487,336 38,417 Employee compensation and stock option plans (21,765) (3,148) Repurchase of common stock 21,760 3,221 Balance at January 3, 2021 487,331 38,490 Employee compensation and stock option plans (17,399) (2,847) Repurchase of common stock 20,946 3,456 Balance at January 2, 2022 490,878 $ 39,099

Accumulated Other Comprehensi_2

Accumulated Other Comprehensive Income (Loss) (Tables)	12 Months Ended
Accumulated Other Comprehensive Income (Loss) (Tables)	Jan. 02, 2022
Equity [Abstract]
Components of Accumulated Other Comprehensive Income	Components of other comprehensive income (loss) consist of the following: (Dollars in Millions) Foreign Gain/(Loss) On Securities Employee Benefit Plans Gain/ Total December 30, 2018 $ (8,869) — (6,158) (195) (15,222) Net 2019 changes 164 — (733) (100) (669) December 29, 2019 (8,705) — (6,891) (295) (15,891) Net 2020 changes (233) 1 (66) 947 649 January 3, 2021 (8,938) 1 (6,957) 652 (15,242) Net 2021 changes (1,079) (4) 4,255 (988) 2,184 January 2, 2022 $ (10,017) (3) (2,702) (336) (13,058)

Earnings Per Share (Tables)

Earnings Per Share (Tables)	12 Months Ended
Earnings Per Share (Tables)	Jan. 02, 2022
Earnings Per Share [Abstract]
Reconciliation of Basic Net Earnings per Share to Diluted Net Earnings per Share	The following is a reconciliation of basic net earnings per share to diluted net earnings per share for the fiscal years ended January 2, 2022, January 3, 2021 and December 29, 2019: (In Millions Except Per Share Amounts) 2021 2020 2019 Basic net earnings per share $ 7.93 5.59 5.72 Average shares outstanding — basic 2,632.1 2,632.8 2,645.1 Potential shares exercisable under stock option plans 138.0 118.3 136.3 Less: shares repurchased under treasury stock method (96.1) (80.4) (97.8) Convertible debt shares — — 0.7 Adjusted average shares outstanding — diluted 2,674.0 2,670.7 2,684.3 Diluted net earnings per share $ 7.81 5.51 5.63

Common Stock, Stock Option Pl_2

Common Stock, Stock Option Plans and Stock Compensation Agreements (Tables)	12 Months Ended
	Jan. 02, 2022
Share-based Payment Arrangement [Abstract]
Schedule Valuation Assumptions	The average fair value of options granted was $20.86, $16.42 and $17.80, in fiscal years 2021, 2020 and 2019, respectively. The fair value was estimated based on the weighted average assumptions of: 2021 2020 2019 Risk-free rate 0.83 % 1.47 % 2.56 % Expected volatility 18.59 % 15.33 % 16.27 % Expected life (in years) 7.0 7.0 7.0 Expected dividend yield 2.50 % 2.60 % 2.80 %
Summary of Stock Option Activity	A summary of option activity under the Plan as of January 2, 2022, January 3, 2021 and December 29, 2019, and changes during the years ending on those dates is presented below: (Shares in Thousands) Outstanding Shares Weighted Aggregate Shares at December 30, 2018 109,652 $ 98.29 $ 3,214 Options granted 19,745 131.94 Options exercised (14,785) 82.43 Options canceled/forfeited (2,975) 125.11 Shares at December 29, 2019 111,637 105.63 4,478 Options granted 20,723 151.41 Options exercised (16,275) 86.05 Options canceled/forfeited (1,835) 137.62 Shares at January 3, 2021 114,250 116.22 4,703 Options granted 18,525 164.62 Options exercised (13,248) 97.48 Options canceled/forfeited (2,166) 149.75 Shares at January 2, 2022 117,361 $ 125.36 $ 5,364
Summary of Options Outstanding	The following table summarizes stock options outstanding and exercisable at January 2, 2022: (Shares in Thousands) Outstanding Exercisable Exercise Price Range Options Average Life (1) Weighted Average Exercise Price Options Weighted Average Exercise Price $65.08-$90.44 16,007 1.6 $81.92 16,007 $81.92 $100.06-$101.87 22,647 3.6 $101.07 22,647 $101.07 $115.67-$129.51 24,543 5.6 $122.59 23,972 $122.43 $131.94-$151.41 36,304 7.6 $142.23 100 $140.72 $151.42-$164.62 17,860 9.1 $164.62 16 $164.62 117,361 5.8 $125.36 62,742 $104.42 (1) Average contractual life remaining in years.
Summary of Restricted Share Units	A summary of the restricted share units and performance share units activity under the Plans as of January 2, 2022 is presented below: (Shares in Thousands) Outstanding Restricted Share Units Outstanding Performance Share Units Shares at January 3, 2021 14,998 2,236 Granted 4,981 741 Issued (5,101) (610) Canceled/forfeited/adjusted (756) (55) Shares at January 2, 2022 14,122 2,312

Segments of Business and Geog_2

Segments of Business and Geographic Areas (Tables)	12 Months Ended
Segments of Business and Geographic Areas (Tables)	Jan. 02, 2022	Jan. 03, 2021
Segment Reporting [Abstract]
Schedule of Sales by Segment of Business	Sales to Customers % Change (Dollars in Millions) 2021 2020 2019 ’21 vs. ’20 ’20 vs. ’19 Consumer Health OTC U.S. $ 2,594 2,460 2,010 5.4 % 22.4 International 2,634 2,364 2,434 11.4 (2.9) Worldwide 5,227 4,824 4,444 8.4 8.5 Skin Health/Beauty U.S. 2,400 2,350 2,392 2.1 (1.7) International 2,141 2,100 2,201 1.9 (4.6) Worldwide 4,541 4,450 4,593 2.0 (3.1) Oral Care U.S. 637 683 621 (6.7) 9.9 International 1,008 958 906 5.1 5.7 Worldwide 1,645 1,641 1,528 0.2 7.4 Baby Care U.S. 378 376 362 0.5 3.7 International 1,188 1,141 1,313 4.1 (13.1) Worldwide 1,566 1,517 1,675 3.2 (9.4) Women's Health U.S. 13 13 12 (1.6) 8.2 International 905 888 974 1.8 (8.8) Worldwide 917 901 986 1.8 (8.6) Wound Care/Other U.S. 495 480 441 3.1 8.9 International 243 240 230 1.7 4.1 Worldwide 739 720 671 2.6 7.2 TOTAL CONSUMER HEALTH U.S. 6,516 6,362 5,839 2.4 9.0 International 8,119 7,691 8,059 5.6 (4.6) Worldwide 14,635 14,053 13,898 4.1 1.1 PHARMACEUTICAL Immunology U.S. 10,843 10,175 9,641 6.6 5.5 International 5,907 4,880 4,309 21.0 13.2 Worldwide 16,750 15,055 13,950 11.3 7.9 REMICADE ® U.S. 2,019 2,508 3,079 (19.5) (18.5) U.S. Exports 236 346 294 (31.9) 18.0 International 935 893 1,007 4.8 (11.4) Worldwide 3,190 3,747 4,380 (14.9) (14.4) SIMPONI / SIMPONI ARIA ® U.S. 1,127 1,155 1,159 (2.4) (0.3) International 1,148 1,088 1,029 5.5 5.8 Worldwide 2,276 2,243 2,188 1.4 2.6 STELARA ® U.S. 5,938 5,240 4,346 13.3 20.6 International 3,196 2,467 2,015 29.6 22.4 Worldwide 9,134 7,707 6,361 18.5 21.1 TREMFYA ® U.S. 1,503 926 764 62.3 21.3 International 624 421 248 48.2 69.9 Worldwide 2,127 1,347 1,012 57.9 33.2 OTHER IMMUNOLOGY U.S. 21 — — — International 3 11 10 (73.3) 6.4 Worldwide 24 11 10 6.4 Infectious Diseases U.S. 2,249 1,735 1,597 29.7 8.6 International 3,612 1,839 1,815 96.3 1.3 Worldwide 5,861 3,574 3,413 64.0 4.7 COVID-19 VACCINE U.S. 634 — — International 1,751 — — Worldwide 2,385 — — EDURANT ® / rilpivirine U.S. 41 44 50 (7.6) (11.2) International 953 920 812 3.6 13.3 Worldwide 994 964 861 3.1 11.9 PREZISTA ® / PREZCOBIX ® / REZOLSTA ® / SYMTUZA ® U.S. 1,508 1,587 1,422 (4.9) 11.6 International 575 597 689 (3.6) (13.4) Worldwide 2,083 2,184 2,110 (4.6) 3.5 OTHER INFECTIOUS DISEASES U.S. 66 104 126 (36.0) (17.6) International 333 323 315 3.0 2.6 Worldwide 399 427 441 (6.5) (3.2) Neuroscience U.S. 3,347 3,091 2,919 8.3 5.9 International 3,664 3,457 3,409 6.0 1.4 Worldwide 7,011 6,548 6,328 7.1 3.5 CONCERTA ® / methylphenidate U.S. 172 183 233 (5.8) (21.4) International 495 439 463 12.8 (5.1) Worldwide 667 622 696 7.3 (10.6) INVEGA SUSTENNA ® / XEPLION ® / INVEGA TRINZA ® / TREVICTA ® U.S. 2,550 2,314 2,107 10.2 9.8 International 1,472 1,339 1,224 10.0 9.4 Worldwide 4,022 3,653 3,330 10.1 9.7 RISPERDAL CONSTA ® U.S. 287 296 314 (2.9) (5.9) International 305 346 374 (11.8) (7.5) Worldwide 592 642 688 (7.7) (6.8) OTHER NEUROSCIENCE U.S. 338 298 266 13.3 12.4 International 1,391 1,334 1,349 4.3 (1.1) Worldwide 1,729 1,632 1,614 6.0 1.1 Oncology U.S. 5,958 5,092 4,299 17.0 18.5 International 8,590 7,275 6,393 18.1 13.8 Worldwide 14,548 12,367 10,692 17.6 15.7 DARZALEX ® U.S. 3,169 2,232 1,567 42.0 42.4 International 2,854 1,958 1,430 45.8 36.9 Worldwide 6,023 4,190 2,998 43.8 39.8 ERLEADA ® U.S. 813 583 297 39.3 96.1 International 478 176 35 * * * * Worldwide 1,291 760 332 70.0 * * IMBRUVICA ® U.S. 1,747 1,821 1,555 (4.0) 17.1 International 2,622 2,307 1,856 13.6 24.3 Worldwide 4,369 4,128 3,411 5.8 21.0 ZYTIGA ® / abiraterone acetate U.S. 119 373 810 (68.1) (54.0) International 2,178 2,097 1,985 3.9 5.6 Worldwide 2,297 2,470 2,795 (7.0) (11.6) OTHER ONCOLOGY U.S. 110 83 70 31.7 18.6 International 458 738 1,087 (37.9) (32.1) Worldwide 568 821 1,158 (30.8) (29.1) Pulmonary Hypertension U.S. 2,365 2,133 1,684 10.9 26.6 International 1,085 1,015 939 6.9 8.2 Worldwide 3,450 3,148 2,623 9.6 20.0 OPSUMIT ® U.S. 1,147 1,008 766 13.7 31.7 International 672 631 562 6.6 12.3 Worldwide 1,819 1,639 1,327 11.0 23.5 UPTRAVI ® U.S. 1,056 955 714 10.5 33.8 International 181 138 105 31.1 30.9 Worldwide 1,237 1,093 819 13.1 33.5 OTHER U.S. 163 169 205 (3.7) (17.6) International 232 247 272 (5.9) (9.2) Worldwide 395 416 476 (5.0) (12.8) Cardiovascular / Metabolism / Other U.S. 3,192 3,509 3,734 (9.0) (6.0) International 1,268 1,369 1,458 (7.4) (6.1) Worldwide 4,460 4,878 5,192 (8.6) (6.0) XARELTO ® U.S. 2,438 2,345 2,313 4.0 1.4 International — — — — — Worldwide 2,438 2,345 2,313 4.0 1.4 INVOKANA ® / INVOKAMET ® U.S. 308 564 536 (45.4) 5.2 International 254 231 199 9.9 16.3 Worldwide 563 795 735 (29.3) 8.2 PROCRIT ® / EPREX ® U.S. 223 277 505 (19.7) (45.1) International 256 274 285 (6.8) (3.8) Worldwide 479 552 790 (13.3) (30.2) OTHER U.S. 223 323 380 (31.0) (15.1) International 758 864 974 (12.2) (11.3) Worldwide 981 1,186 1,353 (17.3) (12.4) TOTAL PHARMACEUTICAL U.S. 27,954 25,735 23,874 8.6 7.8 International 24,126 19,837 18,324 21.6 8.3 Worldwide 52,080 45,572 42,198 14.3 8.0 MEDICAL DEVICES Interventional Solutions U.S. 1,836 1,452 1,443 26.4 0.6 International 2,135 1,594 1,554 34.0 2.6 Worldwide 3,971 3,046 2,997 30.4 1.6 Orthopaedics U.S. 5,126 4,779 5,319 7.3 (10.2) International 3,462 2,984 3,520 16.0 (15.2) Worldwide 8,588 7,763 8,839 10.6 (12.2) HIPS U.S. 883 793 863 11.4 (8.2) International 602 487 575 23.6 (15.3) Worldwide 1,485 1,280 1,438 16.0 (11.0) KNEES U.S. 787 743 889 5.9 (16.4) International 538 427 591 26.1 (27.8) Worldwide 1,325 1,170 1,480 13.3 (21.0) TRAUMA U.S. 1,819 1,648 1,652 10.4 (0.2) International 1,066 966 1,068 10.4 (9.6) Worldwide 2,885 2,614 2,720 10.4 (3.9) SPINE, SPORTS & OTHER U.S. 1,637 1,595 1,915 2.6 (16.7) International 1,256 1,104 1,286 13.8 (14.1) Worldwide 2,893 2,699 3,201 7.2 (15.7) Surgery U.S. 3,867 3,249 3,828 19.0 (15.1) International 5,945 4,983 5,673 19.3 (12.2) Worldwide 9,812 8,232 9,501 19.2 (13.4) ADVANCED U.S. 1,761 1,535 1,637 14.9 (6.2) International 2,861 2,304 2,458 24.1 (6.2) Worldwide 4,622 3,839 4,095 20.4 (6.2) GENERAL U.S. 2,105 1,714 2,192 22.7 (21.8) International 3,085 2,679 3,215 15.2 (16.7) Worldwide 5,190 4,392 5,406 18.1 (18.8) Vision U.S. 1,857 1,557 1,794 19.3 (13.2) International 2,831 2,362 2,830 19.8 (16.5) Worldwide 4,688 3,919 4,624 19.6 (15.2) CONTACT LENSES / OTHER U.S. 1,398 1,213 1,304 15.2 (7.0) International 2,043 1,781 2,088 14.7 (14.7) Worldwide 3,440 2,994 3,392 14.9 (11.7) SURGICAL U.S. 459 344 490 33.5 (29.7) International 788 581 742 35.7 (21.7) Worldwide 1,248 925 1,232 34.9 (24.9) TOTAL MEDICAL DEVICES U.S. 12,686 11,036 12,384 14.9 (10.9) International 14,374 11,923 13,579 20.6 (12.2) Worldwide 27,060 22,959 25,963 17.9 (11.6) WORLDWIDE U.S. 47,156 43,133 42,097 9.3 2.5 International 46,619 39,451 39,962 18.2 (1.3) Worldwide $ 93,775 82,584 82,059 13.6 % 0.6 Certain prior year amounts have been reclassified to conform to current year presentation *Percentage greater than 100% or not meaningful
Schedule of Segment Reporting Information	Income (Loss) Before Tax Identifiable Assets (Dollars in Millions) 2021 (3) 2020 (4) 2019 (5) 2021 2020 Consumer Health $ 1,294 (1,064) 2,061 $ 25,081 27,355 Pharmaceutical 18,181 15,462 8,816 64,376 66,158 Medical Devices 4,373 3,044 7,286 53,372 49,578 Total 23,848 17,442 18,163 142,829 143,091 Less: Expense not allocated to segments (1) 1,072 945 835 General corporate (2) 39,189 31,803 Worldwide total $ 22,776 16,497 17,328 $ 182,018 174,894 Additions to Property, Depreciation and (Dollars in Millions) 2021 2020 2019 2021 2020 2019 Consumer Health $ 331 248 328 $ 759 785 765 Pharmaceutical 1,198 863 950 4,029 4,006 3,910 Medical Devices 1,933 1,980 1,912 2,286 2,140 2,014 Segments total 3,462 3,091 3,190 7,074 6,931 6,689 General corporate 190 256 308 316 300 320 Worldwide total $ 3,652 3,347 3,498 $ 7,390 7,231 7,009
Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas		Sales to Customers Long-Lived Assets (6) (Dollars in Millions) 2021 2020 2019 2021 2020 United States $ 47,156 43,133 42,097 $ 48,586 49,951 Europe 23,594 18,980 18,466 43,257 49,363 Western Hemisphere excluding U.S. 5,750 5,335 5,941 2,708 2,734 Asia-Pacific, Africa 17,275 15,136 15,555 5,035 5,484 Segments total 93,775 82,584 82,059 99,586 107,532 General corporate 1,014 1,029 Other non long-lived assets 81,418 66,333 Worldwide total $ 93,775 82,584 82,059 $ 182,018 174,894 See Note 1 for a description of the segments in which the Company operates. Export sales are not significant. In fiscal year 2021, the Company utilized three wholesalers distributing products for all three segments that represented approximately 14.0%, 11.0% and 11.0% of the total consolidated revenues. In fiscal year 2020, the Company had three wholesalers distributing products for all three segments that represented approximately 16.0%, 12.0% and 12.0% of the total consolidated revenues. In fiscal year 2019, the Company had three wholesalers distributing products for all three segments that represented approximately 15.0%, 12.0%, and 11.0% of the total consolidated revenues. (1) Amounts not allocated to segments include interest (income) expense and general corporate (income) expense. (2) General corporate includes cash, cash equivalents and marketable securities. (3) Consumer Health includes: • Litigation expense of $1.6 billion, primarily talc related reserves • A restructuring related charge of $0.1 billion Pharmaceutical includes: • Litigation expense of $0.6 billion, primarily related to Risperdal • Divestiture gains of $0.6 billion • Gains on securities of $0.5 billion • A restructuring related charge of $0.1 billion Medical Devices includes: • A restructuring related charge of $0.3 billion • An in-process research and development expense of $0.9 billion • A Medical Device Regulation charge of $0.2 billion • Litigation expense of $0.1 billion (4) Consumer Health includes: • Litigation expense of $3.9 billion, primarily talc related reserves and certain settlements. Pharmaceutical includes: • Litigation expense of $0.8 billion, primarily related to the agreement in principle to settle opioid litigation • An unrealized gain on securities of $0.5 billion • A restructuring related charge of $0.1 billion Medical Devices includes: • A contingent consideration reversal of $1.1 billion related to the timing of certain developmental milestones associated with the Auris Health acquisition. • Litigation expense of $0.3 billion • A restructuring related charge of $0.3 billion • An in-process research and development expense of $0.2 billion • A Medical Device Regulation charge of $0.1 billion (5) Consumer Health includes: • A gain of $0.3 billion related to the Company's previously held equity investment in DR. CI:LABO • Litigation expense of $0.4 billion • A restructuring related charge of $0.1 billion Pharmaceutical includes: • Litigation expense of $4.3 billion of which $4.0 billion is related to the agreement in principle to settle opioid litigation • An in-process research and development expense of $0.9 billion related to the Alios asset • A research and development expense of $0.3 billion for an upfront payment related to argenx • An unrealized gain on securities of $0.6 billion • Actelion acquisition and integration related costs of $0.2 billion • A restructuring charge of $0.1 billion Medical Devices includes: • A gain of $2.0 billion from the divestiture of the ASP business • A restructuring related charge of $0.4 billion • Litigation expense of $0.4 billion • Auris Health acquisition and integration related costs of $0.1 billion (6) Long-lived assets include property, plant and equipment, net for fiscal years 2021, and 2020 of $18,962 and $18,766, respectively, and intangible assets and goodwill, net for fiscal years 2021 and 2020 of $81,638 and $89,795, respectively.

Restructuring (Tables)

Restructuring (Tables)	12 Months Ended
Restructuring (Tables)	Jan. 02, 2022
Restructuring and Related Activities [Abstract]
Summary of Severance Charges and Associated Spending	The following table summarizes the severance charges and the associated spending under these initiatives through the fiscal year ended 2021: (Dollars in Millions) Severance Asset Write-offs/Sales Other (2) Total Reserve balance, December 29, 2019 $ 164 — 16 180 2020 activity (29) — (7) (36) Reserve balance, January 3, 2021 135 — 9 144 Current year activity: Charges — 53 420 473 Cash settlements (23) (404) (427) Settled non cash — (53) (53) Reserve balance, January 2, 2022 (1) $ 112 — 25 137 (1) Cash outlays for severance are expected to be substantially paid out over the next year in accordance with the Company's plans and local laws. (2) Other includes project expense such as salaries for employees supporting these initiatives and consulting expenses.

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Narrative (Details) $ in Millions	12 Months Ended
	Jan. 02, 2022USD ($)SegmentEmployee	Jan. 03, 2021USD ($)	Dec. 29, 2019USD ($)	Dec. 30, 2018	Dec. 31, 2017
Concentration of Credit Risk [Line Items]
Number of employees \| Employee	141,700
Number of business segments \| Segment	3
Minimum reverse repurchase agreement collateral (as a percent)	102.00%
Accrued Rebates Returns And Promotions	$ 12,095	$ 11,513
Sales return reserve (as a percent)	1.00%	1.00%	1.00%
Percentage of profit share payments (less than)	3.00%	3.00%	3.00%
Cost of products sold	$ 29,855	$ 28,427	$ 27,556
Shipping and handling costs as a percent of sales	0.50%	0.50%	0.50%
Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]	Other assets, noncurrent	Other assets, noncurrent
Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]	Accrued Liabilities, Current	Accrued Liabilities, Current
Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]	Other Liabilities, Noncurrent	Other Liabilities, Noncurrent
Operating lease, right-of-use asset	$ 900	$ 1,000
Operating lease liabilities	1,000	1,100
Operating lease costs	300	300	$ 300
Cash paid for operating leases	300	300	300
Advertising expense	$ 2,700	$ 2,100	$ 2,200
U.S. statutory rate	21.00%	21.00%	21.00%	21.00%	35.00%
TCJA, undistributed foreign earnings percent related to cash and cash equivalents				15.50%
TCJA, undistributed foreign earnings percent related to earnings other than cash and cash equivalents				8.00%
TCJA, provisional liability	$ 6,900
TJCA , provisional liability, non-current	6,100
Repatriation of foreign earnings amount	$ 700
Minimum \| Software Development
Concentration of Credit Risk [Line Items]
Estimated useful lives of the assets	3 years
Maximum \| Software Development
Concentration of Credit Risk [Line Items]
Estimated useful lives of the assets	8 years
R&D Expense \| Project Concentration Risk
Concentration of Credit Risk [Line Items]
Concentration risk, threshold percentage (as a percent)	0.05	0.05	0.05
Shipping and Handling
Concentration of Credit Risk [Line Items]
Cost of products sold	$ 1,100	$ 1,000	$ 1,000
Pharmaceutical
Concentration of Credit Risk [Line Items]
Accrued Rebates Returns And Promotions	$ 7,700	$ 7,200

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Estimated Useful Lives of Assets (Details)	12 Months Ended
	Jan. 02, 2022
Minimum \| Building and building equipment
Property, Plant and Equipment [Line Items]
Estimated useful lives of the assets	20 years
Minimum \| Land and leasehold improvements
Property, Plant and Equipment [Line Items]
Estimated useful lives of the assets	10 years
Minimum \| Machinery and equipment
Property, Plant and Equipment [Line Items]
Estimated useful lives of the assets	2 years
Maximum \| Building and building equipment
Property, Plant and Equipment [Line Items]
Estimated useful lives of the assets	30 years
Maximum \| Land and leasehold improvements
Property, Plant and Equipment [Line Items]
Estimated useful lives of the assets	20 years
Maximum \| Machinery and equipment
Property, Plant and Equipment [Line Items]
Estimated useful lives of the assets	13 years

Cash, Cash Equivalents and Cu_3

Cash, Cash Equivalents and Current Marketable Securities - Cash and Cash Equivalent Composition (Details) - USD ($) $ in Millions	Jan. 02, 2022	Jan. 03, 2021
Cash, Cash Equivalents, and Short-term Investments [Abstract]
Fair value, available-for-sale	$ 19,727	$ 14,042
Cash & Cash Equivalents	14,487	13,985
Current Marketable Securities	17,121	11,200
Held-to-maturity Securities
Cash, Cash Equivalents, and Short-term Investments [Abstract]
Carrying Amount, held-to-maturity	11,881	11,143
Fair value, held-to-maturity	11,880	11,143
Cash & Cash Equivalents	7,686	9,230
Current Marketable Securities	4,195	1,913
Held-to-maturity, unrecognized loss	(1)
Held-to-maturity, unrecognized gain		0
Held-to-maturity Securities \| Cash
Cash, Cash Equivalents, and Short-term Investments [Abstract]
Carrying Amount, held-to-maturity	2,936	2,863
Fair value, held-to-maturity	2,936	2,863
Cash & Cash Equivalents	2,936	2,863
Current Marketable Securities	0	0
Held-to-maturity, unrecognized loss	0
Held-to-maturity, unrecognized gain		0
Held-to-maturity Securities \| Non-U.S. Sovereign Securities
Cash, Cash Equivalents, and Short-term Investments [Abstract]
Carrying Amount, held-to-maturity	1,006	690
Fair value, held-to-maturity	1,006	690
Cash & Cash Equivalents	90	0
Current Marketable Securities	916	690
Held-to-maturity, unrecognized loss	0
Held-to-maturity, unrecognized gain		0
Held-to-maturity Securities \| U.S. Reverse repurchase agreements
Cash, Cash Equivalents, and Short-term Investments [Abstract]
Carrying Amount, held-to-maturity	1,659	1,937
Fair value, held-to-maturity	1,659	1,937
Cash & Cash Equivalents	1,659	1,937
Current Marketable Securities	0	0
Held-to-maturity, unrecognized loss	0
Held-to-maturity, unrecognized gain		0
Held-to-maturity Securities \| Corporate debt securities
Cash, Cash Equivalents, and Short-term Investments [Abstract]
Carrying Amount, held-to-maturity	3,479	2,674
Fair value, held-to-maturity	3,478	2,674
Cash & Cash Equivalents	200	1,451
Current Marketable Securities	3,279	1,223
Held-to-maturity, unrecognized loss	(1)
Held-to-maturity, unrecognized gain		0
Held-to-maturity Securities \| Money market funds
Cash, Cash Equivalents, and Short-term Investments [Abstract]
Carrying Amount, held-to-maturity	1,901	2,102
Fair value, held-to-maturity	1,901	2,102
Cash & Cash Equivalents	1,901	2,102
Current Marketable Securities	0	0
Held-to-maturity, unrecognized loss	0
Held-to-maturity, unrecognized gain		0
Held-to-maturity Securities \| Time deposits
Cash, Cash Equivalents, and Short-term Investments [Abstract]
Carrying Amount, held-to-maturity	900	877
Fair value, held-to-maturity	900	877
Cash & Cash Equivalents	900	877
Current Marketable Securities	0	0
Held-to-maturity, unrecognized loss	0
Held-to-maturity, unrecognized gain		0
Available-for-sale Securities
Cash, Cash Equivalents, and Short-term Investments [Abstract]
Carrying Amount, available-for-sale	19,731	14,041
Fair value, available-for-sale	19,727	14,042
Cash & Cash Equivalents	6,801	4,755
Current Marketable Securities	12,926	9,287
Available-for-sale, unrecognized loss	(4)
Available-for-sale, unrecognized gain		1
Available-for-sale Securities \| Corporate debt securities
Cash, Cash Equivalents, and Short-term Investments [Abstract]
Carrying Amount, available-for-sale	245	250
Fair value, available-for-sale	245	250
Cash & Cash Equivalents	15	24
Current Marketable Securities	230	226
Available-for-sale, unrecognized loss	0
Available-for-sale, unrecognized gain		0
Available-for-sale Securities \| U.S. Gov't Securities
Cash, Cash Equivalents, and Short-term Investments [Abstract]
Carrying Amount, available-for-sale	19,485	13,777
Fair value, available-for-sale	19,481	13,778
Cash & Cash Equivalents	6,785	4,731
Current Marketable Securities	12,696	9,047
Available-for-sale, unrecognized loss	(4)
Available-for-sale, unrecognized gain		1
Available-for-sale Securities \| Other Sovereign Securities
Cash, Cash Equivalents, and Short-term Investments [Abstract]
Carrying Amount, available-for-sale	1	14
Fair value, available-for-sale	1	14
Cash & Cash Equivalents	1	0
Current Marketable Securities	0	14
Available-for-sale, unrecognized loss	$ 0
Available-for-sale, unrecognized gain		$ 0

Cash, Cash Equivalents and Cu_4

Cash, Cash Equivalents and Current Marketable Securities - Contractual Maturities of Available for Sale Securities (Details) $ in Millions	Jan. 02, 2022USD ($)
Cost Basis
Due within one year	$ 19,709
Due after one year through five years	22
Due after five years through ten years	0
Total debt securities	19,731
Fair Value
Due within one year	19,705
Due after one year through five years	22
Due after five years through ten years	0
Total debt securities	$ 19,727

Inventories (Details)

Inventories (Details) - USD ($) $ in Millions	Jan. 02, 2022	Jan. 03, 2021
Summary of Inventories
Raw materials and supplies	$ 1,592	$ 1,410
Goods in process	2,287	2,040
Finished goods	6,508	5,894
Total inventories	$ 10,387	$ 9,344

Property, Plant and Equipment -

Property, Plant and Equipment - Property, Plant and Equipment at Cost and Accumulated Depreciation (Details) - USD ($) $ in Millions	Jan. 02, 2022	Jan. 03, 2021
Property, Plant and Equipment [Line Items]
Total property, plant and equipment, gross	$ 47,679	$ 46,804
Less accumulated depreciation	28,717	28,038
Total property, plant and equipment, net	18,962	18,766
Land and leasehold improvements
Property, Plant and Equipment [Line Items]
Total property, plant and equipment, gross	884	882
Building and building equipment
Property, Plant and Equipment [Line Items]
Total property, plant and equipment, gross	12,882	12,502
Machinery and equipment
Property, Plant and Equipment [Line Items]
Total property, plant and equipment, gross	29,774	29,104
Construction in progress
Property, Plant and Equipment [Line Items]
Total property, plant and equipment, gross	$ 4,139	$ 4,316

Property, Plant and Equipment_2

Property, Plant and Equipment - Narrative (Details) - USD ($) $ in Millions	12 Months Ended
	Jan. 02, 2022	Jan. 03, 2021	Dec. 29, 2019
Property, Plant and Equipment [Abstract]
Interest expense capitalized	$ 49	$ 63	$ 70
Depreciation expense, including the amortization of capitalized interest	$ 2,700	$ 2,600	$ 2,500

Intangible Assets and Goodwil_2

Intangible Assets and Goodwill - Schedule of Intangible Assets and Goodwill (Details) - USD ($) $ in Millions	3 Months Ended		12 Months Ended
	Oct. 03, 2021	Sep. 27, 2020	Jan. 02, 2022	Jan. 03, 2021
Intangible assets with indefinite lives:
Indefinite lived intangible assets			$ 16,822	$ 19,044
Total intangible assets - net			46,392	53,402
Trademarks
Intangible assets with indefinite lives:
Indefinite lived intangible assets			6,985	7,195
Purchased in-process research and development
Intangible assets with indefinite lives:
Indefinite lived intangible assets			9,837	11,849
Patents And Trademarks
Intangible assets with definite lives:
Finite lived intangible assets gross			38,572	39,990
Less accumulated amortization			(20,088)	(17,618)
Finite lived intangible assets net			18,484	22,372
Customer relationships and other intangible assets
Intangible assets with definite lives:
Finite lived intangible assets gross			23,011	22,898
Less accumulated amortization			(11,925)	(10,912)
Finite lived intangible assets net			11,086	$ 11,986
In Process Research and Development
Intangible assets with indefinite lives:
Impairment of intangible assets, excluding goodwill	$ 900	$ 100
Auris Health \| In Process Research and Development
Intangible assets with indefinite lives:
Impairment of intangible assets, excluding goodwill			$ 900

Intangible Assets and Goodwil_3

Intangible Assets and Goodwill - Goodwill (Details) - USD ($) $ in Millions	12 Months Ended
	Jan. 02, 2022	Jan. 03, 2021
Goodwill [Roll Forward]
Goodwill beginning of period	$ 36,393	$ 33,639
Goodwill, related to acquisitions	0	1,460
Goodwill, related to divestitures	(9)
Currency translation/other	(1,138)	1,294
Goodwill end of period	35,246	36,393
Consumer Health
Goodwill [Roll Forward]
Goodwill beginning of period	10,336	9,736
Goodwill, related to acquisitions	0	0
Goodwill, related to divestitures	(9)
Currency translation/other	(517)	600
Goodwill end of period	9,810	10,336
Pharmaceutical
Goodwill [Roll Forward]
Goodwill beginning of period	11,009	9,169
Goodwill, related to acquisitions	0	1,222
Goodwill, related to divestitures	0
Currency translation/other	(429)	618
Goodwill end of period	10,580	11,009
Medical Devices
Goodwill [Roll Forward]
Goodwill beginning of period	15,048	14,734
Goodwill, related to acquisitions	0	238
Goodwill, related to divestitures	0
Currency translation/other	(192)	76
Goodwill end of period	$ 14,856	$ 15,048

Intangible Assets and Goodwil_4

Intangible Assets and Goodwill - Narrative (Details) - USD ($) $ in Billions	12 Months Ended
	Jan. 02, 2022	Jan. 03, 2021	Dec. 29, 2019
Finite-Lived Intangible Assets [Line Items]
Amortization expense of amortizable intangible assets	$ 4.7	$ 4.7	$ 4.5
Patents And Trademarks
Finite-Lived Intangible Assets [Line Items]
Intangible assets useful life	12 years
Customer relationships and other intangible assets
Finite-Lived Intangible Assets [Line Items]
Intangible assets useful life	21 years

Intangible Assets and Goodwil_5

Intangible Assets and Goodwill - Estimated Amortization of Intangible Assets (Details) $ in Millions	Jan. 02, 2022USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
2022	$ 4,600
2023	4,600
2024	4,400
2025	3,600
2026	$ 3,000

Fair Value Measurements - Narra

Fair Value Measurements - Narrative (Details) - USD ($) $ in Millions	12 Months Ended
	Jan. 02, 2022	Jan. 03, 2021
Derivative [Line Items]
Deferred net losses (gains) on derivatives included in accumulated other comprehensive income	$ 336
Description of reclassification of cash flow hedge gain (loss)	next 12 months
Maximum length of time for hedging transaction exposure	18 months
Foreign exchange contracts
Derivative [Line Items]
Collateral paid	$ 570
Derivative, notional amount	45,800	$ 37,800
Cross currency interest rate swaps
Derivative [Line Items]
Derivative, notional amount	37,400	30,600
Interest Rate Swap
Derivative [Line Items]
Derivative, notional amount	10,000
Equity securities \| Equity Investments without readily determinable value
Derivative [Line Items]
Equity, fair value adjustment, impairment loss	(28)	(76)
Equity, fair value adjustment, change in observable prices	$ 422	$ 21

Fair Value Measurements - Summa

Fair Value Measurements - Summary of Derivative Activity (Details) - USD ($) $ in Millions	12 Months Ended
	Jan. 02, 2022	Jan. 03, 2021	Dec. 29, 2019
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) reclassified from AOCI into income	$ 789	$ 53	$ (7)
Amount of gain or (loss) recognized in AOCI	(199)	1,000	$ (107)
Sales \| Interest Rate Swap \| Fair Value Hedging
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing	0	0
Amount of gain or (loss) recognized in AOCI	0	0
Sales \| Cross currency interest rate swaps contracts: \| Fair Value Hedging
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing	0	0
Amount of gain or (loss) recognized in AOCI	0	0
Sales \| Cross currency interest rate swaps contracts: \| Cash Flow Hedging
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) reclassified from AOCI into income	0	0
Amount of gain or (loss) recognized in AOCI	0	0
Sales \| Forward foreign exchange contracts: \| Cash Flow Hedging
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) reclassified from AOCI into income	17	12
Amount of gain or (loss) recognized in AOCI	(94)	44
Cost of Products Sold \| Interest Rate Swap \| Fair Value Hedging
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing	0	0
Amount of gain or (loss) recognized in AOCI	0	0
Cost of Products Sold \| Cross currency interest rate swaps contracts: \| Fair Value Hedging
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing	0	0
Amount of gain or (loss) recognized in AOCI	0	0
Cost of Products Sold \| Cross currency interest rate swaps contracts: \| Cash Flow Hedging
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) reclassified from AOCI into income	0	0
Amount of gain or (loss) recognized in AOCI	0	0
Cost of Products Sold \| Forward foreign exchange contracts: \| Cash Flow Hedging
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) reclassified from AOCI into income	119	(329)
Amount of gain or (loss) recognized in AOCI	(557)	298
R&D Expense \| Interest Rate Swap \| Fair Value Hedging
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing	0	0
Amount of gain or (loss) recognized in AOCI	0	0
R&D Expense \| Cross currency interest rate swaps contracts: \| Fair Value Hedging
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing	0	0
Amount of gain or (loss) recognized in AOCI	0	0
R&D Expense \| Cross currency interest rate swaps contracts: \| Cash Flow Hedging
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) reclassified from AOCI into income	0	0
Amount of gain or (loss) recognized in AOCI	0	0
R&D Expense \| Forward foreign exchange contracts: \| Cash Flow Hedging
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) reclassified from AOCI into income	30	(137)
Amount of gain or (loss) recognized in AOCI	123	(91)
Interest (Income) Expense \| Interest Rate Swap \| Fair Value Hedging
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing	(109)	0
Amount of gain or (loss) recognized in AOCI	109	0
Interest (Income) Expense \| Cross currency interest rate swaps contracts: \| Fair Value Hedging
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing	174	153
Amount of gain or (loss) recognized in AOCI	174	153
Interest (Income) Expense \| Cross currency interest rate swaps contracts: \| Cash Flow Hedging
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) reclassified from AOCI into income	402	370
Amount of gain or (loss) recognized in AOCI	9	748
Interest (Income) Expense \| Forward foreign exchange contracts: \| Cash Flow Hedging
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) reclassified from AOCI into income	0	0
Amount of gain or (loss) recognized in AOCI	0	0
Other (Income) Expense \| Interest Rate Swap \| Fair Value Hedging
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing	0	0
Amount of gain or (loss) recognized in AOCI	0	0
Other (Income) Expense \| Cross currency interest rate swaps contracts: \| Fair Value Hedging
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing	0	0
Amount of gain or (loss) recognized in AOCI	0	0
Other (Income) Expense \| Cross currency interest rate swaps contracts: \| Cash Flow Hedging
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) reclassified from AOCI into income	0	0
Amount of gain or (loss) recognized in AOCI	0	0
Other (Income) Expense \| Forward foreign exchange contracts: \| Cash Flow Hedging
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) reclassified from AOCI into income	47	(16)
Amount of gain or (loss) recognized in AOCI	$ 146	$ (52)

Fair Value Measurements - Sched

Fair Value Measurements - Schedule of Derivatives Recorded in Consolidated Balance Sheets (Details) - USD ($) $ in Millions	Jan. 02, 2022	Jan. 03, 2021
Derivative Instruments, Gain (Loss) [Line Items]
Carrying Amount of the Hedged Liability	$ 1,888	$ 2,309
Long-term Debt \| Designated as Hedging Instrument
Derivative Instruments, Gain (Loss) [Line Items]
Carrying Amount of the Hedged Liability	9,793	0
Cumulative Amount of Fair Value Hedging Adjustment Included in the Carrying Amount of the Hedged Liability	$ (142)	$ 0

Fair Value Measurements - Sch_2

Fair Value Measurements - Schedule of Effect of Derivatives not Designated as Hedging Instruments (Details) - USD ($) $ in Millions	12 Months Ended
	Jan. 02, 2022	Jan. 03, 2021
Forward foreign exchange contracts: \| Not Designated as Hedging Instrument \| Other (Income) Expense
Derivative Instruments, Gain (Loss) [Line Items]
Gain/(Loss) Recognized In Income on Derivative	$ (70)	$ 24

Fair Value Measurements - Sch_3

Fair Value Measurements - Schedule of Effect of Net Investment Hedges (Details) - USD ($) $ in Millions	3 Months Ended		12 Months Ended
	Jan. 02, 2022	Jan. 03, 2021	Jan. 02, 2022	Jan. 03, 2021
Derivative Instruments, Gain (Loss) [Line Items]
Gain/(Loss) Recognized In Accumulated OCI			$ 387	$ (473)
Cross currency interest rate swaps contracts:
Derivative Instruments, Gain (Loss) [Line Items]
Gain/(Loss) Recognized In Accumulated OCI			$ 548	$ 65
Other (Income) Expense
Derivative Instruments, Gain (Loss) [Line Items]
Gain/(Loss) Reclassified From Accumulated OCI Into Income	$ 0	$ 0
Other (Income) Expense \| Cross currency interest rate swaps contracts:
Derivative Instruments, Gain (Loss) [Line Items]
Gain/(Loss) Reclassified From Accumulated OCI Into Income	$ 0	$ 0

Fair Value Measurements - Sum_2

Fair Value Measurements - Summary of Activity Related to Equity Investments (Details) - USD ($) $ in Millions	12 Months Ended
	Jan. 02, 2022	Jan. 03, 2021	Dec. 29, 2019
Equity Investment [Roll Forward]
Other assets, noncurrent	$ 10,216	$ 6,562
Equity securities \| Equity Investments with readily determinable value
Equity Investment [Roll Forward]
Marketable securities, noncurrent	1,884	1,481	$ 1,148
Equity, fair value adjustment	198	527
Equity investments, increase (decrease) from acquisition (sale) during period	205	(194)
Other assets, noncurrent	1,884	1,481
Equity securities \| Equity Investments without readily determinable value
Equity Investment [Roll Forward]
Equity, fair value adjustment	394	(55)
Equity investments, increase (decrease) from acquisition (sale) during period	(632)	81
Other assets, noncurrent	500	738
Equity securities without readily determinable fair value, amount	$ 500	$ 738	$ 712

Fair Value Measurements - Finan

Fair Value Measurements - Financial Assets and Liabilities at Fair Value (Details) - USD ($) $ in Millions	12 Months Ended
	Jan. 02, 2022	Jan. 03, 2021	Dec. 29, 2019	Apr. 01, 2019
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	$ 1,336
Derivatives designated as hedging instruments : Liabilities	1,860
Equity Investments	1,884	$ 1,481
Debt securities	19,727	14,042
Contingent consideration liability	533	633
Total Gross Assets	1,360	1,138
Credit Support Agreement (CSA)	(1,285)	(1,107)
Total Net Asset	75	31
Total Gross Liabilities	1,888	2,309
Credit Support Agreement (CSA)	(1,855)	(2,172)
Total Net Liabilities	33	137
Beginning Balance	633	1,715	$ 397
Changes in estimated fair value	(52)	(1,089)	151
Additions	0	106	1,246
Payments	(48)	(99)	(79)
Ending Balance	533	633	1,715
Contingent consideration reversal	0	(1,148)	0
Other Noncurrent Liabilities
Financial assets and liabilities at fair value
Contingent consideration liability	520	594	1,631
Other Current Liabilities
Financial assets and liabilities at fair value
Contingent consideration liability	13	39	$ 84
Auris Health
Financial assets and liabilities at fair value
Contingent consideration liability		1,100		$ 2,350
Contingent consideration reversal	(1,148)
Level 1
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	0
Derivatives designated as hedging instruments : Liabilities	0
Equity Investments	1,884	1,481
Debt securities	0
Level 2
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	1,336	1,089
Derivatives designated as hedging instruments : Liabilities	1,860	2,271
Equity Investments	0
Debt securities	19,727
Level 3
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	0
Derivatives designated as hedging instruments : Liabilities	0
Equity Investments	0
Debt securities	0
Contingent consideration liability	533	633
Interest rate swaps contracts:
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	796
Derivatives designated as hedging instruments : Liabilities	979
Interest rate swaps contracts: \| Level 1
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	0
Derivatives designated as hedging instruments : Liabilities	0
Interest rate swaps contracts: \| Level 2
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	796	240
Derivatives designated as hedging instruments : Liabilities	979	1,569
Interest rate swaps contracts: \| Level 3
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	0
Derivatives designated as hedging instruments : Liabilities	0
Foreign exchange contracts
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	540
Derivatives designated as hedging instruments : Liabilities	881
Derivatives not designated as hedging instruments : Assets	24
Derivatives not designated as hedging instruments : Liabilities	28
Foreign exchange contracts \| Level 1
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	0
Derivatives designated as hedging instruments : Liabilities	0
Derivatives not designated as hedging instruments : Assets	0
Derivatives not designated as hedging instruments : Liabilities	0
Foreign exchange contracts \| Level 2
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	540	849
Derivatives designated as hedging instruments : Liabilities	881	702
Derivatives not designated as hedging instruments : Assets	24	49
Derivatives not designated as hedging instruments : Liabilities	28	$ 38
Foreign exchange contracts \| Level 3
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	0
Derivatives designated as hedging instruments : Liabilities	0
Derivatives not designated as hedging instruments : Assets	0
Derivatives not designated as hedging instruments : Liabilities	$ 0

Borrowings - Schedule of Long-t

Borrowings - Schedule of Long-term Debt Instruments (Details) € in Millions, £ in Millions, $ in Millions	12 Months Ended
	Jan. 02, 2022USD ($)	Jan. 03, 2021USD ($)	Jan. 02, 2022EUR (€)	Jan. 02, 2022GBP (£)	Jan. 03, 2021EUR (€)	Jan. 03, 2021GBP (£)
Debt Instrument [Line Items]
Effective interest rate	2.89%	2.85%	2.89%	2.89%	2.85%	2.85%
Long-term debt	$ 32,116	$ 34,434
Less current portion	2,131	1,799
Total long-term debt	29,985	32,635
Excess of fair value over carrying value of debt	$ 3,200	$ 5,400
3.55% Notes due 2021
Debt Instrument [Line Items]
Effective interest rate	0.00%	3.67%	0.00%	0.00%	3.67%	3.67%
Long-term debt	$ 0	$ 450
Stated interest rate (as a percent)	3.55%		3.55%	3.55%
2.45% Notes due 2021
Debt Instrument [Line Items]
Effective interest rate	0.00%	2.48%	0.00%	0.00%	2.48%	2.48%
Long-term debt	$ 0	$ 350
Stated interest rate (as a percent)	2.45%		2.45%	2.45%
1.65% Notes due 2021
Debt Instrument [Line Items]
Effective interest rate	0.00%	1.65%	0.00%	0.00%	1.65%	1.65%
Long-term debt	$ 0	$ 999
Stated interest rate (as a percent)	1.65%		1.65%	1.65%
0.250% Notes due 2022 (1B Euro 1.1311)(2)/(1B Euro 1.2281)(3)
Debt Instrument [Line Items]
Effective interest rate	0.26%	0.26%	0.26%	0.26%	0.26%	0.26%
Long-term debt	$ 1,131	$ 1,227
Stated interest rate (as a percent)	0.25%		0.25%	0.25%
Debt Instrument, Face Amount \| €			€ 1,000		€ 1,000
Foreign currency exchange rate, translation	1.1311	1.2281	1.1311	1.1311	1.2281	1.2281
2.25% Notes due 2022
Debt Instrument [Line Items]
Effective interest rate	2.31%	2.31%	2.31%	2.31%	2.31%	2.31%
Long-term debt	$ 1,000	$ 999
Stated interest rate (as a percent)	2.25%		2.25%	2.25%
6.73% Debentures due 2023
Debt Instrument [Line Items]
Effective interest rate	6.73%	6.73%	6.73%	6.73%	6.73%	6.73%
Long-term debt	$ 250	$ 250
Stated interest rate (as a percent)	6.73%		6.73%	6.73%
3.375% Notes due 2023
Debt Instrument [Line Items]
Effective interest rate	3.18%	3.17%	3.18%	3.18%	3.17%	3.17%
Long-term debt	$ 802	$ 803
Stated interest rate (as a percent)	3.375%		3.375%	3.375%
2.05% Notes due 2023
Debt Instrument [Line Items]
Effective interest rate	2.09%	2.09%	2.09%	2.09%	2.09%	2.09%
Long-term debt	$ 499	$ 499
Stated interest rate (as a percent)	2.05%		2.05%	2.05%
0.650% Notes due 2024 (750MM Euro 1.1311)(2)/(750MM Euro 1.2281)(3)
Debt Instrument [Line Items]
Effective interest rate	0.68%	0.68%	0.68%	0.68%	0.68%	0.68%
Long-term debt	$ 847	$ 919
Stated interest rate (as a percent)	0.65%		0.65%	0.65%
Debt Instrument, Face Amount \| €			€ 750		€ 750
Foreign currency exchange rate, translation	1.1311	1.2281	1.1311	1.1311	1.2281	1.2281
5.50% Notes due 2024 (500MM 1.3485 GBP )(2)/(500MM GBP 1.3654)(3)
Debt Instrument [Line Items]
Effective interest rate	6.75%	6.75%	6.75%	6.75%	6.75%	6.75%
Long-term debt	$ 672	$ 679
Stated interest rate (as a percent)	5.50%		5.50%	5.50%
Debt Instrument, Face Amount \| £				£ 500		£ 500
Foreign currency exchange rate, translation	1.3485	1.3654	1.3485	1.3485	1.3654	1.3654
2.625% Notes due 2025
Debt Instrument [Line Items]
Effective interest rate	2.63%	2.63%	2.63%	2.63%	2.63%	2.63%
Long-term debt	$ 749	$ 748
Stated interest rate (as a percent)	2.625%		2.625%	2.625%
0.55% Notes due 2025
Debt Instrument [Line Items]
Effective interest rate	0.57%	0.57%	0.57%	0.57%	0.57%	0.57%
Long-term debt	$ 983	$ 996
Stated interest rate (as a percent)	0.55%		0.55%	0.55%
2.45% Notes due 2026
Debt Instrument [Line Items]
Effective interest rate	2.47%	2.47%	2.47%	2.47%	2.47%	2.47%
Long-term debt	$ 1,995	$ 1,994
Stated interest rate (as a percent)	2.45%		2.45%	2.45%
2.95% Notes due 2027
Debt Instrument [Line Items]
Effective interest rate	2.96%	2.96%	2.96%	2.96%	2.96%	2.96%
Long-term debt	$ 978	$ 997
Stated interest rate (as a percent)	2.95%		2.95%	2.95%
0.95% Notes due 2027
Debt Instrument [Line Items]
Effective interest rate	0.96%	0.96%	0.96%	0.96%	0.96%	0.96%
Long-term debt	$ 1,478	$ 1,494
Stated interest rate (as a percent)	0.95%		0.95%	0.95%
1.150% Notes due 2028 (750MM Euro 1.1311)(2)/(750MM Euro 1.2281)(3)
Debt Instrument [Line Items]
Effective interest rate	1.21%	1.21%	1.21%	1.21%	1.21%	1.21%
Long-term debt	$ 843	$ 915
Stated interest rate (as a percent)	1.15%		1.15%	1.15%
Debt Instrument, Face Amount \| €			€ 750		€ 750
Foreign currency exchange rate, translation	1.1311	1.2281	1.1311	1.1311	1.2281	1.2281
2.90% Notes due 2028
Debt Instrument [Line Items]
Effective interest rate	2.91%	2.91%	2.91%	2.91%	2.91%	2.91%
Long-term debt	$ 1,495	$ 1,495
Stated interest rate (as a percent)	2.90%		2.90%	2.90%
6.95% Notes due 2029
Debt Instrument [Line Items]
Effective interest rate	7.14%	7.14%	7.14%	7.14%	7.14%	7.14%
Long-term debt	$ 298	$ 297
Stated interest rate (as a percent)	6.95%		6.95%	6.95%
1.30% Notes due 2030
Debt Instrument [Line Items]
Effective interest rate	1.30%	1.30%	1.30%	1.30%	1.30%	1.30%
Long-term debt	$ 1,723	$ 1,743
Stated interest rate (as a percent)	1.30%		1.30%	1.30%
4.95% Debentures due 2033
Debt Instrument [Line Items]
Effective interest rate	4.95%	4.95%	4.95%	4.95%	4.95%	4.95%
Long-term debt	$ 498	$ 498
Stated interest rate (as a percent)	4.95%		4.95%	4.95%
4.375% Notes due 2033
Debt Instrument [Line Items]
Effective interest rate	4.24%	4.24%	4.24%	4.24%	4.24%	4.24%
Long-term debt	$ 854	$ 855
Stated interest rate (as a percent)	4.375%		4.375%	4.375%
1.650% Notes due 2035 (1.5B Euro 1.1311)(2)/(1.5B Euro 1.2281)(3)
Debt Instrument [Line Items]
Effective interest rate	1.68%	1.68%	1.68%	1.68%	1.68%	1.68%
Long-term debt	$ 1,683	$ 1,827
Stated interest rate (as a percent)	1.65%		1.65%	1.65%
Debt Instrument, Face Amount \| €			€ 1,500		€ 1,500
Foreign currency exchange rate, translation	1.1311	1.2281	1.1311	1.1311	1.2281	1.2281
3.55% Notes due 2036
Debt Instrument [Line Items]
Effective interest rate	3.59%	3.59%	3.59%	3.59%	3.59%	3.59%
Long-term debt	$ 974	$ 989
Stated interest rate (as a percent)	3.55%		3.55%	3.55%
5.95% Notes due 2037
Debt Instrument [Line Items]
Effective interest rate	5.99%	5.99%	5.99%	5.99%	5.99%	5.99%
Long-term debt	$ 993	$ 992
Stated interest rate (as a percent)	5.95%		5.95%	5.95%
3.625% Notes due 2037
Debt Instrument [Line Items]
Effective interest rate	3.64%	3.64%	3.64%	3.64%	3.64%	3.64%
Long-term debt	$ 1,475	$ 1,488
Stated interest rate (as a percent)	3.625%		3.625%	3.625%
5.85% Debentures due 2038
Debt Instrument [Line Items]
Effective interest rate	5.85%	5.85%	5.85%	5.85%	5.85%	5.85%
Long-term debt	$ 696	$ 696
Stated interest rate (as a percent)	5.85%		5.85%	5.85%
3.400% Notes due 2038
Debt Instrument [Line Items]
Effective interest rate	3.42%	3.42%	3.42%	3.42%	3.42%	3.42%
Long-term debt	$ 992	$ 991
Stated interest rate (as a percent)	3.40%		3.40%	3.40%
4.50% Debentures due 2040
Debt Instrument [Line Items]
Effective interest rate	4.63%	4.63%	4.63%	4.63%	4.63%	4.63%
Long-term debt	$ 540	$ 539
Stated interest rate (as a percent)	4.50%		4.50%	4.50%
2.10% Notes due 2040
Debt Instrument [Line Items]
Effective interest rate	2.14%	2.14%	2.14%	2.14%	2.14%	2.14%
Long-term debt	$ 974	$ 986
Stated interest rate (as a percent)	2.10%		2.10%	2.10%
4.85% Notes due 2041
Debt Instrument [Line Items]
Effective interest rate	4.89%	4.89%	4.89%	4.89%	4.89%	4.89%
Long-term debt	$ 297	$ 297
Stated interest rate (as a percent)	4.85%		4.85%	4.85%
4.50% Notes due 2043
Debt Instrument [Line Items]
Effective interest rate	4.52%	4.52%	4.52%	4.52%	4.52%	4.52%
Long-term debt	$ 496	$ 496
Stated interest rate (as a percent)	4.50%		4.50%	4.50%
3.70% Notes due 2046
Debt Instrument [Line Items]
Effective interest rate	3.74%	3.74%	3.74%	3.74%	3.74%	3.74%
Long-term debt	$ 1,975	$ 1,974
Stated interest rate (as a percent)	3.70%		3.70%	3.70%
3.75% Notes due 2047
Debt Instrument [Line Items]
Effective interest rate	3.76%	3.76%	3.76%	3.76%	3.76%	3.76%
Long-term debt	$ 971	$ 991
Stated interest rate (as a percent)	3.75%		3.75%	3.75%
3.500% Notes due 2048
Debt Instrument [Line Items]
Effective interest rate	3.52%	3.52%	3.52%	3.52%	3.52%	3.52%
Long-term debt	$ 743	$ 742
Stated interest rate (as a percent)	3.50%		3.50%	3.50%
2.250% Notes due 2050
Debt Instrument [Line Items]
Effective interest rate	2.29%	2.29%	2.29%	2.29%	2.29%	2.29%
Long-term debt	$ 983	$ 984
Stated interest rate (as a percent)	2.25%		2.25%	2.25%
2.450% Notes due 2060
Debt Instrument [Line Items]
Effective interest rate	2.49%	2.49%	2.49%	2.49%	2.49%	2.49%
Long-term debt	$ 1,222	$ 1,228
Stated interest rate (as a percent)	2.45%		2.45%	2.45%
Other
Debt Instrument [Line Items]
Effective interest rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-term debt	$ 7	$ 7

Borrowings - Narrative (Details

Borrowings - Narrative (Details) - USD ($) $ in Millions	12 Months Ended
Borrowings - Narrative (Details) - USD ($) $ in Millions	Jan. 02, 2022	Sep. 30, 2021	Jan. 03, 2021
Debt Disclosure [Abstract]
Borrowing capacity under credit facility		$ 10,000
Short-term borrowings and the current portion of long-term debt	$ 3,800		$ 2,600
Borrowed under the commercial paper program	2,100		1,800
Current portion of long term debt	2,131		1,799
Short-term Debt [Line Items]
Loans and notes payable	$ 3,766		$ 2,631
Commercial Paper
Debt Disclosure [Abstract]
Debt, weighted average interest rate	0.11%
Debt instrument, term	3 months
Short-term Debt [Line Items]
Loans and notes payable	$ 1,600
Debt, weighted average interest rate	0.11%
Debt instrument, term	3 months

Borrowings - Aggregate Maturiti

Borrowings - Aggregate Maturities of Long Term Obligations (Details) $ in Millions	Jan. 02, 2022USD ($)
Aggregate maturities of long-term obligations
2022	$ 2,131
2023	1,551
2024	1,518
2025	1,732
2026	1,995
After 2026	$ 23,189

Income Taxes - Provision for In

Income Taxes - Provision for Income Taxes (Details) - USD ($) $ in Millions	12 Months Ended
	Jan. 02, 2022	Jan. 03, 2021	Dec. 29, 2019
Currently payable:
U.S. taxes	$ 1,525	$ 1,026	$ 1,941
International taxes	2,452	1,898	2,744
Total currently payable	3,977	2,924	4,685
Deferred:
U.S. taxes	583	(76)	(814)
International taxes	(2,662)	(1,065)	(1,662)
Total deferred	(2,079)	(1,141)	(2,476)
Provision for taxes on income	$ 1,898	$ 1,783	$ 2,209

Income Taxes - Comparison of In

Income Taxes - Comparison of Income Taxes at Statutory Rate and Company's Effective Tax Rate (Details) - USD ($) $ in Millions	3 Months Ended	12 Months Ended
	Jan. 02, 2022	Jan. 02, 2022	Jan. 03, 2021	Dec. 29, 2019	Dec. 30, 2018	Dec. 31, 2017
Comparison Of Income Tax Expense At Statutory Rate And Company's Tax Rate Abstract
U.S.		$ 6,110	$ 4,312	$ 3,543
International		16,666	12,185	13,785
Earnings before provision for taxes on income		$ 22,776	$ 16,497	$ 17,328
Tax rates:
U.S. statutory rate		21.00%	21.00%	21.00%	21.00%	35.00%
International operations		(16.40%)	(9.90%)	(5.90%)
U.S. taxes on international income		6.70%	2.70%	1.80%
Tax benefits from loss on capital assets	(1.30%)	(1.30%)	(1.20%)	(0.30%)
Tax benefits on share-based compensation		(1.00%)	(1.50%)	(0.50%)
TCJA and related impacts		(0.50%)	0.70%	(3.90%)
All other		(0.20%)	(1.00%)	0.50%
Effective Rate		8.30%	10.80%	12.70%

Income Taxes - Narrative (Detai

Income Taxes - Narrative (Details) - USD ($) $ in Millions	1 Months Ended	3 Months Ended		12 Months Ended
Income Taxes - Narrative (Details) - USD ($) $ in Millions	Dec. 29, 2019	Jan. 02, 2022	Dec. 29, 2019	Jan. 02, 2022	Jan. 03, 2021	Dec. 29, 2019	Oct. 31, 2020	Oct. 31, 2019	Dec. 30, 2018
Tax Credit Carryforward [Line Items]
Effective tax rate reconciliation, net increase (decrease) in tax rate, percent				(2.50%)	1.90%
Deferred tax assets, tax basis increase of certain assets due to reorganization		$ 2,300		$ 2,300
Increase (decrease) in deferred tax liabilities, global intangible low-taxed income (GILTI)				$ 1,700
Tax benefits from loss on capital assets		1.30%		1.30%	1.20%	0.30%
Income tax expense recorded related to TRAF					$ 400	$ 100
TRAF effect on tax rate					2.60%	0.60%
Income tax expense related to change in tax rate from TRAF					$ 300	$ 600
Deferred tax asset recorded related to TRAF					450	900
Deferred tax expense related to TRAF					$ 300	450
Effective income tax rate reconciliation, deduction					1.20%
Effective tax rate reconciliation, litigation settlement, percent			(2.10%)
Reversal of deferred tax liability						600
Reversal of deferred tax asset						200
Tax Cuts And Jobs Act Of 2017, foreign tax credits, net deferred tax expense (benefit)						$ (400)
TJCA, foreign tax credit percent	1.70%					(2.20%)
Increase (decrease) in earnings before taxes, percent			(23.50%)
TCJA, increase (decrease) in deferred tax asset	$ 300
Increase (decrease) in unrecognized tax benefits						$ 300
Effective tax rate reconciliation, unrecognized tax benefits, percent						1.50%
Unrecognized tax benefits	$ 3,853	$ 3,323	$ 3,853	$ 3,323	$ 3,373	$ 3,853			$ 3,326
Unrecognized tax benefits, interest on income tax expense				44	32	50
Unrecognized tax benefits, interest on income taxes accrued		512		$ 512	468
State and Local Jurisdiction
Tax Credit Carryforward [Line Items]
Effective tax rate reconciliation, net increase (decrease) in tax rate, percent				2.70%
Deferred tax assets, net		600		$ 600
Auris Health \| Purchased in-process research and development(1)
Tax Credit Carryforward [Line Items]
Impairment of intangible assets, excluding goodwill		$ 900
Effective income tax rate reconciliation, nondeductible expense, impairment losses, percent		22.40%
Internal Revenue Service (IRS)
Tax Credit Carryforward [Line Items]
Payment on unrecognized tax benefit liability					700
Pending Litigation
Tax Credit Carryforward [Line Items]
Loss contingency, estimate of possible loss							$ 5,000	$ 4,000
Consumer Health
Tax Credit Carryforward [Line Items]
Litigation expense				1,600	3,900	400
Pharmaceutical
Tax Credit Carryforward [Line Items]
Litigation expense				600	$ 800	$ 4,300
Talc
Tax Credit Carryforward [Line Items]
Effective income tax rate reconciliation, litigation settlement, percent					0.235
Talc \| Consumer Health
Tax Credit Carryforward [Line Items]
Litigation expense				$ 1,600	$ 4,000
Effective income tax rate reconciliation, litigation settlement, percent				0.235
Risperdal \| Consumer Health
Tax Credit Carryforward [Line Items]
Litigation expense				$ 800
Effective income tax rate reconciliation, litigation settlement, percent				0.164
Opiods
Tax Credit Carryforward [Line Items]
Effective income tax rate reconciliation, litigation settlement, percent					0.214
Opiods \| Pharmaceutical
Tax Credit Carryforward [Line Items]
Litigation expense					$ 1,000

Income Taxes - Temporary Differ

Income Taxes - Temporary Differences and Carryforwards (Details) - USD ($) $ in Millions	Jan. 02, 2022	Jan. 03, 2021
Asset
Employee related obligations	$ 1,244	$ 2,434
Stock based compensation	679	627
R&D capitalized for tax	1,664	1,517
Reserves & liabilities	2,882	3,466
Income reported for tax purposes	2,566	1,777
Net realizable operating loss carryforward	1,073	990
Undistributed foreign earnings	1,015	812
Miscellaneous international	1,006	854
Miscellaneous U.S.	495
Total deferred income taxes	12,624	12,477
Liability
Depreciation of property, plant and equipment	(876)	(823)
Goodwill and intangibles	(2,659)	(5,023)
Undistributed foreign earnings	(1,461)	(1,435)
Global intangible low-taxed income	(4,853)	(3,606)
Miscellaneous international	(39)	(211)
Miscellaneous U.S.		(59)
Total deferred income taxes	(9,888)	$ (11,157)
Deferred tax assets, tax basis increase of certain assets due to reorganization	$ 2,300

Income Taxes - Summary of Activ

Income Taxes - Summary of Activity Related to Unrecognized Tax Benefits (Details) - USD ($) $ in Millions	12 Months Ended
	Jan. 02, 2022	Jan. 03, 2021	Dec. 29, 2019
Summary of unrecognized tax benefits
Beginning of year	$ 3,373	$ 3,853	$ 3,326
Increases related to current year tax positions	242	265	249
Increases related to prior period tax positions	23	668	408
Decreases related to prior period tax positions	(128)	(551)	(105)
Settlements	(187)	(839)	(9)
Lapse of statute of limitations	0	(23)	(16)
End of year	$ 3,323	$ 3,373	$ 3,853

Employee Related Obligations -

Employee Related Obligations - Employee Related Obligations (Details) - USD ($) $ in Millions	Jan. 02, 2022	Jan. 03, 2021
Employee-related Liabilities [Abstract]
Pension benefits	$ 4,088	$ 5,761
Postretirement benefits	2,069	2,229
Postemployment benefits	3,117	3,078
Deferred compensation	181	250
Total employee obligations	9,455	11,318
Less current benefits payable	557	547
Employee related obligations — non-current	$ 8,898	$ 10,771

Employee Related Obligations _2

Employee Related Obligations - Narrative (Details) - USD ($) $ in Millions	Jan. 02, 2022	Jan. 03, 2021
Compensation Related Costs [Abstract]
Prepaid employee related obligations	$ 4,436	$ 656

Pensions and Other Benefit Pl_3

Pensions and Other Benefit Plans - Narrative (Details) - USD ($) $ in Millions	12 Months Ended
	Jan. 02, 2022	Jan. 03, 2021	Dec. 29, 2019
Defined Benefit Plan Disclosure [Line Items]
Amendments	$ (1,800)
Percentage of corridor of greater of market value of assets	10.00%
Accumulated benefit obligation unfunded plans	$ 3,900	$ 8,800
Projected benefit obligation, unfunded plans	4,200	9,800
Plan with accumulated benefit obligation in excess of plan assets, plan assets	300	4,400
Fair value of company's common stock directly held in plan assets	$ 385	$ 946
Percentage of company's common stock to plan asset	0.90%	2.50%
Retirement Plans
Defined Benefit Plan Disclosure [Line Items]
Amendments	$ 5	$ (1,780)
Plan Assets	41,930	38,195	$ 32,201
Other Benefit Plans
Defined Benefit Plan Disclosure [Line Items]
Amendments	0	0
Plan Assets	102	90	$ 115
U.S. Plans
Defined Benefit Plan Disclosure [Line Items]
Contribution to pension plans	102
International Plans
Defined Benefit Plan Disclosure [Line Items]
Contribution to pension plans	867
Commingled funds \| Level 2 \| Other Benefit Plans
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	$ 102	$ 90
Maximum \| Retirement Plans
Defined Benefit Plan Disclosure [Line Items]
Retirement plan benefits Employee compensation Period	5 years

Pensions and Other Benefit Pl_4

Pensions and Other Benefit Plans - Components of Net Periodic Benefit Cost (Details) - USD ($) $ in Millions	12 Months Ended
	Jan. 02, 2022	Jan. 03, 2021	Dec. 29, 2019
Retirement Plans
Defined Benefit Plan Disclosure [Line Items]
Service cost	$ 1,421	$ 1,380	$ 1,163
Interest cost	770	955	1,096
Expected return on plan assets	(2,645)	(2,461)	(2,322)
Amortization of prior service cost	(181)	2	4
Recognized actuarial losses (gains)	1,257	891	579
Curtailments and settlements	1	23	73
Net periodic benefit cost	623	790	593
Other Benefit Plans
Defined Benefit Plan Disclosure [Line Items]
Service cost	309	287	274
Interest cost	81	133	185
Expected return on plan assets	(7)	(7)	(6)
Amortization of prior service cost	(31)	(31)	(31)
Recognized actuarial losses (gains)	151	142	129
Curtailments and settlements	0	0	0
Net periodic benefit cost	$ 503	$ 524	$ 551

Pensions and Other Benefit Pl_5

Pensions and Other Benefit Plans - Rates Used to Develop Actuarial Present Value of Projected Benefit Obligation (Details)	12 Months Ended
	Jan. 02, 2022	Jan. 03, 2021	Dec. 29, 2019
Retirement Plans
Net Periodic Benefit Cost
Service cost discount rate	2.14%	2.82%	3.63%
Interest cost discount rate	2.34%	3.13%	4.13%
Rate of increase in compensation levels	4.01%	4.00%	3.99%
Expected long-term rate of return on plan assets	7.71%	8.12%	8.31%
Benefit Obligation
Discount rate	2.49%	2.14%	2.91%
Rate of increase in compensation levels	4.01%	4.00%	4.01%
Other Benefit Plans
Net Periodic Benefit Cost
Service cost discount rate	2.09%	3.04%	4.45%
Interest cost discount rate	2.33%	3.08%	4.25%
Rate of increase in compensation levels	4.25%	4.25%	4.29%
Benefit Obligation
Discount rate	2.68%	2.23%	3.39%
Rate of increase in compensation levels	4.21%	4.27%	4.29%

Pensions and Other Benefit Pl_6

Pensions and Other Benefit Plans - Assumed Health Care Cost Trend Rates (Details)	12 Months Ended
	Jan. 02, 2022	Jan. 03, 2021
Defined Benefit Plan, Assumed Health Care Cost Trend Rates [Abstract]
Healthcare cost trend rate assumed for next year	5.33%	5.68%
Rate to which the cost trend rate is assumed to decline (ultimate trend)	3.73%	4.49%
Defined Benefit Plan, Year Health Care Cost Trend Rate Reaches Ultimate Trend Rate	2046	2040

Pensions and Other Benefit Pl_7

Pensions and Other Benefit Plans - Schedule of Net Funded Status (Details) - USD ($) $ in Millions	12 Months Ended
	Jan. 02, 2022	Jan. 03, 2021	Dec. 29, 2019
Change in Benefit Obligation
Amendments	$ (1,800)
Amounts Recognized in the Company’s Balance Sheet consist of the following:
Non-current assets	4,436	$ 656
Current liabilities	(557)	(547)
Non-current liabilities	(8,898)	(10,771)
Retirement Plans
Change in Benefit Obligation
Projected benefit obligation - beginning of year	43,300	37,188
Service cost	1,421	1,380	$ 1,163
Interest cost	770	955	1,096
Plan participant contributions	67	61
Amendments	5	(1,780)
Actuarial (gains) losses(2)	(2,132)	5,716
Divestitures & acquisitions	(2)	(88)
Curtailments, settlements & restructuring	(7)	(24)
Benefits paid from plan	(1,157)	(1,111)
Effect of exchange rates	(683)	1,003
Projected benefit obligation - end of year	41,582	43,300	37,188
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]
Plan assets at fair value — beginning of year	38,195	32,201
Actual return on plan assets	4,439	5,524
Company contributions	969	870
Plan participant contributions	67	61
Settlements	(7)	(13)
Divestitures & acquisitions	(2)	(84)
Benefits paid from plan assets	(1,157)	(1,111)
Effect of exchange rates	(574)	747
Plan assets at fair value - End of year	41,930	38,195	32,201
Funded status - end of year	348	(5,105)
Amounts Recognized in the Company’s Balance Sheet consist of the following:
Non-current assets	4,436	656
Current liabilities	(115)	(125)
Non-current liabilities	(3,973)	(5,636)
Total recognized in the consolidated balance sheet — end of year	348	(5,105)
Defined Benefit Plan, Amounts Recognized in Other Comprehensive Income (Loss) [Abstract]
Net actuarial loss	5,539	10,860
Prior service cost (credit)(1)	(1,610)	(1,797)
Unrecognized net transition obligation	0	0
Total before tax effects	3,929	9,063
Accumulated Benefit Obligation	39,049	40,356
Defined Benefit Plan, Amount Recognized in Net Periodic Benefit Cost (Credit) and Other Comprehensive (Income) Loss, before Tax [Abstract]
Net periodic benefit cost	623	790	593
Net actuarial (gain) loss	(3,927)	2,616
Amortization of net actuarial loss	(1,257)	(891)
Prior service cost (credit)	5	(1,780)
Amortization of prior service (cost) credit	181	(2)
Effect of exchange rates	(136)	293
Total loss/(income) recognized in other comprehensive income, before tax	(5,134)	236
Total recognized in net periodic benefit cost and other comprehensive income	(4,511)	1,026
Other Benefit Plans
Change in Benefit Obligation
Projected benefit obligation - beginning of year	5,028	5,076
Service cost	309	287	274
Interest cost	81	133	185
Plan participant contributions	0	0
Amendments	0	0
Actuarial (gains) losses(2)	(188)	(75)
Divestitures & acquisitions	0	0
Curtailments, settlements & restructuring	0	0
Benefits paid from plan	(348)	(396)
Effect of exchange rates	(4)	3
Projected benefit obligation - end of year	4,878	5,028	5,076
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]
Plan assets at fair value — beginning of year	90	115
Actual return on plan assets	17	14
Company contributions	343	357
Plan participant contributions	0	0
Settlements	0	0
Divestitures & acquisitions	0	0
Benefits paid from plan assets	(348)	(396)
Effect of exchange rates	0	0
Plan assets at fair value - End of year	102	90	115
Funded status - end of year	(4,776)	(4,938)
Amounts Recognized in the Company’s Balance Sheet consist of the following:
Non-current assets	0	0
Current liabilities	(438)	(418)
Non-current liabilities	(4,338)	(4,520)
Total recognized in the consolidated balance sheet — end of year	(4,776)	(4,938)
Defined Benefit Plan, Amounts Recognized in Other Comprehensive Income (Loss) [Abstract]
Net actuarial loss	1,113	1,463
Prior service cost (credit)(1)	(13)	(44)
Unrecognized net transition obligation	0	0
Total before tax effects	1,100	1,419
Defined Benefit Plan, Amount Recognized in Net Periodic Benefit Cost (Credit) and Other Comprehensive (Income) Loss, before Tax [Abstract]
Net periodic benefit cost	503	524	$ 551
Net actuarial (gain) loss	(199)	(81)
Amortization of net actuarial loss	(151)	(142)
Prior service cost (credit)	0	0
Amortization of prior service (cost) credit	31	31
Effect of exchange rates	0	1
Total loss/(income) recognized in other comprehensive income, before tax	(319)	(191)
Total recognized in net periodic benefit cost and other comprehensive income	$ 184	$ 333

Pensions and Other Benefit Pl_8

Pensions and Other Benefit Plans - Information Related to the Benefit Obligation and the Fair Value of Plan Assets (Details) - USD ($) $ in Millions	Jan. 02, 2022	Jan. 03, 2021
Qualified Plans \| U.S. Plans
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	$ 27,944	$ 25,554
Projected Benefit Obligation	25,041	25,466
Accumulated Benefit Obligation	23,985	24,158
Projected Benefit Obligation	2,903	88
Accumulated Benefit Obligation	3,959	1,396
Non-Qualified Plans \| U.S. Plans
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	0	0
Projected Benefit Obligation	2,703	2,748
Accumulated Benefit Obligation	2,479	2,495
Projected Benefit Obligation	(2,703)	(2,748)
Accumulated Benefit Obligation	(2,479)	(2,495)
Funded Plans \| International Plans
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	13,986	12,641
Projected Benefit Obligation	13,428	14,541
Accumulated Benefit Obligation	12,212	13,210
Projected Benefit Obligation	558	(1,900)
Accumulated Benefit Obligation	1,774	(569)
Unfunded Plans \| International Plans
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	0	0
Projected Benefit Obligation	410	545
Accumulated Benefit Obligation	373	493
Projected Benefit Obligation	(410)	(545)
Accumulated Benefit Obligation	$ (373)	$ (493)

Pensions and Other Benefit Pl_9

Pensions and Other Benefit Plans - Projected Future Benefit Payments from Company's Retirement and Other Benefit Plans (Details) $ in Millions	Jan. 02, 2022USD ($)
Retirement plans
Defined Benefit Plan Disclosure [Line Items]
2022	$ 1,317
2023	1,386
2024	1,421
2025	1,496
2026	1,572
2027-2031	9,279
Other benefit plans
Defined Benefit Plan Disclosure [Line Items]
2022	447
2023	459
2024	472
2025	485
2026	434
2027-2031	$ 2,379

Pensions and Other Benefit P_10

Pensions and Other Benefit Plans - Projected Future Minimum Contributions to the Company's U.S. and International Unfunded Retirement Plans (Details) $ in Millions	Jan. 02, 2022USD ($)
Retirement Benefits [Abstract]
2022	$ 114
2023	119
2024	126
2025	133
2026	139
2027-2031	$ 794

Pensions and Other Benefit P_11

Pensions and Other Benefit Plans - Company' Retirement Plan Asset Allocation and Target Allocations (Details)	Jan. 02, 2022	Jan. 03, 2021
Defined Benefit Plan Disclosure [Line Items]
Percent of Plan Assets	100.00%	100.00%
Target Allocation	100.00%
Equity securities
Defined Benefit Plan Disclosure [Line Items]
Percent of Plan Assets	65.00%	66.00%
Target Allocation	61.00%
Debt securities
Defined Benefit Plan Disclosure [Line Items]
Percent of Plan Assets	35.00%	34.00%
Target Allocation	39.00%

Pensions and Other Benefit P_12

Pensions and Other Benefit Plans - Schedule of Defined Benefit Plans Disclosures (Details) - Retirement plans - USD ($) $ in Millions	Jan. 02, 2022	Jan. 03, 2021	Dec. 29, 2019
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	$ 41,930	$ 38,195	$ 32,201
Fair Value, Measurements, Recurring
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	41,930	38,195
Investments Measured at Net Asset Value	10,515	9,092
Fair Value, Measurements, Recurring \| Level 1
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	14,209	14,502
Fair Value, Measurements, Recurring \| Level 2
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	17,086	14,420
Fair Value, Measurements, Recurring \| Level 3
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	120	181
Fair Value, Measurements, Recurring \| Short-term investment funds
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	1,135	890
Fair Value, Measurements, Recurring \| Short-term investment funds \| Level 1
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	102	127
Fair Value, Measurements, Recurring \| Short-term investment funds \| Level 2
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	1,033	763
Fair Value, Measurements, Recurring \| Short-term investment funds \| Level 3
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	0	0
Fair Value, Measurements, Recurring \| Government and agency securities
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	7,016	5,023
Fair Value, Measurements, Recurring \| Government and agency securities \| Level 1
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	0	0
Fair Value, Measurements, Recurring \| Government and agency securities \| Level 2
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	7,016	5,023
Fair Value, Measurements, Recurring \| Government and agency securities \| Level 3
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	0	0
Fair Value, Measurements, Recurring \| Debt instruments
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	3,505	3,931
Fair Value, Measurements, Recurring \| Debt instruments \| Level 1
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	0	0
Fair Value, Measurements, Recurring \| Debt instruments \| Level 2
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	3,505	3,931
Fair Value, Measurements, Recurring \| Debt instruments \| Level 3
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	0	0
Fair Value, Measurements, Recurring \| Equity securities
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	14,109	14,377
Fair Value, Measurements, Recurring \| Equity securities \| Level 1
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	14,107	14,375
Fair Value, Measurements, Recurring \| Equity securities \| Level 2
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	2	2
Fair Value, Measurements, Recurring \| Equity securities \| Level 3
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	0	0
Fair Value, Measurements, Recurring \| Commingled funds
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	14,309	13,086
Investments Measured at Net Asset Value	8,708	8,236
Fair Value, Measurements, Recurring \| Commingled funds \| Level 1
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	0	0
Fair Value, Measurements, Recurring \| Commingled funds \| Level 2
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	5,496	4,690
Fair Value, Measurements, Recurring \| Commingled funds \| Level 3
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	105	160
Fair Value, Measurements, Recurring \| Other assets
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	1,856	888
Investments Measured at Net Asset Value	1,807	856
Fair Value, Measurements, Recurring \| Other assets \| Level 1
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	0	0
Fair Value, Measurements, Recurring \| Other assets \| Level 2
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	34	11
Fair Value, Measurements, Recurring \| Other assets \| Level 3
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	$ 15	$ 21

Savings Plan - Narrative (Detai

Savings Plan - Narrative (Details) - USD ($) $ in Millions	12 Months Ended
Savings Plan - Narrative (Details) - USD ($) $ in Millions	Jan. 02, 2022	Jan. 03, 2021	Dec. 29, 2019
Savings Plan [Abstract]
Matching contributions	$ 256	$ 243	$ 235

Capital and Treasury Stock - Ch

Capital and Treasury Stock - Changes in Treasury Stock (Details) - USD ($) shares in Thousands, $ in Millions	12 Months Ended
	Jan. 02, 2022	Jan. 03, 2021	Dec. 29, 2019
Changes in Treasury Stock Shares Outstanding [Roll Forward]
Treasury Stock, beginning balance (shares)	487,331	487,336	457,519
Employee compensation and stock option plans (shares)	(17,399)	(21,765)	(20,053)
Treasury Stock, ending balance (shares)	490,878	487,331	487,336
Changes in treasury stock
Treasury Stock, Balance	$ 38,490	$ 38,417	$ 34,362
Employee compensation and stock option plans	(2,847)	(3,148)	(2,691)
Repurchase of common stock	3,456	3,221	6,746
Treasury Stock, Ending Balance	$ 39,099	$ 38,490	$ 38,417
Treasury Stock
Changes in Treasury Stock Shares Outstanding [Roll Forward]
Repurchase of common stock (shares)	20,946	21,760	49,870
Changes in treasury stock
Repurchase of common stock	$ 3,456	$ 3,221	$ 6,746

Capital and Treasury Stock - Na

Capital and Treasury Stock - Narrative (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Billions	Jan. 04, 2022	Jan. 02, 2022	Jan. 03, 2021	Dec. 29, 2019	Dec. 17, 2018
Equity, Class of Treasury Stock [Line Items]
Common stock, shares issued (in shares)		3,119,843	3,119,843	3,119,843
Cash dividends paid (in dollars per share)		$ 4.19	$ 3.98	$ 3.75
Subsequent Event
Equity, Class of Treasury Stock [Line Items]
Common Stock, Dividends, Per Share, Declared	$ 1.06
December 17, 2018 Share Repurchase Program
Equity, Class of Treasury Stock [Line Items]
Stock repurchase program, authorized amount					$ 5

Accumulated Other Comprehensi_3

Accumulated Other Comprehensive Income (Loss) (Details) - USD ($) $ in Millions	12 Months Ended
	Jan. 02, 2022	Jan. 03, 2021	Dec. 29, 2019
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning Balance	$ 63,278	$ 59,471	$ 59,752
Net change	2,184	649	(669)
Ending Balance	74,023	63,278	59,471
Foreign Currency Translation
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning Balance	(8,938)	(8,705)	(8,869)
Net change	(1,079)	(233)	164
Ending Balance	(10,017)	(8,938)	(8,705)
Gain/(Loss) On Securities
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning Balance	1	0	0
Net change	(4)	1	0
Ending Balance	(3)	1	0
Employee Benefit Plans
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning Balance	(6,957)	(6,891)	(6,158)
Net change	4,255	(66)	(733)
Ending Balance	(2,702)	(6,957)	(6,891)
Gain/ (Loss) On Derivatives & Hedges
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning Balance	652	(295)	(195)
Net change	(988)	947	(100)
Ending Balance	(336)	652	(295)
Accumulated Other Comprehensive Income (Loss)
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning Balance	(15,242)	(15,891)	(15,222)
Net change	2,184	649	(669)
Ending Balance	$ (13,058)	$ (15,242)	$ (15,891)

International Currency Transl_2

International Currency Translation - Narrative (Details) - USD ($) $ in Millions	12 Months Ended
	Jan. 02, 2022	Jan. 03, 2021	Dec. 29, 2019
Foreign Currency Translation [Abstract]
Foreign currency transaction gain (loss), before tax	$ (236)	$ (209)	$ (267)

Earnings Per Share - Reconcilia

Earnings Per Share - Reconciliation of Basic Net Earnings per Share to Diluted Net Earnings per Share (Details) - $ / shares shares in Millions	12 Months Ended
	Jan. 02, 2022	Jan. 03, 2021	Dec. 29, 2019
Reconciliation of basic net earnings per share to diluted net earnings per share
Basic net earnings per share (in dollars per share)	$ 7.93	$ 5.59	$ 5.72
Average shares outstanding — basic (in shares)	2,632.1	2,632.8	2,645.1
Potential shares exercisable under stock option plans (in shares)	138	118.3	136.3
Less: shares repurchased under treasury stock method (in shares)	(96.1)	(80.4)	(97.8)
Convertible debt shares (in shares)	0	0	0.7
Average shares outstanding - diluted (in shares)	2,674	2,670.7	2,684.3
Diluted net earnings per share (in dollars per share)	$ 7.81	$ 5.51	$ 5.63

Earnings Per Share - Narrative

Earnings Per Share - Narrative (Details) - USD ($) shares in Millions, $ in Millions	12 Months Ended
	Jan. 03, 2021	Dec. 29, 2019
Earnings Per Share [Abstract]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	18
Interest expense convertible debt		$ 1

Common Stock, Stock Option Pl_3

Common Stock, Stock Option Plans and Stock Compensation Agreements - Narrative (Details) $ / shares in Units, shares in Thousands, $ in Millions	12 Months Ended
	Jan. 02, 2022USD ($)StockBasedCompensationPlans$ / sharesshares	Jan. 03, 2021USD ($)$ / sharesshares	Dec. 29, 2019USD ($)$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of stock-based compensation plans \| StockBasedCompensationPlans	2
Compensation cost charged for Long term incentive plan	$ 1,135	$ 1,005	$ 977
Total income tax benefit recognized	218	210	227
Exercise of options, tax benefit	223	248	209
Total compensation cost not yet recognized for option	$ 862	$ 804	$ 823
Weighted average period for total compensation cost not yet recognized	1 year 9 months 10 days	1 year 9 months 3 days	1 year 8 months 15 days
Average fair value of option granted (in dollars per share) \| $ / shares	$ 20.86	$ 16.42	$ 17.80
Total intrinsic value of options exercised	$ 919	$ 1,021	$ 807
Stock options outstanding (in shares) \| shares	117,361	114,250	111,637
Stock option average life	5 years 9 months 18 days	6 years	6 years
Stock options exercisable \| shares		61,289	60,761
Stock options average price \| $ / shares		$ 96.97	$ 88.88
Employee Stock Option
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options expiration period	10 years
Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Average fair value of RSU's and PSU's granted \| $ / shares	$ 152.62	$ 139.58	$ 121.31
Fair Value of RSU or PSU units settled	$ 611	$ 650	$ 586
Performance Shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period	3 years
Average fair value of RSU's and PSU's granted \| $ / shares	$ 179.35	$ 160.54	$ 124.67
Fair Value of RSU or PSU units settled	$ 83	$ 91	$ 119
Minimum \| Employee Stock Option
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period	6 months
Minimum \| Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period	6 months
Minimum \| Performance Shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period	6 months
Vesting percentage	0.00%
Maximum \| Employee Stock Option
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period	4 years
Maximum \| Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period	3 years
Maximum \| Performance Shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period	3 years
Vesting percentage	200.00%
2012 Long-Term Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized for issuance under long-term incentive plan \| shares	650,000
Shares available for future grants under long-term incentive plan \| shares	240,000

Common Stock, Stock Option Pl_4

Common Stock, Stock Option Plans and Stock Compensation Agreements - Schedule Valuation Assumptions (Details)	12 Months Ended
	Jan. 02, 2022	Jan. 03, 2021	Dec. 29, 2019
Weighted average assumptions of fair value of options
Risk-free rate	0.83%	1.47%	2.56%
Expected volatility	18.59%	15.33%	16.27%
Expected life (in years)	7 years	7 years	7 years
Expected dividend yield	2.50%	2.60%	2.80%

Common Stock, Stock Option Pl_5

Common Stock, Stock Option Plans and Stock Compensation Agreements - Summary of Stock Option Activity (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Millions	12 Months Ended
	Jan. 02, 2022	Jan. 03, 2021	Dec. 29, 2019	Dec. 30, 2018
Outstanding Shares
Options outstanding beginning of period	114,250	111,637	109,652
Options granted	18,525	20,723	19,745
Options exercised	(13,248)	(16,275)	(14,785)
Options canceled/forfeited	(2,166)	(1,835)	(2,975)
Options outstanding end of period	117,361	114,250	111,637
Weighted Average Exercise Price
Options exercise price beginning of period (in dollars per share)	$ 116.22	$ 105.63	$ 98.29
Options granted, average exercise price (in dollars per share)	164.62	151.41	131.94
Options exercised, average exercise price (in dollars per share)	97.48	86.05	82.43
Options canceled/forfeited, average exercise price (in dollars per share)	149.75	137.62	125.11
Options exercise price end of period (in dollars per share)	$ 125.36	$ 116.22	$ 105.63
Aggregate intrinsic value	$ 5,364	$ 4,703	$ 4,478	$ 3,214

Common Stock, Stock Option Pl_6

Common Stock, Stock Option Plans and Stock Compensation Agreements - Summary of Options Outstanding (Details) - $ / shares shares in Thousands	12 Months Ended
	Jan. 02, 2022	Jan. 03, 2021	Dec. 29, 2019
Stock options outstanding and exercisable
Outstanding number of Options (in shares)	117,361	114,250	111,637
Outstanding, Average Life	5 years 9 months 18 days	6 years	6 years
Outstanding Average Exercise Price (in dollars per share)	$ 125.36
Exercisable number of Options (in shares)	62,742
Exercisable, Average Exercise Price (in dollars per share)	$ 104.42
$65.08-$90.44
Stock options outstanding and exercisable
Price Range, Minimum (in dollars per share)	65.08
Price Range, Maximum (in dollars per share)	$ 90.44
Outstanding number of Options (in shares)	16,007
Outstanding, Average Life	1 year 7 months 6 days
Outstanding Average Exercise Price (in dollars per share)	$ 81.92
Exercisable number of Options (in shares)	16,007
Exercisable, Average Exercise Price (in dollars per share)	$ 81.92
$100.06-$101.87
Stock options outstanding and exercisable
Price Range, Minimum (in dollars per share)	100.06
Price Range, Maximum (in dollars per share)	$ 101.87
Outstanding number of Options (in shares)	22,647
Outstanding, Average Life	3 years 7 months 6 days
Outstanding Average Exercise Price (in dollars per share)	$ 101.07
Exercisable number of Options (in shares)	22,647
Exercisable, Average Exercise Price (in dollars per share)	$ 101.07
$115.67-$129.51
Stock options outstanding and exercisable
Price Range, Minimum (in dollars per share)	115.67
Price Range, Maximum (in dollars per share)	$ 129.51
Outstanding number of Options (in shares)	24,543
Outstanding, Average Life	5 years 7 months 6 days
Outstanding Average Exercise Price (in dollars per share)	$ 122.59
Exercisable number of Options (in shares)	23,972
Exercisable, Average Exercise Price (in dollars per share)	$ 122.43
$131.94-$151.41
Stock options outstanding and exercisable
Price Range, Minimum (in dollars per share)	131.94
Price Range, Maximum (in dollars per share)	$ 151.41
Outstanding number of Options (in shares)	36,304
Outstanding, Average Life	7 years 7 months 6 days
Outstanding Average Exercise Price (in dollars per share)	$ 142.23
Exercisable number of Options (in shares)	100
Exercisable, Average Exercise Price (in dollars per share)	$ 140.72
$151.42-$164.62
Stock options outstanding and exercisable
Price Range, Minimum (in dollars per share)	151.42
Price Range, Maximum (in dollars per share)	$ 164.62
Outstanding number of Options (in shares)	17,860
Outstanding, Average Life	9 years 1 month 6 days
Outstanding Average Exercise Price (in dollars per share)	$ 164.62
Exercisable number of Options (in shares)	16
Exercisable, Average Exercise Price (in dollars per share)	$ 164.62

Common Stock, Stock Option Pl_7

Common Stock, Stock Option Plans and Stock Compensation Agreements - Summary of Restricted Share Units (Details) shares in Thousands	12 Months Ended
	Jan. 02, 2022shares
Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]
Beginning balance (in shares)	14,998
Granted (in shares)	4,981
Issued (in shares)	(5,101)
Canceled/forfeited/adjusted (in shares)	756
Ending balance (in shares)	14,122
Performance Shares
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]
Beginning balance (in shares)	2,236
Granted (in shares)	741
Issued (in shares)	(610)
Canceled/forfeited/adjusted (in shares)	(55)
Ending balance (in shares)	2,312

Segments of Business and Geog_3

Segments of Business and Geographic Areas - Sales by Segment of Business (Details) - USD ($) $ in Millions	12 Months Ended
	Jan. 02, 2022	Jan. 03, 2021	Dec. 29, 2019
Segment Reporting Information [Line Items]
Sales to Customers	$ 93,775	$ 82,584	$ 82,059
Percentage Change In Sales By Segment Of Business	13.60%	0.60%
Consumer Health
Segment Reporting Information [Line Items]
Sales to Customers	$ 14,635	$ 14,053	13,898
Percentage Change In Sales By Segment Of Business	4.10%	1.10%
Pharmaceutical
Segment Reporting Information [Line Items]
Sales to Customers	$ 52,080	$ 45,572	42,198
Percentage Change In Sales By Segment Of Business	14.30%	8.00%
Pharmaceutical \| Immunology
Segment Reporting Information [Line Items]
Sales to Customers	$ 16,750	$ 15,055	13,950
Percentage Change In Sales By Segment Of Business	11.30%	7.90%
Pharmaceutical \| Infectious Diseases
Segment Reporting Information [Line Items]
Sales to Customers	$ 5,861	$ 3,574	3,413
Percentage Change In Sales By Segment Of Business	64.00%	4.70%
Pharmaceutical \| Neuroscience
Segment Reporting Information [Line Items]
Sales to Customers	$ 7,011	$ 6,548	6,328
Percentage Change In Sales By Segment Of Business	7.10%	3.50%
Pharmaceutical \| Oncology
Segment Reporting Information [Line Items]
Sales to Customers	$ 14,548	$ 12,367	10,692
Percentage Change In Sales By Segment Of Business	17.60%	15.70%
Pharmaceutical \| Pulmonary Hypertension
Segment Reporting Information [Line Items]
Sales to Customers	$ 3,450	$ 3,148	2,623
Percentage Change In Sales By Segment Of Business	9.60%	20.00%
Pharmaceutical \| Cardiovascular/Metabolism/Other
Segment Reporting Information [Line Items]
Sales to Customers	$ 4,460	$ 4,878	5,192
Percentage Change In Sales By Segment Of Business	(8.60%)	(6.00%)
Medical Devices
Segment Reporting Information [Line Items]
Sales to Customers	$ 27,060	$ 22,959	25,963
Percentage Change In Sales By Segment Of Business	17.90%	(11.60%)
Medical Devices \| Interventional Solutions
Segment Reporting Information [Line Items]
Sales to Customers	$ 3,971	$ 3,046	2,997
Percentage Change In Sales By Segment Of Business	30.40%	1.60%
Medical Devices \| Orthopaedics
Segment Reporting Information [Line Items]
Sales to Customers	$ 8,588	$ 7,763	8,839
Percentage Change In Sales By Segment Of Business	10.60%	(12.20%)
Medical Devices \| Surgery
Segment Reporting Information [Line Items]
Sales to Customers	$ 9,812	$ 8,232	9,501
Percentage Change In Sales By Segment Of Business	19.20%	(13.40%)
Medical Devices \| Vision
Segment Reporting Information [Line Items]
Sales to Customers	$ 4,688	$ 3,919	4,624
Percentage Change In Sales By Segment Of Business	19.60%	(15.20%)
OTC \| Consumer Health
Segment Reporting Information [Line Items]
Sales to Customers	$ 5,227	$ 4,824	4,444
Percentage Change In Sales By Segment Of Business	8.40%	8.50%
Skin health/Beauty \| Consumer Health
Segment Reporting Information [Line Items]
Sales to Customers	$ 4,541	$ 4,450	4,593
Percentage Change In Sales By Segment Of Business	2.00%	(3.10%)
Oral Care \| Consumer Health
Segment Reporting Information [Line Items]
Sales to Customers	$ 1,645	$ 1,641	1,528
Percentage Change In Sales By Segment Of Business	0.20%	7.40%
Baby Care \| Consumer Health
Segment Reporting Information [Line Items]
Sales to Customers	$ 1,566	$ 1,517	1,675
Percentage Change In Sales By Segment Of Business	3.20%	(9.40%)
Women's Health \| Consumer Health
Segment Reporting Information [Line Items]
Sales to Customers	$ 917	$ 901	986
Percentage Change In Sales By Segment Of Business	1.80%	(8.60%)
Wound Care and Other \| Consumer Health
Segment Reporting Information [Line Items]
Sales to Customers	$ 739	$ 720	671
Percentage Change In Sales By Segment Of Business	2.60%	7.20%
Remicade \| Pharmaceutical \| Immunology
Segment Reporting Information [Line Items]
Sales to Customers	$ 3,190	$ 3,747	4,380
Percentage Change In Sales By Segment Of Business	(14.90%)	(14.40%)
Simponi/Simponi Aria \| Pharmaceutical \| Immunology
Segment Reporting Information [Line Items]
Sales to Customers	$ 2,276	$ 2,243	2,188
Percentage Change In Sales By Segment Of Business	1.40%	2.60%
Stelara \| Pharmaceutical \| Immunology
Segment Reporting Information [Line Items]
Sales to Customers	$ 9,134	$ 7,707	6,361
Percentage Change In Sales By Segment Of Business	18.50%	21.10%
Tremfya \| Pharmaceutical \| Immunology
Segment Reporting Information [Line Items]
Sales to Customers	$ 2,127	$ 1,347	1,012
Percentage Change In Sales By Segment Of Business	57.90%	33.20%
Other Immunology \| Pharmaceutical \| Immunology
Segment Reporting Information [Line Items]
Sales to Customers	$ 24	$ 11	10
Percentage Change In Sales By Segment Of Business		6.40%
COVID-19 \| Pharmaceutical \| Infectious Diseases
Segment Reporting Information [Line Items]
Sales to Customers	2,385	$ 0	0
EDURANT/rilpivirine \| Pharmaceutical \| Infectious Diseases
Segment Reporting Information [Line Items]
Sales to Customers	$ 994	$ 964	861
Percentage Change In Sales By Segment Of Business	3.10%	11.90%
PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA \| Pharmaceutical \| Infectious Diseases
Segment Reporting Information [Line Items]
Sales to Customers	$ 2,083	$ 2,184	2,110
Percentage Change In Sales By Segment Of Business	(4.60%)	3.50%
Other Infectious Diseases \| Pharmaceutical \| Infectious Diseases
Segment Reporting Information [Line Items]
Sales to Customers	$ 399	$ 427	441
Percentage Change In Sales By Segment Of Business	(6.50%)	(3.20%)
CONCERTA/Methylphenidate \| Pharmaceutical \| Neuroscience
Segment Reporting Information [Line Items]
Sales to Customers	$ 667	$ 622	696
Percentage Change In Sales By Segment Of Business	7.30%	(10.60%)
INVEGA SUSTENNA/XEPLION/TRINZA/TREVICTA \| Pharmaceutical \| Neuroscience
Segment Reporting Information [Line Items]
Sales to Customers	$ 4,022	$ 3,653	3,330
Percentage Change In Sales By Segment Of Business	10.10%	9.70%
RISPERDAL CONSTA \| Pharmaceutical \| Neuroscience
Segment Reporting Information [Line Items]
Sales to Customers	$ 592	$ 642	688
Percentage Change In Sales By Segment Of Business	(7.70%)	(6.80%)
OTHER NEUROSCIENCE \| Pharmaceutical \| Neuroscience
Segment Reporting Information [Line Items]
Sales to Customers	$ 1,729	$ 1,632	1,614
Percentage Change In Sales By Segment Of Business	6.00%	1.10%
DARZALEX \| Pharmaceutical \| Oncology
Segment Reporting Information [Line Items]
Sales to Customers	$ 6,023	$ 4,190	2,998
Percentage Change In Sales By Segment Of Business	43.80%	39.80%
ERLEADA \| Pharmaceutical \| Oncology
Segment Reporting Information [Line Items]
Sales to Customers	$ 1,291	$ 760	332
Percentage Change In Sales By Segment Of Business	70.00%
IMBRUVICA \| Pharmaceutical \| Oncology
Segment Reporting Information [Line Items]
Sales to Customers	$ 4,369	$ 4,128	3,411
Percentage Change In Sales By Segment Of Business	5.80%	21.00%
ZYTIGA/abiraterone acetate \| Pharmaceutical \| Oncology
Segment Reporting Information [Line Items]
Sales to Customers	$ 2,297	$ 2,470	2,795
Percentage Change In Sales By Segment Of Business	(7.00%)	(11.60%)
Other Oncology \| Pharmaceutical \| Oncology
Segment Reporting Information [Line Items]
Sales to Customers	$ 568	$ 821	1,158
Percentage Change In Sales By Segment Of Business	(30.80%)	(29.10%)
OPSUMIT \| Pharmaceutical \| Pulmonary Hypertension
Segment Reporting Information [Line Items]
Sales to Customers	$ 1,819	$ 1,639	1,327
Percentage Change In Sales By Segment Of Business	11.00%	23.50%
UPTRAVI \| Pharmaceutical \| Pulmonary Hypertension
Segment Reporting Information [Line Items]
Sales to Customers	$ 1,237	$ 1,093	819
Percentage Change In Sales By Segment Of Business	13.10%	33.50%
Other \| Pharmaceutical \| Pulmonary Hypertension
Segment Reporting Information [Line Items]
Sales to Customers	$ 395	$ 416	476
Percentage Change In Sales By Segment Of Business	(5.00%)	(12.80%)
Other \| Pharmaceutical \| Cardiovascular/Metabolism/Other
Segment Reporting Information [Line Items]
Sales to Customers	$ 981	$ 1,186	1,353
Percentage Change In Sales By Segment Of Business	(17.30%)	(12.40%)
XARELTO \| Pharmaceutical \| Cardiovascular/Metabolism/Other
Segment Reporting Information [Line Items]
Sales to Customers	$ 2,438	$ 2,345	2,313
Percentage Change In Sales By Segment Of Business	4.00%	1.40%
INVOKANA/INVOKAMET \| Pharmaceutical \| Cardiovascular/Metabolism/Other
Segment Reporting Information [Line Items]
Sales to Customers	$ 563	$ 795	735
Percentage Change In Sales By Segment Of Business	(29.30%)	8.20%
PROCRIT/EPREX \| Pharmaceutical \| Cardiovascular/Metabolism/Other
Segment Reporting Information [Line Items]
Sales to Customers	$ 479	$ 552	790
Percentage Change In Sales By Segment Of Business	(13.30%)	(30.20%)
HIPS \| Medical Devices \| Orthopaedics
Segment Reporting Information [Line Items]
Sales to Customers	$ 1,485	$ 1,280	1,438
Percentage Change In Sales By Segment Of Business	16.00%	(11.00%)
KNEES \| Medical Devices \| Orthopaedics
Segment Reporting Information [Line Items]
Sales to Customers	$ 1,325	$ 1,170	1,480
Percentage Change In Sales By Segment Of Business	13.30%	(21.00%)
TRAUMA \| Medical Devices \| Orthopaedics
Segment Reporting Information [Line Items]
Sales to Customers	$ 2,885	$ 2,614	2,720
Percentage Change In Sales By Segment Of Business	10.40%	(3.90%)
SPINE,SPORTS & OTHER \| Medical Devices \| Orthopaedics
Segment Reporting Information [Line Items]
Sales to Customers	$ 2,893	$ 2,699	3,201
Percentage Change In Sales By Segment Of Business	7.20%	(15.70%)
ADVANCED \| Medical Devices \| Surgery
Segment Reporting Information [Line Items]
Sales to Customers	$ 4,622	$ 3,839	4,095
Percentage Change In Sales By Segment Of Business	20.40%	(6.20%)
GENERAL \| Medical Devices \| Surgery
Segment Reporting Information [Line Items]
Sales to Customers	$ 5,190	$ 4,392	5,406
Percentage Change In Sales By Segment Of Business	18.10%	(18.80%)
CONTACT LENSES/OTHER \| Medical Devices \| Vision
Segment Reporting Information [Line Items]
Sales to Customers	$ 3,440	$ 2,994	3,392
Percentage Change In Sales By Segment Of Business	14.90%	(11.70%)
SURGICAL \| Medical Devices \| Vision
Segment Reporting Information [Line Items]
Sales to Customers	$ 1,248	$ 925	1,232
Percentage Change In Sales By Segment Of Business	34.90%	(24.90%)
United States
Segment Reporting Information [Line Items]
Sales to Customers	$ 47,156	$ 43,133	42,097
Percentage Change In Sales By Segment Of Business	9.30%	2.50%
United States \| Consumer Health
Segment Reporting Information [Line Items]
Sales to Customers	$ 6,516	$ 6,362	5,839
Percentage Change In Sales By Segment Of Business	2.40%	9.00%
United States \| Pharmaceutical
Segment Reporting Information [Line Items]
Sales to Customers	$ 27,954	$ 25,735	23,874
Percentage Change In Sales By Segment Of Business	8.60%	7.80%
United States \| Pharmaceutical \| Immunology
Segment Reporting Information [Line Items]
Sales to Customers	$ 10,843	$ 10,175	9,641
Percentage Change In Sales By Segment Of Business	6.60%	5.50%
United States \| Pharmaceutical \| Infectious Diseases
Segment Reporting Information [Line Items]
Sales to Customers	$ 2,249	$ 1,735	1,597
Percentage Change In Sales By Segment Of Business	29.70%	8.60%
United States \| Pharmaceutical \| Neuroscience
Segment Reporting Information [Line Items]
Sales to Customers	$ 3,347	$ 3,091	2,919
Percentage Change In Sales By Segment Of Business	8.30%	5.90%
United States \| Pharmaceutical \| Oncology
Segment Reporting Information [Line Items]
Sales to Customers	$ 5,958	$ 5,092	4,299
Percentage Change In Sales By Segment Of Business	17.00%	18.50%
United States \| Pharmaceutical \| Pulmonary Hypertension
Segment Reporting Information [Line Items]
Sales to Customers	$ 2,365	$ 2,133	1,684
Percentage Change In Sales By Segment Of Business	10.90%	26.60%
United States \| Pharmaceutical \| Cardiovascular/Metabolism/Other
Segment Reporting Information [Line Items]
Sales to Customers	$ 3,192	$ 3,509	3,734
Percentage Change In Sales By Segment Of Business	(9.00%)	(6.00%)
United States \| Medical Devices
Segment Reporting Information [Line Items]
Sales to Customers	$ 12,686	$ 11,036	12,384
Percentage Change In Sales By Segment Of Business	14.90%	(10.90%)
United States \| Medical Devices \| Interventional Solutions
Segment Reporting Information [Line Items]
Sales to Customers	$ 1,836	$ 1,452	1,443
Percentage Change In Sales By Segment Of Business	26.40%	0.60%
United States \| Medical Devices \| Orthopaedics
Segment Reporting Information [Line Items]
Sales to Customers	$ 5,126	$ 4,779	5,319
Percentage Change In Sales By Segment Of Business	7.30%	(10.20%)
United States \| Medical Devices \| Surgery
Segment Reporting Information [Line Items]
Sales to Customers	$ 3,867	$ 3,249	3,828
Percentage Change In Sales By Segment Of Business	19.00%	(15.10%)
United States \| Medical Devices \| Vision
Segment Reporting Information [Line Items]
Sales to Customers	$ 1,857	$ 1,557	1,794
Percentage Change In Sales By Segment Of Business	19.30%	(13.20%)
United States \| OTC \| Consumer Health
Segment Reporting Information [Line Items]
Sales to Customers	$ 2,594	$ 2,460	2,010
Percentage Change In Sales By Segment Of Business	5.40%	22.40%
United States \| Skin health/Beauty \| Consumer Health
Segment Reporting Information [Line Items]
Sales to Customers	$ 2,400	$ 2,350	2,392
Percentage Change In Sales By Segment Of Business	2.10%	(1.70%)
United States \| Oral Care \| Consumer Health
Segment Reporting Information [Line Items]
Sales to Customers	$ 637	$ 683	621
Percentage Change In Sales By Segment Of Business	(6.70%)	9.90%
United States \| Baby Care \| Consumer Health
Segment Reporting Information [Line Items]
Sales to Customers	$ 378	$ 376	362
Percentage Change In Sales By Segment Of Business	0.50%	3.70%
United States \| Women's Health \| Consumer Health
Segment Reporting Information [Line Items]
Sales to Customers	$ 13	$ 13	12
Percentage Change In Sales By Segment Of Business	(1.60%)	8.20%
United States \| Wound Care and Other \| Consumer Health
Segment Reporting Information [Line Items]
Sales to Customers	$ 495	$ 480	441
Percentage Change In Sales By Segment Of Business	3.10%	8.90%
United States \| Remicade \| Pharmaceutical \| Immunology
Segment Reporting Information [Line Items]
Sales to Customers	$ 2,019	$ 2,508	3,079
Percentage Change In Sales By Segment Of Business	(19.50%)	(18.50%)
United States \| Simponi/Simponi Aria \| Pharmaceutical \| Immunology
Segment Reporting Information [Line Items]
Sales to Customers	$ 1,127	$ 1,155	1,159
Percentage Change In Sales By Segment Of Business	(2.40%)	(0.30%)
United States \| Stelara \| Pharmaceutical \| Immunology
Segment Reporting Information [Line Items]
Sales to Customers	$ 5,938	$ 5,240	4,346
Percentage Change In Sales By Segment Of Business	13.30%	20.60%
United States \| Tremfya \| Pharmaceutical \| Immunology
Segment Reporting Information [Line Items]
Sales to Customers	$ 1,503	$ 926	764
Percentage Change In Sales By Segment Of Business	62.30%	21.30%
United States \| Other Immunology \| Pharmaceutical \| Immunology
Segment Reporting Information [Line Items]
Sales to Customers	$ 21	$ 0	0
Percentage Change In Sales By Segment Of Business		0.00%
United States \| COVID-19 \| Pharmaceutical \| Infectious Diseases
Segment Reporting Information [Line Items]
Sales to Customers	634	$ 0	0
United States \| EDURANT/rilpivirine \| Pharmaceutical \| Infectious Diseases
Segment Reporting Information [Line Items]
Sales to Customers	$ 41	$ 44	50
Percentage Change In Sales By Segment Of Business	(7.60%)	(11.20%)
United States \| PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA \| Pharmaceutical \| Infectious Diseases
Segment Reporting Information [Line Items]
Sales to Customers	$ 1,508	$ 1,587	1,422
Percentage Change In Sales By Segment Of Business	(4.90%)	11.60%
United States \| Other Infectious Diseases \| Pharmaceutical \| Infectious Diseases
Segment Reporting Information [Line Items]
Sales to Customers	$ 66	$ 104	126
Percentage Change In Sales By Segment Of Business	(36.00%)	(17.60%)
United States \| CONCERTA/Methylphenidate \| Pharmaceutical \| Neuroscience
Segment Reporting Information [Line Items]
Sales to Customers	$ 172	$ 183	233
Percentage Change In Sales By Segment Of Business	(5.80%)	(21.40%)
United States \| INVEGA SUSTENNA/XEPLION/TRINZA/TREVICTA \| Pharmaceutical \| Neuroscience
Segment Reporting Information [Line Items]
Sales to Customers	$ 2,550	$ 2,314	2,107
Percentage Change In Sales By Segment Of Business	10.20%	9.80%
United States \| RISPERDAL CONSTA \| Pharmaceutical \| Neuroscience
Segment Reporting Information [Line Items]
Sales to Customers	$ 287	$ 296	314
Percentage Change In Sales By Segment Of Business	(2.90%)	(5.90%)
United States \| OTHER NEUROSCIENCE \| Pharmaceutical \| Neuroscience
Segment Reporting Information [Line Items]
Sales to Customers	$ 338	$ 298	266
Percentage Change In Sales By Segment Of Business	13.30%	12.40%
United States \| DARZALEX \| Pharmaceutical \| Oncology
Segment Reporting Information [Line Items]
Sales to Customers	$ 3,169	$ 2,232	1,567
Percentage Change In Sales By Segment Of Business	42.00%	42.40%
United States \| ERLEADA \| Pharmaceutical \| Oncology
Segment Reporting Information [Line Items]
Sales to Customers	$ 813	$ 583	297
Percentage Change In Sales By Segment Of Business	39.30%	96.10%
United States \| IMBRUVICA \| Pharmaceutical \| Oncology
Segment Reporting Information [Line Items]
Sales to Customers	$ 1,747	$ 1,821	1,555
Percentage Change In Sales By Segment Of Business	(4.00%)	17.10%
United States \| ZYTIGA/abiraterone acetate \| Pharmaceutical \| Oncology
Segment Reporting Information [Line Items]
Sales to Customers	$ 119	$ 373	810
Percentage Change In Sales By Segment Of Business	(68.10%)	(54.00%)
United States \| Other Oncology \| Pharmaceutical \| Oncology
Segment Reporting Information [Line Items]
Sales to Customers	$ 110	$ 83	70
Percentage Change In Sales By Segment Of Business	31.70%	18.60%
United States \| OPSUMIT \| Pharmaceutical \| Pulmonary Hypertension
Segment Reporting Information [Line Items]
Sales to Customers	$ 1,147	$ 1,008	766
Percentage Change In Sales By Segment Of Business	13.70%	31.70%
United States \| UPTRAVI \| Pharmaceutical \| Pulmonary Hypertension
Segment Reporting Information [Line Items]
Sales to Customers	$ 1,056	$ 955	714
Percentage Change In Sales By Segment Of Business	10.50%	33.80%
United States \| Other \| Pharmaceutical \| Pulmonary Hypertension
Segment Reporting Information [Line Items]
Sales to Customers	$ 163	$ 169	205
Percentage Change In Sales By Segment Of Business	(3.70%)	(17.60%)
United States \| Other \| Pharmaceutical \| Cardiovascular/Metabolism/Other
Segment Reporting Information [Line Items]
Sales to Customers	$ 223	$ 323	380
Percentage Change In Sales By Segment Of Business	(31.00%)	(15.10%)
United States \| XARELTO \| Pharmaceutical \| Cardiovascular/Metabolism/Other
Segment Reporting Information [Line Items]
Sales to Customers	$ 2,438	$ 2,345	2,313
Percentage Change In Sales By Segment Of Business	4.00%	1.40%
United States \| INVOKANA/INVOKAMET \| Pharmaceutical \| Cardiovascular/Metabolism/Other
Segment Reporting Information [Line Items]
Sales to Customers	$ 308	$ 564	536
Percentage Change In Sales By Segment Of Business	(45.40%)	5.20%
United States \| PROCRIT/EPREX \| Pharmaceutical \| Cardiovascular/Metabolism/Other
Segment Reporting Information [Line Items]
Sales to Customers	$ 223	$ 277	505
Percentage Change In Sales By Segment Of Business	(19.70%)	(45.10%)
United States \| HIPS \| Medical Devices \| Orthopaedics
Segment Reporting Information [Line Items]
Sales to Customers	$ 883	$ 793	863
Percentage Change In Sales By Segment Of Business	11.40%	(8.20%)
United States \| KNEES \| Medical Devices \| Orthopaedics
Segment Reporting Information [Line Items]
Sales to Customers	$ 787	$ 743	889
Percentage Change In Sales By Segment Of Business	5.90%	(16.40%)
United States \| TRAUMA \| Medical Devices \| Orthopaedics
Segment Reporting Information [Line Items]
Sales to Customers	$ 1,819	$ 1,648	1,652
Percentage Change In Sales By Segment Of Business	10.40%	(0.20%)
United States \| SPINE,SPORTS & OTHER \| Medical Devices \| Orthopaedics
Segment Reporting Information [Line Items]
Sales to Customers	$ 1,637	$ 1,595	1,915
Percentage Change In Sales By Segment Of Business	2.60%	(16.70%)
United States \| ADVANCED \| Medical Devices \| Surgery
Segment Reporting Information [Line Items]
Sales to Customers	$ 1,761	$ 1,535	1,637
Percentage Change In Sales By Segment Of Business	14.90%	(6.20%)
United States \| GENERAL \| Medical Devices \| Surgery
Segment Reporting Information [Line Items]
Sales to Customers	$ 2,105	$ 1,714	2,192
Percentage Change In Sales By Segment Of Business	22.70%	(21.80%)
United States \| CONTACT LENSES/OTHER \| Medical Devices \| Vision
Segment Reporting Information [Line Items]
Sales to Customers	$ 1,398	$ 1,213	1,304
Percentage Change In Sales By Segment Of Business	15.20%	(7.00%)
United States \| SURGICAL \| Medical Devices \| Vision
Segment Reporting Information [Line Items]
Sales to Customers	$ 459	$ 344	490
Percentage Change In Sales By Segment Of Business	33.50%	(29.70%)
Non-US
Segment Reporting Information [Line Items]
Sales to Customers	$ 46,619	$ 39,451	39,962
Percentage Change In Sales By Segment Of Business	18.20%	(1.30%)
Non-US \| Consumer Health
Segment Reporting Information [Line Items]
Sales to Customers	$ 8,119	$ 7,691	8,059
Percentage Change In Sales By Segment Of Business	5.60%	(4.60%)
Non-US \| Pharmaceutical
Segment Reporting Information [Line Items]
Sales to Customers	$ 24,126	$ 19,837	18,324
Percentage Change In Sales By Segment Of Business	21.60%	8.30%
Non-US \| Pharmaceutical \| Immunology
Segment Reporting Information [Line Items]
Sales to Customers	$ 5,907	$ 4,880	4,309
Percentage Change In Sales By Segment Of Business	21.00%	13.20%
Non-US \| Pharmaceutical \| Infectious Diseases
Segment Reporting Information [Line Items]
Sales to Customers	$ 3,612	$ 1,839	1,815
Percentage Change In Sales By Segment Of Business	96.30%	1.30%
Non-US \| Pharmaceutical \| Neuroscience
Segment Reporting Information [Line Items]
Sales to Customers	$ 3,664	$ 3,457	3,409
Percentage Change In Sales By Segment Of Business	6.00%	1.40%
Non-US \| Pharmaceutical \| Oncology
Segment Reporting Information [Line Items]
Sales to Customers	$ 8,590	$ 7,275	6,393
Percentage Change In Sales By Segment Of Business	18.10%	13.80%
Non-US \| Pharmaceutical \| Pulmonary Hypertension
Segment Reporting Information [Line Items]
Sales to Customers	$ 1,085	$ 1,015	939
Percentage Change In Sales By Segment Of Business	6.90%	8.20%
Non-US \| Pharmaceutical \| Cardiovascular/Metabolism/Other
Segment Reporting Information [Line Items]
Sales to Customers	$ 1,268	$ 1,369	1,458
Percentage Change In Sales By Segment Of Business	(7.40%)	(6.10%)
Non-US \| Medical Devices
Segment Reporting Information [Line Items]
Sales to Customers	$ 14,374	$ 11,923	13,579
Percentage Change In Sales By Segment Of Business	20.60%	(12.20%)
Non-US \| Medical Devices \| Interventional Solutions
Segment Reporting Information [Line Items]
Sales to Customers	$ 2,135	$ 1,594	1,554
Percentage Change In Sales By Segment Of Business	34.00%	2.60%
Non-US \| Medical Devices \| Orthopaedics
Segment Reporting Information [Line Items]
Sales to Customers	$ 3,462	$ 2,984	3,520
Percentage Change In Sales By Segment Of Business	16.00%	(15.20%)
Non-US \| Medical Devices \| Surgery
Segment Reporting Information [Line Items]
Sales to Customers	$ 5,945	$ 4,983	5,673
Percentage Change In Sales By Segment Of Business	19.30%	(12.20%)
Non-US \| Medical Devices \| Vision
Segment Reporting Information [Line Items]
Sales to Customers	$ 2,831	$ 2,362	2,830
Percentage Change In Sales By Segment Of Business	19.80%	(16.50%)
Non-US \| OTC \| Consumer Health
Segment Reporting Information [Line Items]
Sales to Customers	$ 2,634	$ 2,364	2,434
Percentage Change In Sales By Segment Of Business	11.40%	(2.90%)
Non-US \| Skin health/Beauty \| Consumer Health
Segment Reporting Information [Line Items]
Sales to Customers	$ 2,141	$ 2,100	2,201
Percentage Change In Sales By Segment Of Business	1.90%	(4.60%)
Non-US \| Oral Care \| Consumer Health
Segment Reporting Information [Line Items]
Sales to Customers	$ 1,008	$ 958	906
Percentage Change In Sales By Segment Of Business	5.10%	5.70%
Non-US \| Baby Care \| Consumer Health
Segment Reporting Information [Line Items]
Sales to Customers	$ 1,188	$ 1,141	1,313
Percentage Change In Sales By Segment Of Business	4.10%	(13.10%)
Non-US \| Women's Health \| Consumer Health
Segment Reporting Information [Line Items]
Sales to Customers	$ 905	$ 888	974
Percentage Change In Sales By Segment Of Business	1.80%	(8.80%)
Non-US \| Wound Care and Other \| Consumer Health
Segment Reporting Information [Line Items]
Sales to Customers	$ 243	$ 240	230
Percentage Change In Sales By Segment Of Business	1.70%	4.10%
Non-US \| Remicade \| Pharmaceutical \| Immunology
Segment Reporting Information [Line Items]
Sales to Customers	$ 935	$ 893	1,007
Percentage Change In Sales By Segment Of Business	4.80%	(11.40%)
Non-US \| Simponi/Simponi Aria \| Pharmaceutical \| Immunology
Segment Reporting Information [Line Items]
Sales to Customers	$ 1,148	$ 1,088	1,029
Percentage Change In Sales By Segment Of Business	5.50%	5.80%
Non-US \| Stelara \| Pharmaceutical \| Immunology
Segment Reporting Information [Line Items]
Sales to Customers	$ 3,196	$ 2,467	2,015
Percentage Change In Sales By Segment Of Business	29.60%	22.40%
Non-US \| Tremfya \| Pharmaceutical \| Immunology
Segment Reporting Information [Line Items]
Sales to Customers	$ 624	$ 421	248
Percentage Change In Sales By Segment Of Business	48.20%	69.90%
Non-US \| Other Immunology \| Pharmaceutical \| Immunology
Segment Reporting Information [Line Items]
Sales to Customers	$ 3	$ 11	10
Percentage Change In Sales By Segment Of Business	(73.30%)	6.40%
Non-US \| COVID-19 \| Pharmaceutical \| Infectious Diseases
Segment Reporting Information [Line Items]
Sales to Customers	$ 1,751	$ 0	0
Non-US \| EDURANT/rilpivirine \| Pharmaceutical \| Infectious Diseases
Segment Reporting Information [Line Items]
Sales to Customers	$ 953	$ 920	812
Percentage Change In Sales By Segment Of Business	3.60%	13.30%
Non-US \| PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA \| Pharmaceutical \| Infectious Diseases
Segment Reporting Information [Line Items]
Sales to Customers	$ 575	$ 597	689
Percentage Change In Sales By Segment Of Business	(3.60%)	(13.40%)
Non-US \| Other Infectious Diseases \| Pharmaceutical \| Infectious Diseases
Segment Reporting Information [Line Items]
Sales to Customers	$ 333	$ 323	315
Percentage Change In Sales By Segment Of Business	3.00%	2.60%
Non-US \| CONCERTA/Methylphenidate \| Pharmaceutical \| Neuroscience
Segment Reporting Information [Line Items]
Sales to Customers	$ 495	$ 439	463
Percentage Change In Sales By Segment Of Business	12.80%	(5.10%)
Non-US \| INVEGA SUSTENNA/XEPLION/TRINZA/TREVICTA \| Pharmaceutical \| Neuroscience
Segment Reporting Information [Line Items]
Sales to Customers	$ 1,472	$ 1,339	1,224
Percentage Change In Sales By Segment Of Business	10.00%	9.40%
Non-US \| RISPERDAL CONSTA \| Pharmaceutical \| Neuroscience
Segment Reporting Information [Line Items]
Sales to Customers	$ 305	$ 346	374
Percentage Change In Sales By Segment Of Business	(11.80%)	(7.50%)
Non-US \| OTHER NEUROSCIENCE \| Pharmaceutical \| Neuroscience
Segment Reporting Information [Line Items]
Sales to Customers	$ 1,391	$ 1,334	1,349
Percentage Change In Sales By Segment Of Business	4.30%	(1.10%)
Non-US \| DARZALEX \| Pharmaceutical \| Oncology
Segment Reporting Information [Line Items]
Sales to Customers	$ 2,854	$ 1,958	1,430
Percentage Change In Sales By Segment Of Business	45.80%	36.90%
Non-US \| ERLEADA \| Pharmaceutical \| Oncology
Segment Reporting Information [Line Items]
Sales to Customers	$ 478	$ 176	35
Non-US \| IMBRUVICA \| Pharmaceutical \| Oncology
Segment Reporting Information [Line Items]
Sales to Customers	$ 2,622	$ 2,307	1,856
Percentage Change In Sales By Segment Of Business	13.60%	24.30%
Non-US \| ZYTIGA/abiraterone acetate \| Pharmaceutical \| Oncology
Segment Reporting Information [Line Items]
Sales to Customers	$ 2,178	$ 2,097	1,985
Percentage Change In Sales By Segment Of Business	3.90%	5.60%
Non-US \| Other Oncology \| Pharmaceutical \| Oncology
Segment Reporting Information [Line Items]
Sales to Customers	$ 458	$ 738	1,087
Percentage Change In Sales By Segment Of Business	(37.90%)	(32.10%)
Non-US \| OPSUMIT \| Pharmaceutical \| Pulmonary Hypertension
Segment Reporting Information [Line Items]
Sales to Customers	$ 672	$ 631	562
Percentage Change In Sales By Segment Of Business	6.60%	12.30%
Non-US \| UPTRAVI \| Pharmaceutical \| Pulmonary Hypertension
Segment Reporting Information [Line Items]
Sales to Customers	$ 181	$ 138	105
Percentage Change In Sales By Segment Of Business	31.10%	30.90%
Non-US \| Other \| Pharmaceutical \| Pulmonary Hypertension
Segment Reporting Information [Line Items]
Sales to Customers	$ 232	$ 247	272
Percentage Change In Sales By Segment Of Business	(5.90%)	(9.20%)
Non-US \| Other \| Pharmaceutical \| Cardiovascular/Metabolism/Other
Segment Reporting Information [Line Items]
Sales to Customers	$ 758	$ 864	974
Percentage Change In Sales By Segment Of Business	(12.20%)	(11.30%)
Non-US \| XARELTO \| Pharmaceutical \| Cardiovascular/Metabolism/Other
Segment Reporting Information [Line Items]
Sales to Customers	$ 0	$ 0	0
Percentage Change In Sales By Segment Of Business	0.00%	0.00%
Non-US \| INVOKANA/INVOKAMET \| Pharmaceutical \| Cardiovascular/Metabolism/Other
Segment Reporting Information [Line Items]
Sales to Customers	$ 254	$ 231	199
Percentage Change In Sales By Segment Of Business	9.90%	16.30%
Non-US \| PROCRIT/EPREX \| Pharmaceutical \| Cardiovascular/Metabolism/Other
Segment Reporting Information [Line Items]
Sales to Customers	$ 256	$ 274	285
Percentage Change In Sales By Segment Of Business	(6.80%)	(3.80%)
Non-US \| HIPS \| Medical Devices \| Orthopaedics
Segment Reporting Information [Line Items]
Sales to Customers	$ 602	$ 487	575
Percentage Change In Sales By Segment Of Business	23.60%	(15.30%)
Non-US \| KNEES \| Medical Devices \| Orthopaedics
Segment Reporting Information [Line Items]
Sales to Customers	$ 538	$ 427	591
Percentage Change In Sales By Segment Of Business	26.10%	(27.80%)
Non-US \| TRAUMA \| Medical Devices \| Orthopaedics
Segment Reporting Information [Line Items]
Sales to Customers	$ 1,066	$ 966	1,068
Percentage Change In Sales By Segment Of Business	10.40%	(9.60%)
Non-US \| SPINE,SPORTS & OTHER \| Medical Devices \| Orthopaedics
Segment Reporting Information [Line Items]
Sales to Customers	$ 1,256	$ 1,104	1,286
Percentage Change In Sales By Segment Of Business	13.80%	(14.10%)
Non-US \| ADVANCED \| Medical Devices \| Surgery
Segment Reporting Information [Line Items]
Sales to Customers	$ 2,861	$ 2,304	2,458
Percentage Change In Sales By Segment Of Business	24.10%	(6.20%)
Non-US \| GENERAL \| Medical Devices \| Surgery
Segment Reporting Information [Line Items]
Sales to Customers	$ 3,085	$ 2,679	3,215
Percentage Change In Sales By Segment Of Business	15.20%	(16.70%)
Non-US \| CONTACT LENSES/OTHER \| Medical Devices \| Vision
Segment Reporting Information [Line Items]
Sales to Customers	$ 2,043	$ 1,781	2,088
Percentage Change In Sales By Segment Of Business	14.70%	(14.70%)
Non-US \| SURGICAL \| Medical Devices \| Vision
Segment Reporting Information [Line Items]
Sales to Customers	$ 788	$ 581	742
Percentage Change In Sales By Segment Of Business	35.70%	(21.70%)
UNITED STATES Exports \| Remicade \| Pharmaceutical \| Immunology
Segment Reporting Information [Line Items]
Sales to Customers	$ 236	$ 346	$ 294
Percentage Change In Sales By Segment Of Business	(31.90%)	18.00%

Segments of Business and Geog_4

Segments of Business and Geographic Areas - Schedule of Segment Reporting Information (Details) $ in Millions	12 Months Ended
	Jan. 02, 2022USD ($)Segment	Jan. 03, 2021USD ($)	Dec. 29, 2019USD ($)Segment	Oct. 31, 2020USD ($)	Oct. 31, 2019USD ($)
Segment Reporting Information [Line Items]
Earnings before provision for taxes on income	$ 22,776	$ 16,497	$ 17,328
Identifiable Assets	182,018	174,894
Additions to Property, Plant & Equipment	3,652	3,347	3,498
Depreciation and Amortization	7,390	7,231	7,009
Sales to Customers	$ 93,775	82,584	$ 82,059
Number of segments \| Segment	3		3
Restructuring charges	$ 252	247	$ 266
In-process research and development	900	181	890
Contingent consideration reversal	0	(1,148)	0
AdvancedSterilizationProducts
Segment Reporting Information [Line Items]
Gain (loss) on divestiture			$ 2,000
Property, Plant and Equipment
Segment Reporting Information [Line Items]
Long-Lived Assets	18,962	18,766
Other Intangible Assets
Segment Reporting Information [Line Items]
Long-Lived Assets	81,638	$ 89,795
Pending Litigation
Segment Reporting Information [Line Items]
Loss contingency, estimate of possible loss				$ 5,000	$ 4,000
Auris Health
Segment Reporting Information [Line Items]
Contingent consideration reversal	$ (1,148)
Wholesaler 1 \| Sales Revenue, Net \| Wholesaler Concentration Risk
Segment Reporting Information [Line Items]
Concentration risk (as a percent)	14.00%	16.00%	15.00%
Wholesaler 2 \| Sales Revenue, Net \| Wholesaler Concentration Risk
Segment Reporting Information [Line Items]
Concentration risk (as a percent)	11.00%	12.00%	12.00%
Wholesaler 3 \| Sales Revenue, Net \| Wholesaler Concentration Risk
Segment Reporting Information [Line Items]
Concentration risk (as a percent)	11.00%	12.00%	11.00%
United States
Segment Reporting Information [Line Items]
Sales to Customers	$ 47,156	$ 43,133	$ 42,097
Consumer Health
Segment Reporting Information [Line Items]
Sales to Customers	14,635	14,053	13,898
Litigation expense	1,600	3,900	400
Restructuring charges	100		100
Consumer Health \| Ci:z Holdings Co. Ltd.
Segment Reporting Information [Line Items]
Gain (loss) on sale of equity investments			300
Consumer Health \| United States
Segment Reporting Information [Line Items]
Sales to Customers	6,516	6,362	5,839
Pharmaceutical
Segment Reporting Information [Line Items]
Sales to Customers	52,080	45,572	42,198
Litigation expense	600	800	4,300
Restructuring charges	100	100	100
Gain (loss) on divestiture	600
Marketable securities, realized gain (loss)	500
In-process research and development			900
Research and development expense			300
Pharmaceutical \| Auris Health
Segment Reporting Information [Line Items]
Acquisition related costs			100
Pharmaceutical \| Actelion
Segment Reporting Information [Line Items]
Acquisition related costs			200
Pharmaceutical \| United States
Segment Reporting Information [Line Items]
Sales to Customers	27,954	25,735	23,874
Medical Devices
Segment Reporting Information [Line Items]
Sales to Customers	27,060	22,959	25,963
Litigation expense	100	300	400
Restructuring charges	300	300	400
In-process research and development	900	200
Regulation charge	200	100
Medical Devices \| Auris Health \| Other Income
Segment Reporting Information [Line Items]
Contingent consideration reversal		(1,100)
Medical Devices \| United States
Segment Reporting Information [Line Items]
Sales to Customers	12,686	11,036	12,384
Segments Total
Segment Reporting Information [Line Items]
Identifiable Assets	142,829	143,091
Additions to Property, Plant & Equipment	3,462	3,091	3,190
Depreciation and Amortization	7,074	6,931	6,689
Corporate, Non-Segment
Segment Reporting Information [Line Items]
Less: Expense not allocated to segments	1,072	945	835
Other Non Long Lived Assets	81,418	66,333
Corporate, Non-Segment \| General Corporate
Segment Reporting Information [Line Items]
Identifiable Assets	39,189	31,803
Additions to Property, Plant & Equipment	190	256	308
Depreciation and Amortization	316	300	320
Long-Lived Assets	1,014	1,029
Operating Segments
Segment Reporting Information [Line Items]
Earnings before provision for taxes on income	23,848	17,442	18,163
Sales to Customers	93,775	82,584	82,059
Long-Lived Assets	99,586	107,532
Operating Segments \| United States
Segment Reporting Information [Line Items]
Sales to Customers	47,156	43,133	42,097
Long-Lived Assets	48,586	49,951
Operating Segments \| Europe
Segment Reporting Information [Line Items]
Sales to Customers	23,594	18,980	18,466
Long-Lived Assets	43,257	49,363
Operating Segments \| Western Hemisphere excluding U.S.
Segment Reporting Information [Line Items]
Sales to Customers	5,750	5,335	5,941
Long-Lived Assets	2,708	2,734
Operating Segments \| Asia-Pacific, Africa
Segment Reporting Information [Line Items]
Sales to Customers	17,275	15,136	15,555
Long-Lived Assets	5,035	5,484
Operating Segments \| Consumer Health
Segment Reporting Information [Line Items]
Earnings before provision for taxes on income	1,294	(1,064)	2,061
Identifiable Assets	25,081	27,355
Additions to Property, Plant & Equipment	331	248	328
Depreciation and Amortization	759	785	765
Operating Segments \| Pharmaceutical
Segment Reporting Information [Line Items]
Earnings before provision for taxes on income	18,181	15,462	8,816
Identifiable Assets	64,376	66,158
Additions to Property, Plant & Equipment	1,198	863	950
Depreciation and Amortization	4,029	4,006	3,910
Unrealized gain (loss) on securities		500	600
Operating Segments \| Medical Devices
Segment Reporting Information [Line Items]
Earnings before provision for taxes on income	4,373	3,044	7,286
Identifiable Assets	53,372	49,578
Additions to Property, Plant & Equipment	1,933	1,980	1,912
Depreciation and Amortization	2,286	2,140	2,014
Operating Segments \| Medical Devices \| AdvancedSterilizationProducts
Segment Reporting Information [Line Items]
Gain (loss) on divestiture			2,000
Immunology \| Pharmaceutical
Segment Reporting Information [Line Items]
Sales to Customers	16,750	15,055	13,950
Immunology \| Pharmaceutical \| United States
Segment Reporting Information [Line Items]
Sales to Customers	$ 10,843	$ 10,175	$ 9,641

Acquisitions and Divestitures -

Acquisitions and Divestitures - Narrative (Details) $ / shares in Units, shares in Millions, SFr in Millions, $ in Millions, ¥ in Billions

Jan. 28, 2022USD ($)

Oct. 01, 2020USD ($)

Apr. 01, 2019USD ($)

Jan. 17, 2019USD ($)

Jan. 17, 2019JPY (¥)

Oct. 03, 2021USD ($)

Jan. 03, 2021USD ($)$ / shares

Sep. 27, 2020USD ($)

Mar. 29, 2020USD ($)

Mar. 31, 2019USD ($)

Jan. 02, 2022USD ($)shares

Jan. 02, 2022CHF (SFr)shares

Jan. 03, 2021USD ($)$ / sharesshares

Jan. 03, 2021CHF (SFr)shares

Dec. 29, 2019USD ($)

Jan. 03, 2021CHF (SFr)

Jan. 16, 2019

Business Acquisition [Line Items]

Consideration transferred

$ 7,300

Liabilities assumed

$ 400

400

$ 1,400

Goodwill (Notes 1 and 5)

36,393

$ 35,246

36,393

33,639

Acquisitions, net of cash acquired

7,323

5,810

Other (income) expense, net

(489)

(2,899)

(2,525)

Contingent consideration liability

633

533

633

Long-term debt

34,434

32,116

34,434

In Process Research and Development

Business Acquisition [Line Items]

Impairment of intangible assets, excluding goodwill

$ 900

$ 100

2019 Acquisitions | In Process Research and Development

Business Acquisition [Line Items]

Purchase price over fair value of assets acquired

6,800

Auris Health

Business Acquisition [Line Items]

Liabilities assumed

$ 1,800

Intangible assets assumed

$ 3,000

Discount rate

9.50%

Goodwill (Notes 1 and 5)

$ 2,000

Acquisitions, net of cash acquired

3,400

Contingent consideration liability

2,350

$ 1,100

Marketable securities assumed

$ 200

Auris Health | In Process Research and Development

Business Acquisition [Line Items]

Impairment of intangible assets, excluding goodwill

900

Ci:z Holdings Co. Ltd.

Business Acquisition [Line Items]

Consideration transferred

$ 2,100

¥ 230

Liabilities assumed

$ 400

Intangible assets assumed

1,500

Goodwill (Notes 1 and 5)

1,200

Foreign currency exchange rate, translation

109.06

Other (income) expense, net

$ 300

Weighted average useful life of acquired intangibles

15 years 3 months 18 days

Idorsia

Business Acquisition [Line Items]

Sale of stock, number of shares issued in transaction (in shares) | shares

11.8

Sale of stock, percentage of ownership before transaction

8.30%

Proceeds from sale of equity interests

$ 357

SFr 337

Sale of stock (in USD per share) | $ / shares

$ 28.55

Convertible note, equity Interest (in shares) | shares

38.7

Momenta

Business Acquisition [Line Items]

Consideration transferred

$ 6,100

Liabilities assumed

$ 1,600

Discount rate

13.00%

Goodwill (Notes 1 and 5)

$ 1,200

Other assets assumed

500

Momenta | In Process Research and Development

Business Acquisition [Line Items]

Intangible assets assumed

$ 6,000

2020 Acquisitions | In Process Research and Development

Business Acquisition [Line Items]

Purchase price over fair value of assets acquired

$ 7,500

bermekimab

Business Acquisition [Line Items]

Consideration transferred

800

Intangible assets assumed

$ 800

Discount rate

16.00%

bermekimab | Subsequent Event

Business Acquisition [Line Items]

Impairment of intangible assets, excluding goodwill

$ 600

Verb Surgical Inc.

Business Acquisition [Line Items]

Liabilities assumed

$ 300

Intangible assets assumed

400

Goodwill (Notes 1 and 5)

200

Other assets assumed

200

Equity method investments, fair value

$ 400

Maximum | Auris Health

Business Acquisition [Line Items]

Probability of success factor

66.00%

Maximum | Momenta

Business Acquisition [Line Items]

Probability of success factor

77.00%

Maximum | bermekimab

Business Acquisition [Line Items]

Probability of success factor

60.00%

Minimum | Auris Health

Business Acquisition [Line Items]

Probability of success factor

18.00%

Minimum | Momenta

Business Acquisition [Line Items]

Probability of success factor

20.00%

Minimum | bermekimab

Business Acquisition [Line Items]

Probability of success factor

20.00%

Convertible Debt | Idorsia

Business Acquisition [Line Items]

Long-term debt | SFr

SFr 445

Convertible debt, amount of loan converted

$ 120

SFr 110

Convertible Debt, number of equity instruments (in shares) | shares

9.6

AdvancedSterilizationProducts

Business Acquisition [Line Items]

Gain (loss) on divestiture

2,000

Evra and Doxil

Business Acquisition [Line Items]

Proceeds from divestiture of brands

$ 600

Discontinued Operations, Held-for-sale or Disposed of by Sale | AdvancedSterilizationProducts

Business Acquisition [Line Items]

Disposal group, including discontinued operation, consideration

2,800

Disposal group, including discontinued operation, cash

2,700

Disposal group, including discontinued operation, receivables retained

$ 100

Legal Proceedings (Details)

Legal Proceedings (Details) $ in Millions

Jan. 20, 2020USD ($)

Oct. 31, 2021USD ($)

Jun. 30, 2021USD ($)

Jun. 28, 2020USD ($)

Jan. 31, 2020USD ($)

Oct. 31, 2019USD ($)

Jul. 31, 2018USD ($)

Dec. 29, 2019USD ($)

Feb. 28, 2022cases

Jan. 02, 2022claimant

Sep. 30, 2021cases

May 31, 2021claimantcases

Oct. 31, 2020USD ($)

Apr. 30, 2015claim

ASR

Legal Proceeding (Textuals)

Product liability contingency, number of claimants

250

Pinnacle Acetabular Cup System

Legal Proceeding (Textuals)

Product liability contingency, number of claimants

5,300

Pelvic Meshes

Legal Proceeding (Textuals)

Product liability contingency, number of claimants

10,100

Risperdal

Legal Proceeding (Textuals)

Product liability contingency, number of claimants

8,800

XARELTO

Legal Proceeding (Textuals)

Product liability contingency, number of claimants

5,500

Talc

Legal Proceeding (Textuals)

Product liability contingency, number of claimants

40,400

Invokana

Legal Proceeding (Textuals)

Product liability contingency, number of claimants

100

Physiomesh

Legal Proceeding (Textuals)

Product liability contingency, number of claimants

4,700

Opioid

Legal Proceeding (Textuals)

Product liability contingency, number of claimants

3,400

Contact Lenses

Legal Proceeding (Textuals)

Number of pending claims | claim

Settled Litigation | Opioid

Legal Proceeding (Textuals)

Damages awarded | $

$ 5,000

Damages awarded, including settlement for related issues, reimbursement for legal fees, and removal from related claims | $

297

263

Judicial Ruling

Legal Proceeding (Textuals)

Damages awarded | $

$ 6.8

$ 8,000

Pending Litigation

Legal Proceeding (Textuals)

Loss contingency, estimate of possible loss | $

$ 4,000

$ 5,000

Loss contingency, estimate of additional possible loss | $

$ 1,000

Pending Litigation | Physiomesh

Legal Proceeding (Textuals)

Number of pending claims | cases

3,600

Product liability contingency, number of claimants

4,300

Number of claims within settlement agreement | cases

3,729

Pending Litigation | Physiomesh | Subsequent Event

Legal Proceeding (Textuals)

Number of pending claims | cases

Pending Litigation | Opioid | State Level Jurisdiction

Legal Proceeding (Textuals)

Product liability contingency, number of claimants

380

Pending Litigation | Opioid | Federal Level Jurisdiction

Legal Proceeding (Textuals)

Product liability contingency, number of claimants

3,000

DePuy ASR U.S. | Settled Litigation

Legal Proceeding (Textuals)

Number of patients in settlement

10,000

Baby Powder | Talc

Legal Proceeding (Textuals)

Reserve established | $

$ 2,000

Baby Powder | Judicial Ruling | Damages from Product Defects

Legal Proceeding (Textuals)

Litigation contingency | $

$ 2,100

$ 4,700

Payments for legal settlements | $

$ 2,500

Oklahoma Attorney General vs. Johnson & Johnson and JPI | Settled Litigation

Legal Proceeding (Textuals)

Damages awarded | $

$ 465

Surgical Mesh Products Marketing | Judicial Ruling

Legal Proceeding (Textuals)

Damages awarded | $

$ 344

Restructuring - Narrative (Deta

Restructuring - Narrative (Details) - USD ($) $ in Millions	12 Months Ended
Restructuring - Narrative (Details) - USD ($) $ in Millions	Jan. 02, 2022	Jan. 03, 2021	Dec. 29, 2019
Restructuring Cost and Reserve [Line Items]
Restructuring charges	$ 252	$ 247	$ 266
Supply Chain
Restructuring Cost and Reserve [Line Items]
Restructuring charges	473
Restructuring costs incurred since announced	1,800
Supply Chain \| Restructuring Charges
Restructuring Cost and Reserve [Line Items]
Restructuring charges	300
Supply Chain \| Cost of products sold
Restructuring Cost and Reserve [Line Items]
Restructuring charges	100
Supply Chain \| Other Income Expense Net
Restructuring Cost and Reserve [Line Items]
Restructuring charges	100
Supply Chain \| Minimum
Restructuring Cost and Reserve [Line Items]
Restructuring and related cost, expected future savings	600
Pre-tax restructuring charges	$ 2,100
Restructuring and related cost, duration of restructuring plan	4 years
Supply Chain \| Maximum
Restructuring Cost and Reserve [Line Items]
Restructuring and related cost, expected future savings	$ 800
Pre-tax restructuring charges	$ 2,300
Restructuring and related cost, duration of restructuring plan	5 years

Restructuring - Summary of Seve

Restructuring - Summary of Severance Charges and Associated Spending (Details) - USD ($) $ in Millions	12 Months Ended
	Jan. 02, 2022	Jan. 03, 2021	Dec. 29, 2019
Restructuring Reserve [Roll Forward]
Restructuring charges	$ 252	$ 247	$ 266
Supply Chain
Restructuring Reserve [Roll Forward]
Reserve balance beginning	144	180
Activity during the period		(36)
Restructuring charges	473
Cash settlements	(427)
Settled non cash	(53)
Reserve balance ending		144	180
Supply Chain \| Supply Chain
Restructuring Reserve [Roll Forward]
Reserve balance ending	137
Severance \| Supply Chain
Restructuring Reserve [Roll Forward]
Reserve balance beginning	135	164
Activity during the period		(29)
Restructuring charges	0
Cash settlements	(23)
Settled non cash	0
Reserve balance ending		135	164
Severance \| Supply Chain \| Supply Chain
Restructuring Reserve [Roll Forward]
Reserve balance ending	112
Asset Write-offs/Sales \| Supply Chain
Restructuring Reserve [Roll Forward]
Reserve balance beginning	0	0
Activity during the period		0
Restructuring charges	53
Cash settlements
Settled non cash	(53)
Reserve balance ending		0	0
Asset Write-offs/Sales \| Supply Chain \| Supply Chain
Restructuring Reserve [Roll Forward]
Reserve balance ending	0
Other \| Supply Chain
Restructuring Reserve [Roll Forward]
Reserve balance beginning	9	16
Activity during the period		(7)
Restructuring charges	420
Cash settlements	(404)
Settled non cash
Reserve balance ending		$ 9	$ 16
Other \| Supply Chain \| Supply Chain
Restructuring Reserve [Roll Forward]
Reserve balance ending	$ 25